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Summary 
In the search for effective and minimally toxic anticancer drugs, G-quadruplex (G4) structures 
emerged as appealing targets for their crucial roles in human telomeres and oncogene 
promoters. G4s are non-canonical nucleic acid secondary structures exhibiting marked 
structural polymorphism. To achieve an optimal recognition selectivity, thus reducing drug 
toxicity, a major challenge is to identify ligands which are not only structure-selective, i.e. able 
to discriminate G4 vs. duplex DNA, but also conformation-selective, i.e. able to specifically 
recognize different G4 conformations. Thus, considerable efforts are currently devoted to the 
design of molecules able to selectively target conformationally different G4s and discriminate 
duplex DNA. To be effective, the huge impulse to synthesize putative conformation-selective 
ligands has to be coupled with fast and reliable High Throughput Screening (HTS). 
Fully inserted in this context is this PhD project, whose objectives were: i) the design and 
synthesis of oligonucleotide functionalized-solid supports for affinity chromatography; ii) the 
development of an affinity chromatography-based method for the screening of potential 
conformation-selective G4 ligands; iii) the identification of effective ligands from focused 
libraries by the here developed affinity chromatography-based method; iv) the evaluation of the 
recognition specificity of the selected ligands using proper controls, i.e. duplex structures-
functionalized supports; v) the biophysical characterization in solution of the best ligands in 
their interaction with the target DNA; vi) in vitro biological tests to assess the anticancer activity 
of the selected ligands. 
In the search for HTS method enabling a rapid and efficient identification of candidate 
anticancer drugs, our group recently described an affinity chromatography-based assay, named 
G-quadruplex on Oligo Affinity Support (G4-OAS), for the screening of libraries of putative 
G4-binders. It consists in flowing solutions of the potential ligands through a polystyrene resin 
functionalized with a G4-forming DNA sequence and quantifying the bound ligand by 
spectrophotometric measurements. Though rapid and simple, using this method we observed 
some problems with ligands featuring large aromatic cores and low hydrophilicity, which gave 
unspecific interactions with the polystyrene resin and could not therefore be analyzed.  
With the aim of addressing this issue and particularly obtaining universal supports for effective 
screenings of putative conformation-selective G4-ligands, these studies were extended to 
Controlled Pore Glass (CPG). CPG is the support of choice for oligonucleotide synthesis; its 
success is essentially due to its chemical inertness, which in principle renders it more 
convenient than polystyrene also for affinity chromatography. Crucial in our design was the 
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choice of the linker, which must attach the first nucleoside to the solid support via a covalent 
bond chemically stable under basic conditions used in the final deprotection step of 
oligonucleotide synthesis, so to obtain the support-bound, fully deprotected oligonucleotides 
on which the affinity chromatography binding assays can be performed. Therefore, we designed 
a novel functionalization for CPG supports, involving a linker – made of a flexible spacer of 
hexaethylene glycol attached to the first nucleoside monomer (i.e., 5’-O-DMT-3’-O-
acetylthymidine) through the nucleobase – suitable for the oligonucleotide elongation by 
standard protocols and chemically stable to the final deprotection procedure. Hence, using 
classical phosphoramidite chemistry, biologically relevant G4-forming DNA sequences, taken 
from human telomeres (tel26, tel46) and oncogene promoters (cmyc, ckit1, ckit2, hTERT1), 
were synthesized. Furthermore, to evaluate the G4 vs. duplex recognition specificity of the 
putative ligands, the novel synthesized CPG support was also functionalized with an 
oligonucleotide able to fold into a stable unimolecular hairpin duplex (ds27). Molecules having 
good or no affinity for G4s (distamycin, netropsin, resveratrol, RHPS4, TO, TMPyP4, 9-Acr-
COOH), as well as molecules taken from a library of G4 ligands (7A, 5B, 10B, 1C, 3C, 7D, 7E, 
7F) previously proved to have strong unspecific interactions with OAS, were then exploited to 
validate and optimize the affinity chromatography-based method with the novel functionalized 
CPG supports. The general procedure adopted for the binding assays was as follows: a weighed 
amount of each support was left in contact with a ligand solution in a column equipped with a 
frit. After incubation on a vibrating shaker, each support was eluted with defined volumes of a 
washing solution and all the eluted fractions were separately analyzed by spectrophotometric 
measurements. The composition of the washing solution was optimized so to reach the best 
compromise in terms of solubility of the tested ligands, minimization of undesired absorption 
of the tested ligands on the assay equipment and capacity of the oligonucleotide sequences to 
form stable secondary structures. From spectrophotometric measurements of the fractions 
eluted from the nude CPG, the amount of ligand unspecifically adsorbed on the support was 
evaluated. In turn, spectrophotometric analysis of the fractions recovered from G4- and hairpin 
duplex-functionalized supports allowed estimating the amount of ligand bound to the supports 
carrying the secondary structure-forming oligonucleotides. In all cases, the amount of bound 
ligand was calculated by subtracting the ligand eluted upon washing, derived by direct 
spectrophotometric measurements, from the ligand amount initially loaded on each support. 
Moreover, as further control, the direct measurement of the bound ligand was obtained by 
treating each support with a releasing solution, followed by spectrophotometric analysis of the 
eluted fractions. The amounts of bound ligands thus measured were in good agreement with 
3 
 
those previously determined as a difference with respect to the unbound amounts. The 
composition of the releasing solution was optimized on the basis of its ability to obtain a fast 
and quantitative recovery of the bound ligand. To allow the correct G4s and hairpin duplex 
refolding after this treatment, and thus reuse the same batch of support for subsequent binding 
assays, each support was resuspended in the washing solution and then subjected to an 
annealing procedure. This consisted in taking the functionalized support at 75 °C for 5 min, 
followed by slow cooling to room temperature. The reversibility of the process of 
folding/unfolding of the G4s and the hairpin duplex allowed effectively recycling the support; 
indeed, a large number of binding assays (typically more than 50) could be performed on the 
same batch of CPG without losing in efficiency and reliability of the experiments.  
Notably, experimental results showed that the nude CPG has much lower unspecific 
interactions with all the tested model ligands than previously used OAS resin, allowing higher 
recovery of the ligands with smaller volumes of the washing solution. In addition, the affinity 
trend found for the tested ligands on the G4- and hairpin duplex-functionalized supports well 
reflects what observed for the same systems in solution, confirming the general reliability of 
the method. 
Additionally, to gain a deeper insight into the conformations effectively adopted by the G4s on 
the glass beads, we exploited a fluorescent core extended naphthalene diimide (cex-NDI) 
recently designed to give different fluorescence responses upon interaction with different 
secondary structure-forming oligonucleotides, thus discriminating hybrid G4s, parallel G4s and 
duplex DNA. By confocal microscopy, we proved that the oligonucleotides, when anchored to 
CPG and left in contact with the selected buffer, adopt the same conformations they typically 
have in solution. This can be mainly attributed to the long and flexible hexaethylene glycol, 
chosen as the spacer in our synthetic protocol to guarantee proper flexibility and distance from 
the CPG support of the oligonucleotides, thus minimizing possible steric effects. 
This result provided proof-of concept that our novel approach is a powerful tool to identify not 
only structure-selective G4-ligands, but even conformation-selective G4-ligands. 
After full optimization of the G4-CPG assay, two different libraries of putative G4 selective 
ligands, based either on furobenzoxazine naphthoquinone or naphthalene diimide scaffold, 
were evaluated. 
As far as the focused library of furobenzoxazine naphthoquinone derivatives is concerned, 
eleven molecules were selected as analogs of a lead-like G-quadruplex targeting compound (4), 
previously proved to be a strong G4 ligand, differing for the pendant groups on the N-atom of 
the oxazine ring. These molecules were tested vs. topologically different G4s by the G4-CPG 
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assay. The obtained results showed that all the compounds were able to bind several G4 
structures, even though with peculiar preferences, and one of them (S4-5) fully discriminated 
G4 vs. duplex DNA. Biological assays proved that almost all the compounds produced effective 
DNA damage, also at the telomeric level, showing marked antiproliferative effects on tumour 
cells in the low µM range. Combined analysis of the G4-CPG binding assays and biological 
data led us to focus on compound S4-5, being less cytotoxic than the parent compound 4 on 
normal cells. An in-depth biophysical characterization of the binding of S4-5 to different G4s 
was carried out by CD, NMR and Microscale Thermophoresis, demonstrating that the here 
identified ligand had higher affinity for parallel-type G4s than hybrid-type G4s and duplex 
DNA. Molecular docking studies in agreement with the NMR data suggested that S4-5 
interacted with the accessible grooves of the target G4 structures, giving clues for its increased 
binding selectivity. Considering that targeting the most variable regions of the G4 structures, 
i.e. the grooves and the loops, could be a successful, even though still poorly explored, approach 
for the specific recognition of different G4 conformations, and that very few G4-groove binders 
have been thus far characterized, these results are of great relevance to develop novel effective 
candidate anticancer drugs. 
As far as the naphthalene diimides (NDIs) library is concerned, twelve novel functionalized 
monomeric and dimeric NDIs were designed, synthesized and evaluated by the G4-CPG assay. 
Overall, all the tested compounds proved to be effective G4 ligands, also more efficiently 
targeting intramolecular dimeric than monomeric G4s. In detail, NDI-3, NDI-4, NDI-6, NDI-
8 and NDI-9 emerged as the most promising ligands, due to their high G4s vs. duplex DNA 
selectivity. In addition, G4-CPG assay results provided clear evidence that mitigating the 
affinity of the NDI binding core for G4s allowed the core selectivity emerging. 
In vitro biological assays unambiguously designated, among the five selected NDIs, NDI-8 as 
the most promising candidate due to its strong activity against cancer cells (IC50 = 6.6 nM) and 
high selectivity in killing cancer cells vs. normal cells. Therefore, NDI-8 was further 
investigated by CD, fluorescence, NMR and gel electrophoresis analyses. By combination of 
CD titrations and CD-melting experiments, NDI-8 was proved to preferentially affect the 
structure and thermal stability of G4s rather than duplex DNA. Moreover, the ability of NDI-8 
to induce G4 structures formation in the absence of cations was proved by CD and native PAGE 
experiments. Furthermore, fluorescence experiments revealed binding stoichiometries of 1:1 
and 3:2 for complexes of NDI-8 with a telomeric G4 monomer, while binding stoichiometries 
of 1:1 and 5:1 were found for NDI complexes with a telomeric G4 dimer. In-depth NMR 
analyses – performed during my three months-research stay at the Slovenian NMR Centre of 
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Ljubljana under the supervision of prof. Janez Plavec – showed the preferential binding of NDI-
8 to the 5’-end spatially close residues, the upper quartet and half of the middle quartet of a 
modified G4 structure (m-tel24) taken from the human telomeric DNA. Finally, the remarkable 
ability of NDI-8 to promote the formation of dimeric G4 species was demonstrated by DOSY 
experiments. 
Overall, the novel developed G4-CPG method based on our newly designed CPG support 
allowed us selecting two promising candidate drugs for in vivo studies, S4-5 and NDI-8, 
showing respectively binding preferences for parallel G4s and monomeric or higher order 
telomeric G-quadruplex structures, in addition to their high G4s vs. duplex DNA selectivity. 
Future work will be directed to extend the G4-CPG assay to biologically relevant human i-
motif-forming and viral G4-forming DNA sequences, as well as automate our method. 
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CHAPTER 1 – INTRODUCTION 
“DNA comes in many forms”. This review, written twenty-five years ago by Alexander Rich, 
well-summarized 40 years of molecular genetics supporting the polymorphic nature of DNA.[1] 
Only few years after the discovery of the three-dimensional structure of the DNA double helix 
in 1953,[2] it was found that polynucleotide strands are able to form also triple- and quadruple-
stranded nucleic acids.[3] Nevertheless, only three decades ago, when also the biological 
relevance of these peculiar structures was recognized, non-canonical DNA architectures started 
to be the object of dedicated investigations.[4–7] The possibility to control genetic pathways 
responsible for a plethora of pathologies, especially cancer, is a still open and revolutionary 
challenge from both a medical and scientific point of view. Indeed, getting a deeper insight into 
the complex biological functions of peculiar DNA structures, as well as selectively targeting 
them by proper drugs, are among the hottest issues in the scientific research field, especially for 
the development of effective and minimally toxic targeted therapies.  
Focus of this PhD thesis are the G-quadruplex (G4) structures of DNA, proved to have crucial 
roles in telomeres, replication origins and gene promoters, with G4-forming sequences found 
in regulatory regions of humans, as well as in virus genomes.[8–15] 
1.1 G-quadruplexes: an overview of their structural features 
A quadruple-stranded nucleic acid was first observed in 1958 when a fiber of polyinosinic acid 
was studied by X-ray diffraction.[3] Two different structures were proposed, a three- and a four-
stranded one,[3] but only in 1974 the actual structure was determined to be quadruple-
stranded.[16] Few years before, in 1962, Gellert and co-workers – likely inspired by Bang’s 
observations on the ability of guanylic acid to form gels, dated back to the beginning of 19th 
century[17] – characterized the first guanine quartet from a gelatinous substance formed by 
guanosine monophosphates (Figure 1).[18]  
 
Figure 1. A) X-ray diffraction pattern of 5’-GMP; B) X-ray diffraction pattern of 3’-GMP. (Adapted 
from Gellert et al.[18]) 
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They suggested that four guanines formed a cyclic system and were bound through four pairs 
of hydrogen bonds. In detail, we know today that each G-quartet (also defined as G-tetrad) is 
stabilized by eight Hoogsteen-type hydrogen bonds involving, for each guanine, the N1 and the 
exocyclic NH2 on C2 as H-bond donors, and the O6 and N7 as H-bond acceptors (Figure 2).
[15] 
 
Figure 2. Structure of a G-quartet and a G-quadruplex. 
 
Guanine arrangement in a G-tetrad determines the formation of a cavity in the centre of the 
planar structure, delimited by guanine carbonyl oxygens, which represents a specific binding 
site for metal ions, typically K+ or Na+.[15,19] 
Two or more parallel planes of G-quartets can stack on each other resulting in a G-quadruplex 
structure (Figure 2), normally featured by a right-handed helical motif with a rise of 3.13-3.30 
Å, right-handed twist of 30°, and a diameter of 25 Å.[15]  
Moreover, G-quadruplexes exhibit a marked structural polymorphism,[15] which depends on: 
 the number of strands involved in the structure; 
 the type of linking loops; 
 the relative strands orientation; 
 the syn/anti conformation of the guanine residues; 
 the nature of the associated metal cations.  
G-quadruplexes can be formed from one (unimolecular), two (bimolecular) or four 
(tetramolecular) polynucleotide strands (Figure 3). 
Three different types of loops can be found in G-quadruplex structures: propeller loops, linking 
adjacent parallel strands on opposite G-quadruplex surfaces; lateral loops, linking adjacent 
antiparallel strands on the same G-quadruplex surface; and diagonal loops, linking opposite 
antiparallel strands on the same surface (Figure 4).[15] 
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Figure 3. A) Unimolecular, B) bimolecular and C) tetramolecular G-quadruplex structures. 
 
Figure 4. Different types of linking loops in G-quadruplex structures: A) propeller, B) lateral and C) 
diagonal. (Adapted from Musumeci et al.[20]) 
Moreover, based on the orientation of the four strands, G-quadruplexes are classified in the 
following topologies: i) parallel (all parallel strands), ii) antiparallel (all antiparallel) or iii) 
hybrid (3 parallel and 1 antiparallel) (Figure 5).[15,21–24] In particular, two different antiparallel-
type topologies can be observed: i) chair-type, in which all the three loops are lateral, and ii) 
basket-type, with two lateral loops and one diagonal (Figures 5C and 5D).[21,23]  
The G-quadruplexes can also be classified according to the conformation adopted by the 
guanines, which can be syn or anti along the N-glycosidic bond (Figure 6).[15,25] Interestingly, 
while in B-DNA nucleobases adopt only the anti conformation, in G-quadruplex structures 
guanines can adopt either syn or anti conformation, thus giving rise to a variety of different 
arrangements within the G-tetrads, which sensibly contribute to increase the topological 
diversity of G-quadruplexes.[26] 
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Differently from B-DNA, in which there are only two different grooves, a major and a minor 
one, the sugar-phosphate backbone of a G-quadruplex generates four grooves that can 
accommodate a well-defined network of ordered water molecules.[15] Groove dimension is a 
consequence of the variation in the glycosidic torsion angles (Figure 7).[27,28] 
 
Figure 5. Different G-quadruplex topologies classified on the basis of strands orientation: A) parallel, 
B) hybrid, C) antiparallel (chair-type), D) antiparallel (basket-type). (Adapted from Musumeci et al.[20]) 
 
Figure 6. Syn and anti conformations of the guanines along the N-glycosidic bond. 
G-syn G-anti
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Figure 7. G-quadruplex groove dimensions as a consequence of the different glycosidic torsion angles. 
Indeed, if a guanosine in the syn conformation points its H-bond donor groups towards a 
guanosine in the anti conformation, the groove formed between them is narrow.[27,28] 
Conversely, if a guanosine in the anti conformation directs the N1 and the exocyclic NH2 
towards a guanosine in the syn conformation, the groove is wide.[27,28] Finally, if neighbouring 
guanosines in the G-tetrad adopt the same glycosidic conformation, the groove is medium.[27,28]  
In particular, in a parallel four-stranded G-quadruplex, where all the guanosines adopt the anti 
conformation, all the four grooves are of medium width (Figure 7A). Different groove widths 
alter the hydration network of the resulting structure and determine a different accessibility to 
hydrogen-bond donors and acceptors of proteins, nucleic acids and small ligands.[27,28] 
Intrinsically related to glycosidic conformation of the bases are also the different stacking 
geometries that two adjacent tetrads can adopt.[29] Considering that, within a G-tetrad, the 
hydrogen bonds polarity is defined in the direction of hydrogen bond donor to acceptor, from 
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NH2 on C2 to N7 and from N1 to O6 (Figure 8), three different stacking geometries in a single 
G-quadruplex have been experimentally found: i) “partial 5/6-ring” stacking of the anti/anti 
step, formed by same-polarity stacked tetrads with a partial overlap of the 5-membered ring of 
one guanine with the 6-membered ring of another; ii) “5-ring” stacking of the syn/anti step, 
formed by opposite-polarity stacked tetrads with an overlap of the 5-membered rings of stacked 
guanines; iii) “partial 6-ring” stacking of the anti/syn step, formed by opposite-polarity stacked 
tetrads with a partial overlap of the 6-membered rings of stacked guanines (Figure 9).[29] 
 
 
Figure 8. A) Hydrogen bonds polarity is defined in the direction of hydrogen bond donor to acceptor; 
B) Stacking between two tetrads with opposite polarities; C) Stacking between two tetrads with the same 
polarity. (Adapted from Lech et al.[29]) 
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Figure 9. Different stacking geometries experimentally found for two adjacent tetrads in a single G-
quadruplex. (Adapted from Lech et al.[29]) 
Furthermore, two or more G-quadruplexes can stack on each other forming dimeric and higher-
order structures. By analysing all the NMR and crystallographic dimeric G-quadruplex 
structures in the Protein Data Bank archive, the following stacking geometries were found at 
the interface of stacked G-quadruplexes: “partial 6-ring”, “6-ring”, “5/6-ring” and “5-ring” 
(Figure 10).[29] 
 
Figure 10. Different stacking geometries experimentally found at the interface of two stacked G-
quadruplexes. (Adapted from Lech et al.[29]) 
By computational studies, tetrad stacking energies for experimental geometries were calculated 
and ranked as follows, core stacking modes: partial 5/6-ring < 5-ring < partial 6-ring, interface 
stacking modes: 5/6-ring < 6-ring < 5-ring < partial 6-ring. 
Finally, investigation of PDB structures and computational studies suggested that 5’-5’ ends 
stacking with 5/6-ring geometry is the favourite arrangement for two stacked G-quadruplexes 
and probably is a good model also for higher-order structures.[29] 
Additional key elements in the modulation of G-quadruplex topology and stability are the 
associated metal cations. Several metal cations with different radii can be hosted in the central 
cavity of a G-quadruplex. Circular dichroism (CD) studies revealed that cations with ionic radii 
between 1.3 and 1.5 Å, such as K+, Rb+, NH4
+, Sr2+ and Ba2+, stabilize the G-quadruplex better 
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than other ions, such as Li+, Na+, Cs+, Mg2+ and Ca2+, due to their optimal fit between two 
adjacent G-tetrads coordinating eight guanines carbonyl oxygens.[30] Smaller cations, such as 
Li+, or larger cations, such as Cs+, do not fit well within two consecutive G-tetrads.[30] The 
general ranking of G4 stabilization by cations is Sr2+ > Ba2+ > K+ > Ca2+ > Na+, NH4
+, Rb+ > 
Mg2+ > Li+ ≥ Cs+.[31] Notably, if G-quadruplex and monovalent cation concentrations are low 
enough, some divalent cations, such as Ca2+, Co2+, Mn2+, Zn2+, Ni2+ and Mg2+ can instead 
induce G4 instability and dissociation.[32] Presumably, the divalent ions interact with the G-
quadruplex structures in two different ways: they can bind to the phosphate groups, reducing 
the charge repulsion, and, at higher concentrations, also coordinate in a bidentate manner the 
6-keto and 7-imine groups of guanines involved in hydrogen bonding, thus disrupting the G-
quadruplex structure.[33] Therefore, even cations with similar ionic radii, e.g. Ca2+ (0.99 Å) and 
Na+ (0.97 Å), can have different effects on G-quadruplex stability.[34] Indeed, not only the ionic 
radius but also other properties of the cations, including the dehydration energy and the 
coordination number, are essential to determine their overall effect on folding and stability of 
G-quadruplex structures.[34,35]  
 
Figure 11. Side view (A, D), top view (B, E) and schematic representations (C, F) of G4 structures 
obtained from Oxytricha nova telomeric DNA d(GGGGTTTTGGGG) in the presence of K+ (A, B, C) 
or Na+ (D, E, F).  K+ ions are located between two adjacent G-tetrads (PDB entry: 1JPQ), while Na+ 
ions are in the G-tetrads planes (PDB entry: 1JB7). (Adapted from Bhattacharyya et al.[36]) 
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Finally, the precise location of the cations in the G-quadruplex structures is dependent on the 
nature of the ion: Na+ ions can be located between two G-tetrads in some structures, whereas 
they lie within the G-tetrad planes in others; K+ ions always form sandwich complexes between 
two adjacent G-tetrads, coordinating eight carbonyl oxygen atoms (Figure 11).[36] 
Structural polymorphism of G-quadruplexes, just outlined, is probably the main reason why 
nature chose them as key elements for the fine regulation of specific biological mechanisms. 
 
 
1.2 Biologically relevant G-quadruplex structures 
By sequencing many genomes it readily came out that they are rich in sequence motifs 
containing more consecutive guanines. In particular, bioinformatic analyses, exploiting the 
Quadparser algorithm based on the consensus sequence d(G3+N1–7G3+N1–7G3+N1–7G3+), 
suggested that there could potentially be about 376,000 sequences in the human genome able 
to fold into G-quadruplex structures.[37] Besides, the above algorithm represents a simplification 
significantly underestimating the actual number of G4-forming sequences in the genome for 
several reasons.[37] First of all, since G4s composed of two stacked tetrads are generally less 
stable than single-stranded or duplex DNA, only sequences able to form three or more G-tetrads 
are considered physiologically relevant; secondly, loops with lengths from 1 to 7 bases were 
found to form G4s, with stability decreasing on length increasing; finally, sequences with 
discontinuities in the G-tracts are not very stable.[37] Indeed, many experimental studies proved 
that Quadparser algorithm generates both false positives and negatives. To overcome these 
limitations, Mergny and co-workers recently developed a different algorithm called 
G4Hunter.[38] It considers the G-richness of a sequence, as well as the C-richness of its 
complementary strand able to form a stable duplex competing with the potential G-quadruplex 
structure, and, on this basis, gives a quadruplex propensity score as the output. After validation 
of the model by analysis of a large dataset of sequences, it was applied to the human genome 
proving that the number of sequences able to fold into G-quadruplex structures is higher than 
what previously estimated by a factor of 2-10.[38] Moreover, high-resolution sequencing-based 
methods to detect G4s in the human genome also confirmed the higher number of G4s that can 
be formed in the genome (> 700,000) than previously predicted by computational methods.[39]  
Notably, G4 location is non-random, with putative G4-forming sequences found in functional 
and highly conserved human, as well as viral, genomic regions. Indeed, G4-forming sequences 
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have been found in telomeres, oncogene promoters, around transcription start sites regions, 
introns, immunoglobulin switch regions and 5’ untranslated regions.[9,10,14] 
This PhD thesis will focus on DNA G-quadruplex structures found in oncogene promoters and 
telomeres.[40]  
A proto-oncogene is a normal gene coding for a protein responsible for cell growth and 
division.[41] If a mutation occurs in this gene, it can turn into an oncogene.[41] An oncogene is a 
gene that encodes for a protein capable of transforming normal cells and inducing cancer.[41] 
The formation of G-quadruplex structures in oncogene promoters is one of the regulation 
systems of their transcription.[13] In this context, ligands able to interact with oncogene promoter 
G-quadruplexes can inhibit a specific mutated proto-oncogene (Figure 12, left).[9] 
Telomeres are the ends of eukaryotic chromosomes protecting chromosomal termini from 
unwanted recombination and degradation, thus guaranteeing proper replication.[42,43] They are 
made up of double-stranded DNA of 2-20 kb, and of a 3′ single-stranded overhang of 
approximately 200 nucleotides containing repetitive nucleotide sequences.[44,45] 
Telomerase is the enzyme that adds copies of these repetitive sequences to the end of the single-
stranded overhang, providing the main mechanism of telomere length maintenance.[46] This 
enzyme is transcriptionally repressed in human somatic cells, while it is overexpressed in about 
85% of cancer cells. In the remaining 15% of human tumours, telomere lengthening is provided 
by a different mechanism, known as alternative lengthening of telomere (ALT), based on 
homologous recombination between telomeric sequences.[44,47] 
Thus, while in normal cells telomeres get shorter and shorter over time, leading to irreversible 
cell growth arrest, also known as cellular senescence, in cancer cells telomeres are maintained 
to a stable length, making cancer cells immortal.[40] Based on this mechanism, it is now widely 
accepted that telomere maintenance has a key role in the development of tumours.[42] Hence, 
interfering with telomere homeostasis is an attractive strategy in the search of new anticancer 
therapies. The 3′ single-stranded overhang of the telomeric DNA, being a G-rich region with 
repetitive sequences, can fold into G-quadruplex structures.[48] Ligands able to stabilize these 
peculiar conformations can alter the single-stranded overhang structure, which consequently is 
no more recognized and elongated by telomerase or by ALT, thus inducing cancer cells 
senescence and apoptosis (Figure 12, right).[14,47] 
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Figure 12. Inhibition of oncogene transcription and telomerase activity through G-quadruplexes 
formation mediated by ligands. 
Hence, there are many advantages in using telomerase activity inhibition mediated by G4 
ligands as anticancer therapeutic strategy.[47,49] First of all, telomerase is a specific enzyme for 
most cancer cells and the most widely expressed tumour marker. Secondly, the risk for 
development of therapy resistance is very limited because telomeres elongation is the most 
efficient mechanism for cell immortalization. Thirdly, the very low expression of telomerase in 
normal cells, along with the longer telomeres in normal stem and germ cells than cancer cells, 
in principle guarantee specificity towards cancer cells, low toxicity in normal cells, and limited 
risks in stem and germ cells if the treatment is restricted in time.[47] 
The presence of G-quadruplex structures has been proved in the genetic material of human cells 
by using specific antibodies,[50–52] thus validating both their biological relevance and their role 
as targets for anticancer strategies (Figure 13).[53–56] In addition, several experiments have fully 
ascertained that G-quadruplex formation in DNA is modulated during the cell cycle (Figure 
13B) and that DNA G-quadruplex structures can be stabilized by small molecule ligands 
(Figure 13C).[51]  
These findings account for the growing interest in the synthesis of small organic molecules as 
G4 ligands able to interfere with the G-quadruplex functions, essentially aimed at the 
development of antitumor targeted therapies. 
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Figure 13. A) Visualization of G-quadruplex structures in telomeres and extra-telomeric regions of 
metaphase chromosomes by BG4 specific antibody; B) Increase in BG4 foci number during cell cycle, 
from G0/G1 to S phase; C) Increase in BG4 foci number after treatment with G4 ligand pyridostatin 
(PDS). Chromosomes and nuclei are counterstained with DAPI (blue). Scale bars correspond to 2.5 μm 
in A) and 20 μm in B) and C). (Adapted from Biffi et al.[51]) 
 
1.2.1 Telomerase, telomeres and telomeric G-quadruplexes 
The DNA polymerase is not able to replicate the chromosome up to its termination. This 
problem is referred to as “end replication problem”.[57] In the absence of an effective mechanism 
to solve it, at each cell duplication, a stretch of DNA is not replicated, thus resulting into a loss 
of genetic information. The solution to this problem is provided by telomerase.[57] 
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Telomerase is an RNA-dependent ribonucleoprotein consisting of two subunits:  
 hTERT (Telomerase Reverse Transcriptase), which has reverse transcriptase enzymatic 
activity;  
 hTR (Telomerase RNA Component), the RNA template used for the synthesis of new 
telomeric repeats.[58,59] 
Telomerase adds repetitive units of oligonucleotide sequences to the 3' end of the chromosomes 
(Figure 14).[58,59]  
 
Figure 14. Mechanism of action of telomerase. 
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The RNA template hybridizes to the strand at the 3' end of the target DNA; the nucleotides not 
complementary to this strand are used as a template for the addition of a defined number of 
nucleotides; the telomerase moves to the new 3’-end and the elongation step is repeated. When 
the telomerase has added a high number of repetitions, a primase synthesizes RNA primers and 
DNA polymerase copies the second strand of the telomere. The primer is then removed, leaving 
the 3' end as a single strand (Figure 14).[60] 
Telomeric repeat sequence is species-specific, but in general is a guanine-rich oligonucleotide. 
In particular, human telomeres comprise tandem repeats of the short DNA motif 
d(TTAGGG).[58,59,61]  
Electron microscopy studies proved that the 3’-overhang of the telomere invades the double 
stranded region of telomeric DNA, making a structure defined displacement loop or D-loop.[62] 
Probably, the G-rich 3’-overhang interacts with the double stranded telomeric region by base 
pairing with the C-rich strand. Consequence of strand invasion is the formation of a duplex 
lariat structure, defined t-loop (Figure 15A).[45] Recently, a structural study suggested that the 
stabilization of the t-loop is mediated by the formation of G-quadruplexes at the level of the D-
loop (Figure 15B).[63] 
 
 
Figure 15. Structure of the 3’ telomeric overhang: A) D- and t-loop; B) stabilization of D-loop mediated 
by a G-quadruplex structure. (Adapted from Xu et al.[62]) 
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Moreover, a six-protein complex, called shelterin, is associated to the human telomere (Figure 
16).[62] Three shelterin proteins, TRF1, TRF2, and POT1, directly recognize telomere DNA 
sequences: TRF1 and TRF2 bind the double-stranded telomeric DNA while POT1 binds the 3’-
single stranded overhanging of the chromosome end.[64,65] POT1 is involved in the telomerase 
maintenance mechanism since it disrupts telomeric G-quadruplexes.[66] Conversely, another 
shelterin protein, Rap1, interacts with TRF2 and promote G-quadruplex formation.[67] The other 
two shelterin proteins are TIN2 and TPP1. TIN2 interconnects TRF1 and TRF2 with the TPP1-
POT1 heterodimer, while TPP1 interacts with POT1 and TIN2 and has the fundamental role of 
recruiting POT1 at the level of telomeres.[64,65] In conclusion, the shelterin proteins have the 
complex role of protecting telomeres and regulating their length together with telomerase.[62] 
 
Figure 16. Six protein-complex shelterin. 
As mentioned above, telomerase is transcriptionally repressed in healthy somatic cells, 
therefore telomeres get shorter and shorter over time, and when their length is about 4-6 kb, 
replicative senescence, also known as mortality stage 1 (M1), is triggered.[68] Hence, normal 
cells have a defined number of possible cell divisions, the so-called Hayflick limit; once reached 
this limit, cells undergo to apoptosis. However, some cells can escape M1 and continue to 
shorten their telomeres, eventually entering mortality stage 2 (M2), featured by genomic 
instability, fusion/breakage mutagenic events and huge cell death.[68] Furthermore, some cells 
can reactivate and overexpress telomerase during M1 or M2, leading to immortalization. Even 
if immortalization is not enough to induce malignant transformation, immortalization acquired 
from reactivated telomerase in combination with genome instability and mutation from 
telomere shortening promote cancer onset.[68] 
Small molecules, able to stabilize telomeric single strand into G-quadruplex structures can 
interfere with telomere lengthening by telomerase, leading to cancer cell death. 
Two mechanisms of action have been proposed for telomeric G4 binding ligands as anticancer 
agents:[11,14] i) the classical, slow one, according to which inhibition of telomerase activity due 
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to ligand-G4 interaction results in telomere shortening, and, after a defined number of cell 
divisions, cancer cells enter in senescence and finally in apoptosis (Figure 17A); and ii) the fast 
one, according to which telomeric G4 binding ligands compete with POT1 protein; loss of 
POT1 deprotects telomeres, and initiates DNA damage-response mediated cancer cell death 
(Figure 17B).[11,14] 
If G4 ligands followed the slow mechanism, senescence would be reached in about 40-50 days 
after first treatment with drug. Contrarily, experimental evidence proved that several G4 ligands 
induce senescence after few days of exposure, validating the fast mechanism as the effective 
one.[11] 
 
Figure 17. Two different mechanisms of action proposed for telomeric G4 binding ligands as anticancer 
agents: A) slowly triggered apoptosis by telomere shortening after several cell divisions; B) fast 
triggered apoptosis by immediate DNA damage response after POT1 protein displacement. G4 ligands 
are represented as yellow circles. 
1.2.2 Structural characterization of telomeric G-quadruplexes 
G-quadruplexes formed at telomeric level have been characterized in detail by NMR 
spectroscopy, X-ray crystallography and circular dichroism.  
By NMR studies, the structure of the G-quadruplex telomeric sequence d[AGGG(TTAGGG)3] 
(tel22) has been obtained in solution containing Na+ ions (Figure 18A).[27,69] In these conditions, 
the oligonucleotide tel22 adopts a basket-type topology formed by three planes of G-tetrads 
connected through three TTA loops, one diagonal and two lateral ones, and featured by the 
following N-glycosidic conformations: syn:syn:anti:anti in the upper and lower tetrads, and 
anti:syn:syn:anti in the middle one.[27,70] On the other hand, crystallographic studies have 
revealed a different conformation for tel22 in the presence of K+ ions (Figure 18B).[71] Indeed, 
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in the solid state it adopts a parallel G-quadruplex structure with three propeller loops TTA, 
with the adenine intercalating between the two thymines in each loop, and all the guanosines in 
anti conformation.[70,71] 
 
 
Figure 18. Schematic drawings of the folding topologies of G-quadruplex telomeric sequence 
d[AGGG(TTAGGG)3] (tel22): A) Basket-type unimolecular G-quadruplex in Na+ solution, as 
determined by NMR studies; B) Propeller-type parallel-stranded unimolecular G-quadruplex in the 
presence of K+, obtained by X-ray crystallography. Yellow box = (anti) guanine, red box = (syn) 
guanine. (Adapted from Dai et al.[70]) 
More recent studies, carried out by NMR and CD, have shown that in solutions containing K+ 
ions, telomeric sequences do not adopt a single G-quadruplex conformation, but present 
multiple conformations.[72] In particular, two are the major ones. These structures, indicated as 
hybrid 1 and hybrid 2 (Figure 19), differ significantly from the basket-type or parallel 
conformations, respectively adopted by telomeric DNA in Na+ solutions or found in the 
presence of K+ in crystals. 
Hybrid structures, both constituted by three planes of G-tetrads, differ in the arrangement of the 
loops, in the relative orientation of the strands and in the conformation of the N-glycosidic 
bonds.[72,73] In both structures, there are three parallel strands and one antiparallel, and for this 
reason they are also known as (3 + 1) structures: the antiparallel strand is the third in hybrid 1, 
while the second in hybrid 2.[72,73] As far as the conformation of the N-glycosidic bonds is 
concerned, for hybrid 1 the upper tetrad is syn:syn:anti:syn, and the other two are 
anti:anti:syn:anti, while for hybrid 2 the upper tetrad is syn:syn:syn:anti and the lower ones are 
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anti:syn:anti:anti.[72,73] Another feature that distinguishes the two hybrid conformations is the 
size of the grooves, which is obviously different for the two structures.[72,73] 
 
 
Figure 19. Schematic drawings of: A) hybrid 1 and B) hybrid 2 folding topologies of unimolecular 
telomeric G-quadruplexes in K+ solution, determined by NMR using the following sequences: A) 
d[AAA(GGGTTA)3GGGAA] and B) d[(TTAGGG)4TT]. Yellow box = (anti) guanine, red box = (syn) 
guanine. (Adapted from Dai et al.[72]) 
It was also demonstrated that the folding of telomeric sequences in one of two possible hybrid 
conformations is sensibly affected by the flanking sequences.[74] Indeed, while the hybrid 2 
conformation seems to be the predominant form in the case of sequences with TT stretches at 
the 3' end (for example, the 26-mer native sequence d[(TTAGGG)4TT], tel26), hybrid 1 is the 
conformation adopted by telomeric sequences which lack the 3’-flanking segment, as in the 
case of the 24-mer d[(TTAGGG)4] (tel24).
[72,75] 
This is explained considering that the 3’-flanking TT nucleotides are important for the 
formation of a stable T:A:T triple capping structure below the lower quartet, that selectively 
stabilizes the hybrid-2 topology (Figure 20A).[72] Instead, an adenine triple capping structure 
above the upper quartet was found to form in the hybrid-1 structure, which provides additional 
stabilization specific to the hybrid-1 topology (Figure 20B).[75] 
Another technique extremely useful in structural studies in solution of nucleic acids, and, in 
particular, for the characterization of the conformations adopted by G-quadruplex-forming 
oligonucleotides, is circular dichroism spectroscopy.[15,76] 
 
HYBRID 1 HYBRID 2
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Figure 20. A) Bottom view of the T:A:T triple structure capping the bottom G-tetrad (blue) of hybrid 2 
structure (Adapted from Dai et al.[72]); B) Top view of the adenine triple structure capping the top G-
tetrad (light blue) of hybrid 1 structure. The potential hydrogen bonds are depicted with yellow dash 
lines. (Adapted from Dai et al.[75]) 
 
CD spectral signature of G-quadruplex structures is mainly affected by the relative strands 
orientation and G-tetrads stacking geometries.[77,78] Parallel-stranded G-quadruplexes, in which 
all guanines have the anti glycosidic conformation, are characterized by CD spectra with a 
positive peak at ~265 nm and a small negative peak at 240 nm (Figure 21A).[21] Antiparallel-
stranded G-quadruplexes, in which guanines have alternating anti and syn glycosidic 
conformations along each DNA strand, have CD spectra exhibiting a positive peak at 295 nm, 
a small negative peak at 265 nm, and a small positive peak at 245 nm (Figure 21B).[21] 
Conversely, the CD spectrum of a hybrid-type G-quadruplex shows a strong positive peak 
around 290 nm with a shoulder peak around 270 nm, and a small negative peak at 240 nm 
(Figure 21C). The positive peak around 290 nm is due to the alternating anti and syn glycosidic 
conformations along the G-strands between the top and middle G-tetrads, and its shifting from 
295 nm is probably due to the presence of the positive peak at 260 nm. The positive peak around 
270 nm and the small negative peak around 240 nm are due to the non-alternating anti and syn 
glycosidic conformations between the middle and bottom G-tetrads, as elucidated by Ambrus 
et al.[21]  
A) B)
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Figure 21. Average CD spectra, obtained from analysis of several G4-forming oligonucleotide 
sequences, showing CD spectral features for: A) parallel-type G-quadruplex, B) antiparallel, C) hybrid. 
(Adapted from del Villar-Guerra et al.[79]) 
 
Using CD spectroscopy, the ability of telomeric sequences to interconvert among different G-
quadruplex conformations in the presence of different cations has been investigated by means 
of titration experiments.[21] Stepwise additions of K+ ions to preformed tel26 G-quadruplex in 
Na+ produces clear spectral changes (Figure 22A), indicating the conversion from a basket-type 
to a hybrid-type topology. The inverse titration, i.e. adding Na+ ions to preformed tel26 G-
quadruplex in K+, does not induce changes in the CD spectrum (Figure 22B), indicating that 
the presence of Na+, even in large excess, does not affect the conformation induced by K+.[21] 
These results indicate that the hybrid-type telomeric G-quadruplex is the predominant form in 
the presence of K+. The lower stability of the basket-type conformation is generally attributed 
to the steric interference of the flanking sequences with the diagonal loop, both positioned on 
the same side of the structure.[21] 
Furthermore, considering that the intracellular environment is featured by higher concentrations 
of K+ ions than Na+,[80] the above study also suggests that hybrid-type is the predominant 
conformation adopted by telomeric G-quadruplexes in cellulo. 
In addition, a peculiar structural feature of human telomeric DNA is the ability of forming 
higher-order structures, known as multimers.[70,78] Indeed, since telomeric DNA is ca. 100-200 
nucleotides long, it can potentially fold into about 8 consecutive G-quadruplexes.[81,82] 
However, unfavourable coupling free energies could limit complete folding of the 3’-
overhang.[83]  
An elongated telomeric sequence, depicted in Figure 23A, has been visualized by atomic force 
microscopy (AFM).[84] The AFM image clearly shows that the higher-order G-quadruplex 
A) B) C)
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consists of blob-shaped protrusions arranged end-to-end and formed by adjacent G-quadruplex 
units (Figures 23B, 23C and 23D). 
Further studies proved that higher-order telomeric G-quadruplexes preferentially adopt 
structures in which two adjacent quadruplex units have different folding motifs, thus forming a 
characteristic hybrid1-hybrid2 interface stabilized by stacking interactions (Figure 24).[85,86] 
Therefore, it can be concluded that monomeric and multimeric G-quadruplexes folded into 
hybrid topologies can be considered as biologically relevant targets with unique binding sites 
for ligands,[87,88] and used for the design of novel classes of telomeric-specific DNA drugs. 
 
 
 
Figure 22. A) CD titration experiments of tel26 by adding K+ in the presence of 150 mM Na+; B) CD 
titration experiments of tel26 by adding Na+ in the presence of 100 mM K+. (Adapted from Ambrus et 
al.[21]) 
 
 
 
A)
B)
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Figure 23. A) Schematic drawing of a DNA model used for AFM visualization. The model has a 
TTAGGG repeat sequence (96 nt) at both ends and a single-stranded DNA segment (240 nt) linked by 
a 15 nt duplex; B) AFM image of a DNA model and schematic drawing of its dumbbell-shaped structure; 
C) High resolution AFM image of higher-order telomeric DNA structures; D) Putative model for the 
higher-order telomeric DNA structure: four G-quadruplex units linked by TTA linkers. (Adapted from 
Xu et al.[84]) 
 
 
Figure 24. Schematic model of G-quadruplex multimers in human telomeres alternating hybrid 1 and 2 
topologies. (Adapted from Dai et al.[70]) 
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B)
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1.2.3 G-quadruplexes in extra-telomeric regions 
Interestingly, even if the highest abundance of G-rich sequences is at telomeres, the majority 
(~75%) of G4s are found in extra-telomeric regions, such as in the tumour-related gene 
promoters c-myc, c-kit and hTERT.[9] 
c-Myc oncoprotein regulates the expression of 15% of all human genes and its main roles are 
to promote cell proliferation and arrest cell differentiation.[89] Regarding the c-myc oncogene, 
many studies have proved that its dysregulation is closely related with tumour initiation and 
progression. Indeed, 20% of human cancers can be associated with the overexpression of c-
myc.[90] Furthermore, c-myc activation increases the expression of hTERT, the gene coding for 
the telomerase catalytic subunit, therefore involved in cell immortalization.[91] Noteworthy, the 
first G4 ligand which entered phase II clinical trials is quarfloxin (ClinicalTrials.gov Identifier: 
NCT00780663), selectively targeting the c-myc G4.[92] Overall, these findings validate c-myc 
G4 as an attractive anticancer target. Although the c-myc transcription is regulated by multiple 
promoters, the nuclease hypersensitivity element III1 (NHE III1), consisting of 33 nucleotides, 
controls 80-90% of the transcriptional activity of c-myc.[93–96] The 33-mer sequence 
d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) (cmyc) in NHE III1 contains six 
G-tracts of unequal length and is potentially able to fold into different G4 conformations, 
involving different guanine runs.[6,97,98] Shorter sequences extracted from the 33-mer involving, 
respectively, the G-tracts 2, 3, 4, and 5 (Myc2345, Figure 25A) and 1, 2, 4 and 5 (Myc1245, 
Figure 25B) have been investigated by NMR and proved to fold into parallel-type topologies, 
with Myc2345 G4 resulting as the most stable one.[22,97,99,100] Interestingly, in contrast to 
stability data obtained by melting experiments, only Myc1234 G-quadruplex (Figure 25C) was 
observed in supercoiled plasmid models, thus pointing out the importance of supercoiling in G-
quadruplex formation and re-evaluating Myc1234 as the potential biologically relevant G-
quadruplex in the c-myc promoter.[101] 
The c-kit protein regulates several signal transduction cascades important for the control of cell 
growth and proliferation.[102–104] Mutations and overexpression of the c-kit oncogene play 
central roles in oncogenic transformation and are especially related to gastrointestinal stromal 
tumours (GIST).[105] Despite c-kit kinase inhibitors have been recently approved for clinical use 
in the treatment of GIST, resistance related to protein mutations remains to be overcome.[106–
108] Therefore, the development of small molecules effective as c-kit G-quadruplex ligands can 
be an alternative and promising strategy. 
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Figure 25. Schematic drawings of: A) Myc2345 d(TGAGGGTGGGGAGGGTGGGGAA) structure in 
K+ solution, obtained by NMR; B) Myc1245 d(TGGGGAGGGTTTTTAGGGTGGGGA) structure in 
K+ solution, determined by NMR; C) Myc1234 structure proposed by in vitro plasmid footprinting 
experiments. (Adapted from Phan et al.[97] and Sun et al.[101]) 
c-kit promoter contains two different G-quadruplexes (ckit1 and ckit2) separated by about three 
turns of DNA.[109] In detail, one is located between -87 and -109 bp and the other between -140 
and -160 bp upstream of the transcription initiation site.[109] The molecular structure of the 22-
mer d(AGGGAGGGCGCTGGGAGGAGGG) ckit1 G4 has been determined by NMR (Figure 
26A).[110] Having a unique topology with respect to the other known G4s, it results a specific 
target for drug design.[110,111] In addition, the crystal structure determined for ckit1 G4 is in good 
agreement with the one solved by NMR.[112] ckit1 G4 adopts a parallel conformation with two 
single-nucleotide propeller loops and a long five-nucleotide lateral stem loop; moreover, one 
non-G-tract guanine is involved in the core of the G-quartets (Figure 26A).[110,112,113] On the 
other hand, the 21-mer ckit2 of sequence d(CGGGCGGGCGCGAGGGAGGGG), depending 
C) Myc1234
Myc2345A) Myc1245B)
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on the K+ concentration in solution, adopts two distinct parallel conformations in slow 
exchange: i) a monomeric one with two single-nucleotide and a long five-nucleotide propeller 
loops (Figure 26B) and ii) an unusual dimeric structure, in which stacking interactions between 
the two G-quadruplexes are mediated by a sandwiched A-A non-canonical pair (Figure 
26C).[114] 
 
 
Figure 26. Schematic drawings of: A) ckit1, B) ckit2 monomeric form and C) ckit2 dimeric form 
determined by NMR respectively in 70 mM KCl, 20 mM potassium phosphate buffer, 20 mM KCl, 5 
mM potassium phosphate buffer and 100 mM KCl, 5 mM potassium phosphate buffer. (Adapted from 
Phan et al.[110] and Kuryavyi et al.[114]) 
 
hTERT is the gene coding for the catalytic subunit of telomerase.[43,115] Its overexpression is 
associated with over 85% of human cancers, and its transcriptional repression accounts for the 
lack of telomerase activity in normal somatic cells.[43,115,116] Expression of hTERT is mainly 
regulated by the core promoter containing five Sp1 (Specificity protein 1) binding sites and one 
c-Myc protein binding site.[91,115] In particular, the middle three Sp1 binding sites (-167÷-100) 
have proved to be crucial for hTERT overexpression.[91] There are two different structural 
models for this G-rich 68-mer sequence, both obtained by low resolution techniques: one 
consisting of a hairpin structure, a hybrid G-quadruplex and a parallel one (Figure 27A),[117] 
and the other consisting of three contiguous stacked parallel G4s (Figure 27B).[118] A detailed 
NMR study was performed for the shorter sequence d(AGGGGAGGGGCTGGGAGGGC) 
taken from hTERT core promoter, proving the coexistence of a hybrid (> 40%) and a propeller-
type parallel-stranded (< 40%) G-quadruplexes in equilibrium (Figure 27C).[119] 
A) B)
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Figure 27. Schematic drawing of two different structural models for the hTERT 68-mer sequence 
obtained by low resolution techniques: A) model consisting of a hairpin structure, a hybrid G-quadruplex 
and a parallel one, and B) model consisting of three contiguous stacked parallel G4s. C) Schematic 
drawing of the structural models obtained by NMR for the shorter sequence taken from hTERT 
d(AGGGGAGGGGCTGGGAGGGC) in K+ solutions: on the left, the hybrid one, on the right the 
parallel one. Light blue box = (anti) guanine, violet box = (syn) guanine. (Adapted from Palumbo et 
al.[117], Chaires et al.[118] and Lim et al.[119]) 
  
A) B)
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32 
 
1.3 G-quadruplex ligands 
Small organic molecules can interact with G-quadruplex structures through non-covalent 
interactions, i.e.: i) stacking with terminal G-tetrads and/or nucleobases in loops or in the 
flanking segments, and/or ii) hydrogen bonds or electrostatic interactions with the grooves or 
loops (Figure 28).[120] 
 
Figure 28. Different binding modes for G-quadruplex ligands: A) stacking with terminal G-tetrads; B) 
hydrogen bonds or electrostatic interactions with grooves. 
Therefore, in order to bind with high affinity G-quadruplex structures, in the design of potential 
small molecule-based ligands three common features are required:[15]  
 a large aromatic core, to realize π-stacking interactions with the G-quartet surface;  
 H-bond donors and/or acceptors, to respectively bind acceptors and donors of the 
oligonucleotide; 
 positive charges, to interact with the negative phosphate groups of the DNA backbone 
through electrostatic interactions. 
Since G-quadruplex binding ligands features are also those generally required to interact with 
duplex DNA, typically ligands recognizing G-quadruplexes are able to interact also with 
double-stranded DNA.[48] Furthermore, considering that DNA in duplex form is present in the 
chromosomes in large excess with respect to G-quadruplex structures, a significant increase in 
selective recognition of G-quadruplexes vs. duplex DNA is one of the main requirements to 
allow the use of G4 ligands as potential anticancer drugs.[48] Essentially, the structural 
requirements to guarantee G-quadruplex/duplex selectivity involve steric features of ligands 
and ability to discriminate between quadruplex and duplex grooves, representing the main 
diversity elements between the two structures. 
Several small molecules were extensively studied by NMR and X-rays to obtain detailed 
information on their interaction with G-quadruplex DNA.  
A) B)
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For the pentacyclic acridinium RHPS4, G-quartets end-stacking binding mode was observed in 
the NMR structure of the complex between the ligand and the parallel human telomere 
d[(TTAGGGT)]4 G-quadruplex (Figure 29).
[121] Several studies showed that the ligand inhibits 
telomerase and induces telomere uncapping and damage. Furthermore, in vivo anticancer 
activity of RHPS4 proved to be very rapid in xenograft models and well-correlated with its 
telomerase-inhibitory properties.[122] 
 
Figure 29. A) NMR structure of the parallel-stranded DNA quadruplex d[(TTAGGGT)4] complexed 
with RHPS4 (PDB entry: 1NZM). RHPS4 is shown as a space-filled model coloured by atom type, the 
two potassium ions as violet balls and the four strands in different colours. B) Chemical structure of 
RHPS4. 
For the 3,6,9-trisubstituted acridine BRACO-19 (Figure 30), a crystal structure of its complex 
with two bimolecular human telomeric G-quadruplexes of sequence d(TAGGGTTAGGGT), 
arranged in a 5’-3’ stacking, was reported.[123] This ligand showed satisfactory G-
quadruplex/duplex selectivity and antitelomerase activity (IC50 = 115 nM).
[124] In vivo 
anticancer activity reported for BRACO-19 in xenograft models is consistent with its ability of 
inhibiting the capping and catalytic functions of telomerase.[125] 
For the tetra-N-methyl-4-pyridyl porphyrin TMPyP4 (Figure 30), high affinity for G-
quadruplex structures and ability to inhibit telomerase activity (IC50 = 6 μM) were proved.[126] 
By X-ray crystallography studies, the structure of TMPyP4 bound to the bimolecular human 
telomere G-quadruplex d(TAGGGTTAGGG) was determined.[127] The observed binding mode 
indicated that two porphyrin molecules stack on the TTA nucleotide tract, either of the external 
A)
B)
RHPS4
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loop or at the 5' region, without direct contacts with the G-quartets.[127] Contrarily to what 
observed for the telomeric sequence, TMPyP4 in the complex with a modified sequence taken 
from c-myc promoter d(TGAGGGTGGIGAGGGTGGGGAAGG) directly stacks on the upper 
quartet, as determined by NMR.[128] Interestingly, TMPyP4 showed promising anticancer 
activities in vivo, down-regulating the transcription of both c-myc oncogene and human 
telomerase reverse transcriptase.[129] 
 
Figure 30. Chemical structures of BRACO-19 and TMPyP4. 
Telomestatin is a natural metabolite extracted from Streptomyces anulatus bacteria.[130] It 
showed a high level of G-quadruplex stabilization, quadruplex/duplex selectivity and 
antitelomerase activity (IC50 = 5 nM).
[131,132] Even if it is one of the most promising G-
quadruplex ligands as anticancer drug candidate, no structure has been solved yet for G4 
complexes with telomestatin. However, a high-resolution structure of the complex between the 
telomestatin derivative and the intramolecular human telomeric G-quadruplex 
d(TTGGGTTAGGGTTAGGGTTAGGGA) was recently determined by NMR (Figure 31).[133] 
This compound interacts with the upper quartet through π-stacking and with the loops by 
electrostatic interactions. Moreover, telomestatin anticancer activity was proved in xenograft 
mouse model, without displaying any relevant toxicity.[134] 
Quinacridine-based molecules also proved to be effective G-quadruplex stabilizing ligands 
(Figure 32).[135] They interact with the tetramolecular telomeric G4 d[(TTAGGGT)4] by 
stacking with two G-quartets and by electrostatic interactions with the grooves.[135] These 
compounds showed remarkable in vitro anticancer activity with IC50 values in the 100-500 nM 
range.[135] 
Perylene diimides are characterized by a broad hydrophobic core with two external amine 
pendant groups. This family of compounds was shown to be active as telomerase inhibitors 
(IC50 = 20 µM).
[136] In particular, the perylene derivative PIPER (Figure 32) proved to induce 
TMPyP4
BRACO-19
35 
 
G-quadruplex formation in vitro from both telomeric DNA and the hTERT promoter region 
and inhibit telomerase in a dose-dependent manner.[137,138] In these experiments, the telomerase 
activity well-correlated with the level of hTERT mRNA, suggesting that the reduction in 
telomerase activity by PIPER is due to the down-regulation of hTERT expression.[137] 
 
Figure 31. A) NMR structure of the unimolecular DNA quadruplex 
d(TTGGGTTAGGGTTAGGGTTAGGGA) complexed with the telomestatin derivative here depicted 
(PDB entry: 2MB3). The backbone is represented as a ribbon. The top G-tetrad and the ligand are 
highlighted: the potassium ion is coloured in orange, the nitrogen atoms are coloured in blue, the oxygen 
atoms are coloured in yellow, the ligand is coloured in magenta and the guanine residues are coloured 
in cyan. B) Chemical structure of the telomestatin derivative used in NMR study. C) Chemical structure 
of telomestatin. (Adapted from Chung et al.[133]) 
 
Figure 32. Chemical structures of a quinacridine-based molecules and PIPER. 
Telomestatin
Telomestatin derivative
A)
B)
C)
PIPER
meta-Quinacridine
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Other interesting molecules as high affinity G-quadruplex ligands are naphthalene diimides 
(NDIs).[139,140] It has been shown that the substitution pattern of the NDI core as well as the 
chemical nature of the substituents play a crucial role in the G4 binding and selectivity toward 
G4 rather than duplex DNA.[141,142] Neidle et al. have shown that in a crystal structure π-π 
stacking of the NDI naphthalene core with the G-tetrad of telomeric G4 d[AGGG(TTAGGG)3] 
occurs at the 3’-end, while the 5’-end is stacked on the 5’-end of a second G4, resulting in the 
formation of a 5’-5’ dimer (Figure 33).[143] In addition, the NDI positively charged substituents 
protrude into the G4 grooves and interact with the phosphates of the DNA backbone (Figure 
33).[143] Recently, some NDIs have been shown to be very cytotoxic on selected cancer cell 
lines,[144] and proved to have antitumor activity in vivo in human pancreatic ductal 
adenocarcinoma (PDAC) animal models.[145] 
 
Figure 33. A) Chemical structures of naphthalene diimide based molecules. B) and C) Cartoon 
representations of the naphthalene diimide-based molecules complexed with telomeric G4 
d[AGGG(TTAGGG)3]. The end-to-end quadruplex dimers are shown, highlighting packing, topology 
and ligand binding orientation. The potassium ions are shown as blue spheres. (Adapted from Collie et 
al.[143]) 
A)
B) C)
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Contrarily to the plethora of end-stacker ligands, few groove binder ligands are known and only 
two were well-characterized: distamycin and netropsin (Figure 34).[146,147] Known as minor 
groove binders of duplex DNA, specifically recognizing AT-rich sequences by electrostatic 
interactions and hydrogen bonds,[148,149] they have been recently recognized also as G-
quadruplex groove binders.[150] By NMR studies on the tetramolecular G-quadruplex 
d[(TGGGGT)4], distamycin proved to bind in dimeric form the target G-quadruplex in two 
opposite grooves, thus forming a 4:1 complex.[151] Conversely, netropsin forms a 2:1 complex, 
probably because its doubly charged nature prevents the formation of dimers.[152] Both ligands 
expand the grooves to which they are bound, reducing the size of the opposite grooves and thus 
hampering interactions with other ligands. 
 
Figure 34. Chemical structures of netropsin and distamycin. 
Unfortunately, none of the above molecules has progressed to clinical trials because of 
unfavourable pharmacokinetics or severe off-target toxicity.[153] 
The only G-quadruplex ligands that reached advanced clinical trials are quarfloxin and CX-
5461 (Figure 35). Quarfloxin has progressed to Phase II for the treatment of 
neuroendocrine/carcinoid tumours (ClinicalTrials.gov Identifier: NCT00780663).[154] Several 
studies suggested that its mechanism of action involves disruption of the interactions between 
ribosomal DNA G-quadruplexes and the abundant protein nucleolin.[92] It is relocated to the 
nucleoplasm, where it binds the c-myc G-quadruplex, thus inhibiting c-myc expression and 
leading to cancer cells apoptosis.[92] Moreover, docking studies showed quarfloxin ability to 
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directly interact with the c-myc G4.[155] Indeed, using the sequence 
d(TGAGGGTGGGTAGGGTGGGTAA), taken from c-myc promoter, quarfloxin proved to 
intercalate between the top tetrad and the 5’-end flanking bases and direct its side chains into 
the two single-base loops (Figure 35A).[155]  
 
 
Figure 35. A) Molecular model of quarfloxin with c-myc G4 d(TGAGGGTGGGTAGGGTGGGTAA). 
Quarfloxin is shown as a space-filled model coloured by atom type and the two potassium ions as white 
balls. (Adapted from Kaiser et al.[155]) B) Chemical structure of quarfloxin. C) Chemical structure of 
CX-5461. 
Quarfloxin did not proceed past Phase II trials because of bioavailability issues, but its toxicity 
profile is very encouraging and suggests that successive optimizations could improve its 
pharmacological properties.[156] 
On the other hand, CX-5461 is currently in advanced phase I clinical trial for the treatment of 
patients with BRCA1/2 deficient tumours (ClinicalTrials.gov Identifier: NCT02719977).[157,158] 
Treatment with CX-5461 induces G4 structures formation and DNA damage in vitro. BRCA1 
and BRCA2 deficient cells, i.e. lacking essential proteins in the process of DNA damage repair, 
A) B)
Quarfloxin
C)
CX-5461
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are less competent to bypass drug stabilized G4 structure during DNA replication and less 
efficient to repair G4 associated DNA damage. As a consequence, the accumulated DNA 
damage in BRCA deficient cells leads to apoptosis. Furthermore, CX-5461 is also effective in 
tumours resistant to poly(ADP-ribose) polymerase (PARP) inhibition and/or platinum 
complexes.[157] 
All these findings prove the complete feasibility and high promise of a general therapeutic 
approach based on the use of G-quadruplex binders as anticancer drugs. However, 
notwithstanding the remarkable and conspicuous achievements in this field, no G-quadruplex 
binder has been approved as a drug yet. Therefore, for a real progress of this anticancer strategy, 
two actions are urgently required: a huge synthetic effort for the production of large libraries of 
novel classes of putative G4 ligands, associated with the development of efficient screening 
methods to quickly identify novel G4 selective ligands as optimized candidates for in vivo 
studies. 
1.4 Aims of the PhD project 
 
The final aim of this PhD project is the discovery and evaluation of novel ligands specifically 
binding to peculiar non-canonical G-quadruplex DNA structures, recognized to play crucial 
roles in regulatory regions of human genome associated with cancer.[13,156] To achieve an 
optimal recognition selectivity, which is the prerequisite to avoid off-target drug toxicity, most 
research efforts have been directed to identify structure-selective ligands, i.e. small molecules 
able to discriminate G4 vs. duplex DNA. One additional, major challenge is the discovery of 
conformation-selective ligands, i.e. able to selectively recognize specific G4 conformations 
over others.  
To this purpose, design and synthesis of a novel universal solid support for affinity 
chromatography-based High Throughput Screening (HTS) of conformation-selective G-
quadruplex ligands is here presented. The support is unique as it allows performing the on-line 
synthesis of the oligonucleotides, as well as the successive binding assays. In addition, the novel 
affinity chromatography-based methodology enabling a fast, simple and reliable screening of 
focused libraries of ligands, recently developed in our laboratories,[159,160] will be here used and 
implemented. It consists in flowing the tested compounds through the novel derivatized glass 
supports functionalized with oligonucleotides able to form conformationally different G4 
structures under proper conditions. The molecules with high affinity for the G4s are retained 
by the solid supports, while those with low affinity are eluted with a washing solution. The 
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specific interaction with a G4 structure is confirmed by inducing its denaturation, resulting in 
full release in solution of the captured ligand. All the here described steps can be quantitatively 
monitored by simple and fast UV measurements. 
Immobilization on the solid support of DNA single strands able to fold into stable hairpin 
duplex structures provides proper controls to evaluate the G4 vs. duplex DNA recognition 
specificity of the ligands. 
Conformational properties of the oligonucleotides linked to the support are also investigated to 
provide a proof-of-concept that our novel approach is a powerful tool to identify not only 
structure-selective G4-ligands, but even conformation-selective G4-ligands, thus assuring 
higher selectivity and lower toxicity of the selected molecules in view of in vivo applications. 
Validation and optimization of the affinity chromatography-based method is achieved by 
exploiting known G4 ligands, and after this step, novel focused libraries of potential 
conformation-selective G4 ligands are analyzed. 
Detailed biophysical characterization in solution of the interactions between the target DNA 
and the best ligands in terms of recognition affinity and specificity is carried out involving 
several spectroscopic techniques in a combined approach. 
Finally, in vitro tests, carried out in collaboration with specialized laboratories to assess the 
anticancer activity of the selected ligands, are also described. 
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CHAPTER 2 – PREPARATION OF A NOVEL SUPPORT FOR THE ON-
LINE SYNTHESIS OF OLIGONUCLEOTIDES 
2.1 Introduction 
The identification of selective G-quadruplex ligands, able to discriminate in vivo different 
nucleic acids conformations having crucial roles in tumours, is of paramount importance for 
the development of effective and minimally toxic anticancer drugs. Thus, considerable efforts 
are currently devoted to the design and synthesis of molecules able to selectively target G4 
structures and discriminate duplex DNA. To be effective, this huge impulse to synthesize new 
potential ligands has to be coupled with fast and reliable High Throughput Screening methods. 
In this context, a highly reproducible affinity chromatography-based method for the 
identification of putative G4-ligands has been recently described by our research group.[159,160] 
Affinity chromatography is a powerful methodology for probing small molecule-biomolecule 
interactions; it consists of simple and efficient assays based on the immobilization of the target 
molecule or, more frequently, biomolecule on a solid support, thus allowing screenings of large 
libraries in a short time. 
In a first design, the Oligo Affinity Support (OAS), a commercially available 
polystyrene/polyethylene glycol copolymer (Glen Research Corporation, Sterling, VA, 
USA),[161] functionalized with a protected adenosine monomer through the adenine exocyclic 
amino group via a stable covalent linkage, was selected to realize the binding assays (Figure 
36A).[161] The OAS resin was hence used for the assembly of the 26-mer d[(TTAGGG)4TT] 
sequence (tel26), a truncation of human telomeric DNA, able to fold, under proper conditions, 
into a unimolecular G4 (Figure 36B).[159] Due to its peculiar functionalization, the final aq. 
ammonia treatment, after the oligonucleotide solid phase synthesis, fully deprotected the 
oligomer without detaching it from the support. The above method was optimized on known 
G4 and non-G4 ligands.[159] After the optimization, the binding assay, named G4-OAS (G4 on 
Oligo Affinity Support), was applied to the screening of a focused library of 60 small organic 
molecules, selected as potential G4 groove binders by virtual screening.[160] For each of the 60 
selected molecules, the absence of unspecific binding on the nude OAS support was verified 
first, and, subsequently, the ability to interact with the G4-functionalized support. Thus, the 
binding assay allowed the identification of 7 telomeric G4 good binders out of the 60 
compounds (Figure 37).[160] Furthermore, biological assays on human tumour cells 
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demonstrated that 3 out of the 7 tested compounds were able to effectively induce a DNA 
damage response at telomeres, even at 1 µM concentration.[160] 
Though rapid, simple and effective, a major limitation emerged on using the G4-OAS assay, 
resulting from the chemical nature of the OAS support. Indeed, about one third of the 60 small 
molecules showed strong unspecific binding on the polystyrene nude OAS resin, due to stacking 
interactions between the polystyrenic resin and the aromatic cores of the ligands, making 
therefore impossible to acquire information on their binding to the G4-functionalized 
support.[160] Hence, taking into account that most known binders of G-quadruplexes share a 
common planar aromatic core, necessary to realize π-π stacking interactions with the 
nucleobases, there is a felt need to provide supports being chemically inert, differently from the 
commercially available OAS, and properly functionalized to elongate secondary structure-
forming oligonucleotides for affinity chromatography-based binding assays. 
With the aim of addressing this issue and realizing a universal support for effective screenings 
of putative conformation-selective G4 ligands, we have conceived a novel functionalization for 
Controlled Pore Glass (CPG) allowing both the on-line synthesis of fully deprotected support-
bound oligonucleotides and subsequent affinity chromatography-based binding assays.[162,163] 
For its intrinsic chemical inertness and peculiar structure, not producing stacking interactions 
with aromatic putative ligands, this solid support is expected to overcome the drawbacks 
(essentially, unspecific ligand binding) associated with the use of polystyrenic Oligo Affinity 
Support. 
 
Figure 36. A) Schematic representation of the commercially available polystyrene/polyethylene glycol 
(PS)-based Oligo Affinity Support (OAS) resin; B) OAS resin functionalized with the 26-mer 
d[(TTAGGG)4TT] sequence (tel26), a truncation of human telomeric DNA, folded into a G4 structure 
in a K+-containing solution. DMT = 4,4'-dimethoxytrityl; Ac = acetyl. (Adapted from Musumeci et 
al.[159]) 
B)A)
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Figure 37. Chemical structures of the 7 telomeric G4 ligands identified by G4-OAS assay.[160] 
 
2.2 Functionalization of Long Chain AlkylAmine-CPG with 5’-O-DMT, 3’-O-
acetylthymidine through a hexaethylene glycol spacer 
In order to prepare the novel functionalized CPG support, a hexaethylene glycol derivative 
(DMT-HEG-COOH) has been selected as the spacer and ad hoc synthesized.[162,163] To prepare 
DMT-HEG-COOH, hexaethylene glycol has been first protected at one end with the DMT 
group using standard procedures (Scheme 1A), and the resulting product 4,4'-dimethoxytrityl-
hexaethylene glycol (DMT-HEG-OH) then oxidized exploiting 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO) as catalyst, finally obtaining the DMT-HEG-COOH (Scheme 1B). 
4D
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8F
2F
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Scheme 1. Synthesis of 4,4'-dimethoxytrityl-hexaethylene glycol-COOH (DMT-HEG-COOH). A) 
Dimethoxytritylation of hexaethylene glycol to obtain its mono 4,4'-dimethoxytritylether DMT-HEG-
OH; B) Oxidation of DMT-HEG-OH to DMT-HEG-COOH. DMT-Cl = 4,4′-dimethoxytrityl chloride; 
DMAP = 4-dimethylaminopyridine; TBA-Cl = tetrabutylammonium chloride; TEMPO = 2,2,6,6-
tetramethyl-1-piperidinyloxy. 
Successively, the commercially available Long Chain AlkylAmine-CPG (LCAA-CPG) solid 
support (Figure 38)[164] has been reacted with DMT-HEG-COOH, in the presence of the 
activators of the carboxylic functional group N,N’-dicyclohexylcarbodiimide (DCC) and 1- 
hydroxybenzotriazole (HOBt) (Scheme 2).[162,163] 
 
Figure 38. Commercially available Long Chain AlkylAmine-CPG (LCAA-CPG) solid support.[164] 
Thus, the CPG solid support has been functionalized with the hexaethylene glycol spacer bound 
through an aliphatic amide function and protected at the terminal hydroxyl moiety with the 4,4’-
dimethoxytrityl (DMT) protecting group. 
In the synthetic protocol, hexaethylene glycol has been chosen as the spacer because of its good 
solubility properties in both apolar and polar solvents, which make it suitable for both 
oligonucleotide synthesis, carried out in organic solvents, and affinity chromatography-based 
assays, carried out in aqueous solutions. Indeed, its length and flexibility guarantee 
minimization of possible steric effects with the solid matrix during both the oligonucleotide 
elongation and binding assays.[165] Remarkably, the spacer also ensures that, once assembled, 
the linked oligonucleotide is kept at an appropriate distance from the solid support, so that in 
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principle it has sufficient conformational freedom to adopt its preferred secondary structure, as 
if in solution. 
After CPG derivatization with the spacer, the DMT group has been removed by acidic treatment 
and the resulting support 1 has been functionalized with 5’-O-DMT, 3’-O-acetyl-thymidine – 
synthesized by standard acetylation of commercially available 5’-O-DMT-thymidine – through 
a Mitsunobu reaction, using triphenylphosphine and diethyl azodicarboxylate (DEAD) as 
activators (Scheme 2).[162,163,166] 
 
 
Scheme 2. Functionalization of LCAA-CPG with 5’-O-DMT, 3’-O-acetyl-thymidine through a 
hexaethylene glycol spacer. Ac = acetyl; DCC = N,N′-dicyclohexylcarbodiimide; DEAD = diethyl 
azodicarboxylate; DMF = N,N-dimethylformamide; DMT = 4,4’-dimethoxytrityl; HOBt = 1-
hydroxybenzotriazole; TCA = trichloroacetic acid; THF = tetrahydrofuran. 
In particular, we have incorporated as first monomer on the support a pyrimidine nucleoside, 
and not a purine, as in functionalized OAS resin, to avoid undesired, unspecific interactions in 
the successive binding assays. Indeed, we reasoned that purines should be discarded in the first 
functionalization step since they might generate additional stacking interactions with both the 
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tested ligands and the oligonucleotide sequence of interest, somehow affecting its conformation 
and thus the binding assays. Following this procedure, we obtained a CPG solid support 
functionalized with a DMT-protected nucleoside attached through the nucleobase (support 2) 
so that, after acidic treatment allowing the DMT removal, the 5’-position is available for 
oligonucleotide elongation. Moreover, the chemically stable bond between the spacer and the 
first nucleoside guarantees, once the oligonucleotide chain elongation is completed, that the 
oligonucleotides can be fully deprotected without detaching them from the solid support.[162,163] 
Standard capping treatments with acetic anhydride in pyridine have been introduced in the 
synthetic protocol to block both the unreacted amino groups on the support after DMT-HEG-
COOH incorporation and the unreacted hydroxyl groups on 1 after the Mitsunobu reaction. 
Spectrophotometric DMT tests, quantifying the DMT cation released upon acidic treatment of 
weighed samples of CPG, allowed monitoring the yield of each reaction step. Overall, this 
synthetic route provided solid support 2 with an average DMT functionalization of 0.023 
meq/g.[162,163] 
2.3 Synthesis of oligonucleotide models on the CPG support 
2.3.1 Assembly and deprotection of a hairpin duplex-forming oligonucleotide covalently 
attached to the CPG support 
The main requirement for a G4 ligand to be a potential anticancer drug in targeted therapies is 
the ability to strongly discriminate G4 vs. duplex DNA. Thus, we have here synthesized a 
duplex-functionalized solid support, as a negative control allowing assessing the ability of 
putative ligands to discriminate non-canonical DNA conformations vs. duplex DNA.  
Bimolecular duplex systems obtained by elongation of a single strand on the support, followed 
by hybridization to its complementary strand – used in the first design of this assay (G4-OAS) 
– proved to be not completely stable in the conditions used for the binding assays, partially 
releasing the complementary strand in solution at each assay and thus providing not fully 
reliable results.[160] To overcome this limitation, we have here chosen, for the elongation on 
support 2, the sequence d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27) as the model, 
because of its ability to fold into a stable hairpin unimolecular duplex under proper conditions, 
well-mimicking a double-stranded DNA. Indeed, it consists of two Dickerson dodecamer tracts 
– a very well-known model for B-DNA duplex[167–169] – connected by a TTT loop.  
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The length and base composition of the loop have been selected on the basis of the following 
observations:  
 loops longer than 3 residues can promote the formation of Z-DNA unimolecular duplex 
structures;[170] 
 among the loops containing 1, 2 and 3 residues, the highest thermal stability is observed 
in the case of a 3 residues loop;[170,171] 
 the nucleobases present in the loop should minimally affect the binding of the putative 
ligands to the duplex; thus, pyrimidine nucleosides are preferred since purines can 
produce additional stacking interactions; 
 the nucleobases not requiring protecting groups (as is the case of thymines) make easier 
and speed up the final deprotection step in solid phase oligonucleotide syntheses. 
The hairpin duplex-forming oligonucleotide has been assembled on support 2 using standard 
phosphoramidite chemistry (Scheme 3), including the following steps: 
 deprotection of the 5’-OH group by removal of the DMT protecting group of the 
nucleoside anchored to the solid support by treatment with 2% trichloroacetic acid 
(TCA) solution;  
 coupling of the 5’-OH position available for oligonucleotide elongation with a 
nucleoside 3’-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidite monomer in the 
presence of the standard phosphoramidite activator 5-ethylthio-1H-tetrazole (ETT) to 
obtain a phosphite triester linkage; 
 capping of the unreacted 5'-OH groups on the solid support by using a mixture of acetic 
anhydride and N-methylimidazole in pyridine; 
 oxidation of the phosphite triester linkage to phosphate triester moiety by using a 
solution of I2/H2O/pyridine in THF; 
 repetition of the coupling, capping and oxidation steps for a number of times 
corresponding to the number of nucleotides contained in the target oligonucleotide 
sequence. 
The coupling efficiency was monitored after each synthetic cycle by spectrophotometric 
measurements of the DMT cation, removed before each coupling step by standard acidic 
treatment. Considering the number of couplings (27 bases) and the average yield per cycle of 
99.2%, the overall yield was determined to be 80%, corresponding to a final functionalization 
of 0.018 meq/g.[162,163] 
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Scheme 3. Schematic illustration of the synthesis cycle of oligodeoxyribonucleotides on novel 
derivatized CPG support. Ac = acetyl; ACN = acetonitrile; DCM = dichloromethane; DMT = 4,4’-
dimethoxytrityl; ETT = 5-ethylthio-1H-tetrazole; MI = N-methylimidazole; TCA = trichloroacetic acid; 
THF = tetrahydrofuran. 
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Aiming at completely deprotecting the oligonucleotide without detaching it from the solid 
support, two different deprotection protocols have been tested. Two batches of oligonucleotide-
bound support – still bearing the terminal 5’ DMT group – were treated in parallel with 30% 
ammonium hydroxide (NH4OH) at r.t. for 24 h, and with 30% ammonium hydroxide/40% 
methylamine 1:1, v/v (AMA) at r.t. for 2 h, respectively. The resulting supports were then 
washed several times with water until neutralization. To verify if the final basic treatment 
promoted even partial detachment of the oligonucleotide from the solid supports, the eluates 
relative to NH4OH and AMA deprotection were collected, taken to dryness, redissolved in H2O 
and analyzed by UV spectroscopy. In both cases, the presence of nucleotidic material was 
observed. This is probably due to silica instability under basic solutions: indeed, pure silica 
partially dissolves under these conditions.[172] The DMT test was then performed on dried and 
weighed samples of the two CPG batches, allowing the determination of the final 
functionalization for hairpin duplex-bound supports, which resulted to be 0.005 meq/g (30% 
oligonucleotide attached to the support) and 0.011 meq/g (60% oligonucleotide attached to the 
support) after the NH4OH and AMA deprotection treatment, respectively.
[162] Taking for 
granted that the NH4OH treatment, carried out under standard conditions, resulted in the full 
deprotection of the oligonucleotide bound to the support,[173] with the aim of evaluating if also 
the AMA deprotection treatment went to completeness, we analyzed the eluate relative to AMA 
deprotection by HPLC. As shown in figure 38, upon AMA deprotection, only two major species 
were present in the eluate: one peak at 10.9 min retention time, i.e. the full-length 
oligonucleotide detached, which had accidentally lost its 5’-DMT protecting group; and one 
peak at 14.0 min, identified as the DMT-ON, full-length oligonucleotide detached. Indeed, upon 
detritylation of the latter species, only one peak, with the same retention time of the first 
product, appeared in the HPLC chromatogram. Furthermore, we compared the experimental 
data for known duplex ligands obtained from our affinity chromatography-based binding assay 
on two oligonucleotide-bound supports previously treated using the mentioned different 
deprotection methods. For all the tested ligands, the results were always in good agreement 
within the experimental error. Overall, these results – even if indirectly – proved that the 2 h 
AMA treatment guarantees complete deprotection for the oligonucleotide bound to support 2, 
in accordance with current protocols of oligonucleotide synthesis, sensibly reducing the 
detachment of the synthesized oligonucleotide from the CPG support compared to the NH4OH 
treatment.[163] 
Considering that the amount of oligonucleotide bound to the support cannot be too low, thus 
allowing the use of small amounts of support for each binding test, nor too high, to avoid steric 
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hindrance due to high functionalization density in the binding assays, the final functionalization 
obtained by our optimized protocol for the on-line oligonucleotide synthesis and deprotection 
proved to be fully suitable for the successive binding assays. 
 
 
Figure 38. HPLC profile of the eluate relative to ammonium hydroxide/methylamine (AMA) 
deprotection of the hairpin duplex-bound support. 
 
2.3.2 Assembly and deprotection of G4-forming oligonucleotides covalently attached to 
the CPG support 
Following the same protocol adopted for the hairpin duplex-forming oligonucleotide, a 
truncation of human telomeric DNA of sequence d[(TTAGGG)4TT] (tel26)
[21] and the 22-mer 
d(AGGGAGGGCGCTGGGAGGAGGG) (ckit1)[110,112] taken from the c-kit oncogene 
promoter, able to fold in proper conditions into unimolecular G4s, have been assembled on 
support 2.[162,163] The coupling efficiency was monitored after each synthetic cycle by 
spectrophotometric measurements of the DMT cation, removed before each coupling step by 
standard acidic treatment. Considering the number of couplings and the average yields per cycle 
of 99.4% and 99.9% for tel26 and ckit1 respectively, the overall yields were determined to be 
86% and 98%, corresponding to a final functionalization of 0.020 meq/g and 0.022 meq/g, 
respectively. After the coupling cycles, aiming at fully deprotecting the oligonucleotides, the 
solid supports were treated with 30% ammonium hydroxide/40% methylamine 1:1, v/v (AMA) 
at r.t. for 2 h. The resulting supports were then washed with water until neutralization. DMT 
tests, performed on dried and weighed samples of the supports, allowed determining the final 
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functionalization for the support-bound G-quadruplex-forming oligonucleotides, which was 
0.012 meq/g and 0.013 meq/g, respectively for tel26 and ckit1, after the AMA deprotection 
treatment. 
2.4 Experimental section 
2.4.1 Synthesis of 4,4’-dimethoxytrityl-hexaethylene glycol-COOH (DMT-HEG-COOH) 
Hexaethylene glycol (887 µL, 3.54 mmol, commercially available from Sigma-Aldrich) was 
reacted with a mixture of 4,4′-dimethoxytrityl chloride (DMT-Cl, 718 mg, 2.12 mmol) and 4-
dimethylaminopyridine (DMAP, 26 mg, 0.212 mmol) in anhydrous pyridine (3 mL) at r.t. 
overnight. The resulting product (DMT-HEG-OH) was purified by flash chromatography on a 
silica gel column eluted with increasing amounts of CH3OH in CH2Cl2, from 0% to 2%, 
containing 1% of triethylamine (recovered yield = 72%). The identity of the purified product 
was confirmed by 1H NMR (C6D6, 400 MHz): δ 7.77 (d, 2H, DMT H2”), 7.55 (d, 4H, DMT H2 
and H2’), 7.19 (t, 2H, DMT H3”), 7.07 (t, 1H, DMT H4”), 6.78 (d, 4H, DMT H3 and H3’), 
3.64 (t, 2H, HOCH2), 3.59-3.28 (complex signals, 22H, 5 x OCH2CH2 and HOCH2CH2), 3.32 
(s, 6H, 2 x OCH3), 2.67 (br, 1H, OH). 
DMT-HEG-OH (450 mg, 0.77 mmol) was then reacted with a mixture of 2,2,6,6-tetramethyl-
1-piperidinyloxy (TEMPO, 19 mg, 0.12 mmol), KBr (20 mg, 0.17 mmol), tetrabutylammonium 
chloride (TBA-Cl, 46 mg, 0.17 mmol), NaHCO3 (1.0 mL of an aq. satd. solution), NaClO (2.5 
mL) and NaCl (1.0 mL of an aq. satd. solution) at r.t. for 4 h. The resulting product (DMT-
HEG-COOH) was purified by flash chromatography on a silica gel column eluted with 
increasing amounts of CH3OH in CH2Cl2, from 5% to 10%, containing 1% of triethylamine 
(recovered yield = 62%). The identity of the purified product was confirmed by 1H NMR (C6D6, 
400 MHz): δ 8.11 (br, 1H, COOH), 7.71 (d, 2H, DMT H2”), 7.69 (d, 4H, DMT H2 and H2’), 
7.54 (t, 2H, DMT H3”), 7.52 (t, 1H, DMT H4”), 7.22 (d, 4H, DMT H3 and H3’), 3.88 (s, 2H, 
CH2CO), 3.34-3.06 (complex signals, 20H, 5 x OCH2CH2), 3.21 (s, 6H, 2 x OCH3). 
2.4.2 Functionalization of LCAA-CPG with the hexaethylene glycol spacer DMT-HEG-
COOH 
LCAA-CPG 1000 Å (155 mg, 0.069 meq/g, 10.7 mmol; Link Technologies, Bellshill, UK)[164] 
was left in contact with a mixture of DMT-HEG-COOH (64 mg, 107 mmol), N,N’-
dicyclohexylcarbodiimide (DCC, 22 mg, 107 mmol) and 1-hydroxybenzotriazole (HOBt, 14.5 
mg, 107 mmol) in anhydrous DMF (500 µL) at r.t. overnight. After removing the excess of the 
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reactants from the resin by exhaustive washings with DMF, CH3OH, AcOEt, n-hexane and 
CH2Cl2, the support was taken to dryness under reduced pressure. DMT tests performed on 
dried and weighed samples of the resulting support allowed determining the incorporation yield 
of DMT-HEG-COOH onto the CPG support, which resulted to be 74% (0.051 meq/g). The 
solid support was then treated with a capping solution, consisting of a mixture of acetic 
anhydride/pyridine (1:1, v/v), at r.t. for 4 h to block the unreacted amino groups, followed by 
exhaustive washings with CH2Cl2, CH3OH, and again CH2Cl2. Finally, the DMT protecting 
group was removed by treatment with 3% trichloroacetic acid (TCA) in CH2Cl2 giving support 
1. The DMT cation collected after this acidic treatment and quantified by UV measurements 
gave a functionalization of 0.051 meq/g, in agreement with the previous value. 
2.4.3 Synthesis of 5’-O-DMT, 3’-O-acetyl-thymidine 
5’-O-DMT-thymidine (94 mg, 0.17 mmol, Sigma-Aldrich) was reacted with 1 mL of a mixture 
of acetic anhydride/pyridine (1:1, v/v) at r.t. for 2 h. The resulting product was taken to dryness 
under reduced pressure, dissolved in CH2Cl2 and purified by water/CH2Cl2 extraction, finally 
giving pure 5’-O-DMT, 3’-O-acetyl-thymidine (87 mg, 0.15 mmol). The identity of the purified 
product was confirmed by 1H NMR (C6D6, 400 MHz): δ 8.81 (br, 1H, NH thymine residue), 
7.62-6.82 (complex signals, 13H, DMT aromatic protons), 7.51 (s, 1H, H6 thymine residue), 
6.64 (t, 1H, H1’), 5.42 (s, 1H, H4’), 4.01 (s, 1H, H3’), 3.54 (s, 2H, H5’), 3.36 (s, 6H, 2 x OCH3), 
2.18 (d, 2H, H2’), 1.59 (s, 6H, thymine CH3 and CH3COO). 
2.4.4 Functionalization of support 1 with 5’-O-DMT, 3’-O-acetylthymidine 
Diethyl azodicarboxylate (DEAD, 118 µL, 0.75 mmol) was added to a mixture of support 1 
(145 mg, 0.051 meq/g, 7.4 mmol), 5’-O-DMT, 3’-O-acetyl-thymidine (87 mg, 0.15 mmol) and 
triphenylphosphine (PPh3, 122 mg, 0.47 mmol) in THF (1.5 mL) and left at r.t. overnight. After 
exhaustive washings with CH2Cl2, CH3OH, CH3CN and again with CH2Cl2, the resulting 
support 2 was dried under reduced pressure. Incorporation yield of 5’-O-DMT, 3’-O-
acetylthymidine was 45% (0.023 meq/g), as determined by DMT tests performed on dried and 
weighed samples of support 2. Reiteration of this reaction did not allow increasing the 
functionalization. A capping reaction with acetic anhydride in pyridine (1:1, v/v) was then 
performed at r.t. for 4 h to block unreacted hydroxyl groups on the support. After exhaustive 
washings with CH2Cl2, CH3OH, and again CH2Cl2, the functionalization, as determined by 
DMT test performed on a dried and weighed sample of the support, proved to be 0.023 meq/g, 
in agreement with the previous value. 
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2.4.5 Assembly and deprotection of hairpin duplex- and G4-forming oligonucleotides on 
support 2 
The automated solid phase oligonucleotide synthesis was performed on an Applied Biosystem 
3400 DNA/RNA synthesizer, using the following reagents: amidite diluent (anhydrous 
CH3CN); deblocking mix (TCA/CH2Cl2); activator (ETT/CH3CN); cap mix A (Ac2O/THF); 
cap mix B (MI/Py/THF); oxidizing solution (I2/H2O/Py/THF). The oligonucleotides of 
sequence d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27), d[(TTAGGG)4TT] (tel26) 
and d(AGGGAGGGCGCTGGGAGGAGGG) (ckit1) were assembled on support 2, using a 1 
µmol-scale protocol (“DMT ON”). The coupling efficiency was monitored by 
spectrophotometric measurements of the DMT cation, removed before each coupling step by 
acidic treatment with 2% TCA in CH2Cl2. Considering the number of couplings and the average 
yield per cycle of 99.2%, 99.4% and 99.9% respectively for ds27, tel26 and ckit1, the overall 
yield was determined to be 80%, 86% and 98% respectively, corresponding to a final 
functionalization of 0.018, 0.020 and 0.022 meq/g. At the end of each synthesis, small samples 
of each solid support were treated with either 30% ammonium hydroxide (NH4OH) at r.t. for 
24 h or 30% ammonium hydroxide/40% methylamine 1:1, v/v (AMA) at r.t. for 2 h. The 
resulting supports were then washed several times with water until neutralization. DMT tests, 
performed on dried and weighed support samples, allowed determining the final 
functionalizations for the support-bound ds27, tel26 and ckit1 oligonucleotides, which were, 
respectively, 0.005, 0.006 and 0.007 meq/g, after the NH4OH deprotection treatment, and 0.011, 
0.012 and 0.013 meq/g, after the AMA deprotection treatment. Eluates of both deprotection 
treatments were analyzed by HPLC on a Phenomenex analytical C18 column (250 x 4 mm) 
using the gradient: 3-40% solution B in A over 15 min (solution A: 0.1 M triethylammonium 
acetate, pH = 7.0; solution B: CH3CN; flow rate: 1 mL/min). 
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CHAPTER 3 – G4-CPG ASSAY: AN AFFINITY CHROMATOGRAPHY-
BASED METHOD FOR THE SCREENING OF CONFORMATION 
SELECTIVE G-QUADRUPLEX LIGANDS 
3.1 General procedure for the binding assays on the novel functionalized CPG supports 
The general procedure adopted for the binding assays is as follows: a weighed amount of the 
oligonucleotide-bound CPG supports, synthesized as described above, is left in contact with a 
ligand solution of known concentration in a polypropylene column equipped with a 
polytetrafluoroethylene frit, a stopcock and a cap (Figure 39).  
 
Figure 39. Assay equipment. PP = polypropylene; PTFE = polytetrafluoroethylene. 
After incubation on a vibrating shaker, the support is eluted with defined volumes of a washing 
solution and all the eluted fractions are separately analyzed by UV measurements (Figure 40). 
From UV measurements of the fractions eluted from the nude CPG  ̶  obtained upon detritylation 
of support 2 (Figure 41A)  ̶ the amount of ligand unspecifically adsorbed on the support is 
evaluated. In turn, UV analysis of the fractions recovered from G4- and hairpin duplex-
functionalized supports (Figures 41B, 41C and 41D) allows estimating the amount of ligand 
bound to the support carrying the secondary structure-forming oligonucleotides (tel26, ckit1 
and ds27). In all cases, the amount of bound ligand is calculated by subtracting the ligand eluted 
upon washing, derived by direct UV measurements, from the ligand amount initially loaded on 
the support. Moreover, as further control, the direct measurement of the bound ligand is 
obtained by treating the support with a releasing solution, followed by UV analysis of the eluted 
fractions (Figure 40). In order to allow the correct G4s and hairpin duplex refolding after this 
treatment, and thus reuse the same functionalized CPG batch for subsequent binding assays, the 
Cap
Stopcock
PTFE frit
CPG support
PP column
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support is resuspended in the washing solution and then subjected to an annealing procedure, 
by taking it at 75 °C for 5 minutes, followed by slow cooling to room temperature (Figure 40).  
 
Figure 40. General scheme depicting the overall procedure used in the here described binding assays.[162] 
CPG = Controlled Pore Glass. 
3.2 Monitoring of possible unspecific binding on the nude CPG support 
Aiming at checking the absence of possible interferences of our modified CPG support in the 
successive binding assays, nude CPG was left in contact with known concentration solutions of 
different molecules, having either good or no affinity for G4 structures. In detail, cationic 
porphyrin 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin (TMPyP4),[127] thiazole orange 
(TO),[174] resveratrol,[175] two acridine derivatives, i.e. 3,11-difluoro-6,8,13-trimethyl-8H-
quino[4,3,2-kl]acridinium methosulfate (RHPS4)[176] and acridine-9-carboxylic acid (9-Acr-
COOH),[177] along with two pyrrole-containing polyamide analogs, i.e. netropsin[152] and 
distamycin,[150] have been used as model ligands in our binding assays (Figure 42). 
Furthermore, also a diverse set of compounds chosen from a library of virtual screening-
selected molecules – previously analyzed on our G4-OAS support and proved to be strongly, 
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unspecifically retained by the polystyrenic OAS[160] – has been tested on the novel 
functionalized CPG support (Figure 43). 
 
Figure 41. A) Chemical structure of LCAA-CPG functionalized with 3’-O-acetyl-thymidine through a 
hexaethylene glycol spacer, here named nude CPG. B), C) and D) Schematic representations of tel26-, 
ckit1- and ds27-bound support 2. 
 
 
 
 
 
 
 
Nude CPG
tel26-2 ds27-2
A)
B) C) D)
ckit1-2
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Figure 42. Chemical structure of the molecules here used as models in our binding assays having either 
good or no affinity for G4 structures. 
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Figure 43. Chemical structure of compounds 7A, 5B, 10B, 1C, 3C, 7D, 7E and 7F, selected from a 
library of putative ligands previously screened employing the G4-OAS assay.[160] 
 
Using the above protocol, after incubation on a vibrating shaker, the surnatant was allowed 
flowing through the support and the nude CPG (Figure 41A) was washed with several volumes 
of the washing solution, i.e. 50 mM KCl, 10% DMSO, 10% CH3CH2OH in H2O. The 
composition of the washing solution was optimized so to achieve the best results in terms of 
solubility of the tested ligands, minimization of undesired absorption of the ligands on the assay 
equipment, and capacity of the oligonucleotide sequences to form stable secondary 
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structures.[162] In detail, K+ ions are essential for a correct folding and stabilization of the G4 
structures bound to the supports, the small percentage of DMSO is made necessary to allow a 
full solubilization of the tested molecules, and, finally, the small percentage of ethanol to avoid 
undesired absorption of the tested ligands on the assay equipment, i.e. the polypropylene 
column and the PTFE frit. However, the total percentage of organic solvent was kept within 
20% to guarantee the solubility of tested ligands without perturbing the correct folding of the 
support-bound oligonucleotides. 
The results of the binding assays on the ligands tested on the nude CPG are shown in Table 1. 
These data were compared with those obtained on the nude OAS (detritylated OAS resin, Figure 
36A). 
Table 1. Summary of the binding assay data obtained for nude CPG and OAS through UV 
measurements. 
Ligand 
Recovered ligand from 
nude CPG (%)a,b 
Recovered ligand from 
nude OAS (%)a,b 
Distamycin 96 93 
Netropsin 95 100 
Resveratrol 98 74 
RHPS4 93 93 
TO 92 90 
TMPyP4 85 97 
9-Acr-COOH 100 95 
7A 99 35 
5B 97 9 
10B 100 79 
1C 96 29 
3C 100 34 
7D 100 27 
7E 96 92 
7F 100 92 
aRecovered ligands were obtained using the washing solution: 50 mM KCl, 10% 
DMSO, 10% CH3CH2OH 
bThe amounts of recovered ligands are expressed as percentage of the quantity 
initially loaded on the support; the errors associated with the reported percentages 
are within ± 2% 
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Remarkably, the ligands were generally recovered in higher amounts from nude CPG, requiring 
smaller volumes of the washing solution for their quantitative recovery compared to nude OAS 
(Δvolume ~ 3 mL).[162] Noteworthy, a significant reduction of unspecific binding to the solid 
support was observed for all the compounds taken from the library of 60 virtual screening-
selected molecules previously investigated on G4-OAS. Among others, a significant example 
is compound 5B: contrarily to what observed on nude OAS resin, for which compound 5B had 
shown high affinity (nude OAS bound ligand = 91%), in the experiments with nude CPG 
complete absence of binding was found (nude CPG bound ligand = 3%).  
Overall, these results proved that the novel support has low-to-null unspecific interactions with 
the tested model ligands, in contrast to previously used OAS. 
3.3 Optimization and validation of the CPG-based method to identify G4-selective ligands 
Before performing the binding assays on G4- and hairpin duplex-functionalized supports, we 
first verified that the model oligonucleotides chosen for the experiments on the CPG supports 
maintain their preferred conformations in the solution adopted for the binding experiments (50 
mM KCl, 10% DMSO, 10% CH3CH2OH). Thus, we analyzed in solution the three selected 
oligonucleotide sequences, i.e. tel26, ckit1 and ds27, by UV and CD spectroscopy. 
Particularly, Thermal Difference Spectra analysis confirmed that tel26 and ckit1, showing the 
typical minimum for G-quadruplexes at 295 nm, form G4 structures, while ds27 a duplex 
structure (Figure 44, left).[178,179] Furthermore, CD spectra showed that tel26 folds into a hybrid-
type G4,[21,83] ckit1 forms a parallel G4,[110] and ds27 adopts a B-DNA conformation,[180] also 
in the here used experimental solution (Figure 44, right). These experiments proved that the 
addition of small amounts of organic solvents in our binding assays (10% DMSO, 10% 
CH3CH2OH), necessary to ensure optimal ligand solubility, does not affect the overall 
conformational behaviour of the studied oligonucleotides. 
Moreover, in order to verify if the TTT loop in ds27 somehow perturbs the duplex conformation 
adopted by the Dickerson dodecamer d(CGCGAATTCGCGC), circular dichroism spectra in 
the here used conditions were recorded also on a sample of this solution. The unimolecular 
hairpin duplex ds27 showed the same CD features as the bimolecular Dickerson dodecamer, 
however with an enhanced structuration (Figure 45), proving to be a good B-DNA duplex 
model. 
CD-melting experiments were then performed for all the investigated oligonucleotides (Figure 
46). Melting temperatures of 60 °C and 72 °C were found for tel26 G4 and ckit1 G4, 
respectively, consistently with literature data. 
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Figure 44. Thermal Difference Spectra (left) for A) tel26, B) ckit1 and C) ds27 sequences dissolved at 
2 µM concentration in 50 mM KCl, 10% DMSO, 10% CH3CH2OH aq. solutions, and related CD spectra 
(right). 
Remarkably, the hairpin duplex gave a Tm of 73 °C, proving to be more stable than the 
bimolecular duplex, showing a Tm of 55 °C under the same conditions, with a ΔTm of 18 °C. 
These results validate the chosen oligonucleotide sequences as stable G4 and duplex models in 
solution. All the here collected data showed that the studied oligonucleotides, after annealing, 
fold into, respectively, stable G-quadruplexes and hairpin-duplex also under the solution 
conditions used for our binding assays and this – taking into account the presence of a long and 
flexible hexaethylene glycol spacer keeping apart the biomolecule from the solid support – 
could be reasonably valid also for the oligonucleotides attached to the CPG . 
A)
B)
C)
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Figure 45. Circular dichroism spectra for 2 µM solutions of unimolecular hairpin duplex ds27 (solid 
line) and bimolecular duplex formed by Dickerson dodecamer (dotted line) in 50 mM KCl, 10% DMSO, 
10% CH3CH2OH aq. solutions. 
 
Figure 46. CD melting curves for 2 µM solutions of: A) tel26, B) ckit1, C) ds27 and D) Dickerson 
duplex in 50 mM KCl, 10% DMSO, 10% CH3CH2OH aq. solutions. CD melting curves were recorded 
at 290 nm (A), 263 nm (B), and 251 nm (C and D). 
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After these preliminary experiments in solution, the set of compounds here used as models of 
good or poor G4-binding ligands (TMPyP4, RHPS4, TO, netropsin, distamycin, resveratrol and 
9-Acr-COOH) were tested on G4- and hairpin duplex-functionalized supports 2 (Figure 41B, 
41C and 41D) and the results compared with those obtained on the OAS support. Before 
performing the binding assays, oligonucleotide-functionalized supports were subjected to an 
annealing procedure in the washing solution by taking them at 75 °C for 5 minutes, followed 
by slow cooling to room temperature (Figure 40). Higher temperatures typically used for 
annealing procedures in solution, i.e. 85-95 °C, were avoided to prevent the detachment of even 
tiny oligonucleotide amounts from the supports. After 16 h at 4 °C, the supernatants on the 
supports, collected along with several washings, were checked by UV analysis. The 
quantification of the detached oligonucleotide amounts was obtained by measuring at 85 °C the 
absorbance at λ = 260 nm, using the molar extinction coefficients calculated for the unstacked 
oligonucleotide.[181] From these analyses, we estimated that up to a maximum of 0.1-0.5% of 
oligonucleotide material was detached from the CPG after each annealing procedure. These 
results show that this support is particularly more advantageous than polystyrene-based resins 
for which, after each annealing, detachment of 0.5-1.0% of nucleotide material was always 
observed. Indeed, less oligonucleotide is detached upon thermal treatments, more binding 
assays can be performed on the same batch of support.[162] 
G4- and hairpin duplex-functionalized supports 2 were then treated, analogously to the control 
nude CPG, with solutions of the ligands dissolved at known concentration in the washing 
solution. After incubation, the supports were treated with the washing solution several times 
and the eluted fractions were collected and analyzed by UV measurements. To allow the 
complete release in solution of the oligonucleotide-bound ligands, the supports were then eluted 
with the releasing solution (Figure 40). The amounts of bound ligands directly measured after 
treatment with the releasing solution were in good agreement with those previously determined 
as a difference with respect to the unbound amounts recovered by the washing solution. The 
composition of the releasing solution, i.e. 2.5 M CaCl2, 15% DMSO in H2O, was optimized on 
the basis of its ability to obtain a fast and quantitative recovery of the bound ligand, as a 
consequence of the oligonucleotide denaturation induced by high concentration of divalent 
cations and/or organic solvents.[162] For ligands not fully soluble in the Ca2+-containing solution, 
pure DMSO was used as alternative, and even stronger, releasing solution.  
The amounts of bound ligand measured on the tel26-2 support were in general agreement with 
those determined for the tel26-OAS support (Table 2). Moreover, the percentages of bound 
ligand on the tel26-OAS support were in some cases overestimated, e.g. for resveratrol, 
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accounting for the unspecific interactions of the tested ligands with the nude OAS resin. Thus, 
the experimental data acquired on tel26-2 support proved to be much cleaner and more reliable 
than those obtained on tel26-OAS. Remarkably, as additional evidence that the novel 
synthesized support has less unspecific interactions with the model ligands than previously used 
polystyrenic tel26-OAS, we found that the ligands tested on the tel26-2 and ds27-2 supports 
could be recovered in higher amounts (Tables 2 and 3) requiring smaller volumes of releasing 
solution than in the case of tel26-OAS (Δvolume ~ 3 mL).[162] 
Moreover, the retention order observed for both tel26-2 and ds27-2 supports (Tables 2 and 3) 
well reflects the affinity trend of the ligands tested in solution for the human telomeric G4 and 
the Dickerson duplex,[150,152,174–177,182,183] confirming the general reliability of the support 2-
based method. 
Adopting the same protocol used for tel26-2 and ds27-2, ckit1-functionalized support (ckit1-2) 
was also tested in its ability to bind known ligands with different affinity for G4s. In particular, 
thiazole orange and resveratrol were selected as representative molecules of a strong and a very 
weak G4 binder,[174,175] respectively. The obtained data, showing high affinity (bound ligand = 
97±2%) for TO and low-to-null affinity (bound ligand = 4±2%) for resveratrol, verified the 
efficacy also of ckit1-2.  
In order to allow the correct G4s and hairpin duplex refolding after the denaturation induced by 
the releasing solution, and thus reuse the same batch of support for subsequent binding assays, 
the supports were resuspended in the washing solution and then left annealing. The reversibility 
of the process of folding/unfolding of the G4s and hairpin duplex allows effectively recycling 
the same support for multiple, sequential experiments; indeed, a large number of binding assays 
could be performed on the same batch of support without losing in efficiency and reliability of 
the analyses. In detail, for its lower unspecific binding and higher thermal stability, typically 
the same batch of functionalized CPG could be used to perform more than 50 experiments, i.e. 
ca. three times the number of binding assays generally carried out on the tel26-OAS resin.[162] 
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Table 2. Summary of the binding assay data obtained for tel26-2 and tel26-OAS through UV 
measurements. 
  Support 2         OAS 
Ligand 
tel26-bound 
ligand (%)a,c 
Recovered ligand 
from tel26-2 (%)b,c 
tel26-bound 
ligand (%)a,c 
Recovered ligand 
from tel26-OAS (%)b,c 
TMPyP4 100 98 99 90 
RHPS4 99 100 96 93 
TO 97 92 98 88 
Netropsin 86 67 93 91 
Distamycin 22 96 28 89 
Resveratrol 4 96 22 96 
9-Acr-COOH 0 - 1 - 
atel26-bound ligand (%) is calculated as a difference from the unbound ligand, recovered with the 
washing solution 50 mM KCl, 10% DMSO, 10% CH3CH2OH. 
bData on % of ligand recovered from tel26-2 and ligand recovered from tel26-OAS are obtained using 
as releasing solution either 2.5 M CaCl2, 15% DMSO or 100% DMSO. 
cThe amounts of bound/recovered ligands are expressed as percentage of the quantity initially loaded on 
the support; the errors associated to the percentages are within ± 2%. 
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Table 3. Summary of the binding assay data obtained for ds27-2 through UV measurements. 
                      Support 2 
Ligand 
ds27-bound 
ligand (%)a,c 
Recovered ligand 
from ds27-2 (%)b,c 
Netropsin 52 98 
TO 51 96 
TMPyP4 50 99 
RHPS4 48 100 
Distamycin 36 93 
Resveratrol 1 99 
9-Acr-COOH 0 100 
aThe amount of ds27-bound ligand (%) was calculated as a 
difference from the unbound ligand recovered with the 
washing solution 50 mM KCl, 10% DMSO, 10% 
CH3CH2OH. 
bThe ligand recovered from ds27-2 (%) was obtained using 
as releasing solution either 2.5 M CaCl2, 15% DMSO or 
100% DMSO. 
cThe amounts of bound/recovered ligands are expressed as 
percentage of the quantity initially loaded on the support; 
the errors associated to the reported percentages are within 
± 2%. 
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3.4 Characterization of the conformations adopted by the oligonucleotide models linked 
to the CPG support 
Main prerequisite for an affinity chromatography-based screening to be effective is that the 
oligonucleotide linked to the support must maintain its native conformation, as in solution. To 
gain a deeper insight into the effective conformations adopted by the G4s on the glass beads, 
we exploited a fluorescent and water-soluble core-extended naphthalene diimide (cex-NDI, 
Figure 47).[184] 
 
Figure 47. Chemical structure of the core-extended naphthalene diimide (cex-NDI), here used as 
fluorescent probe. 
This red fluorescent cex-NDI, carrying a [3-(dimethylamino) propyl]carboxamide moiety at C-
11, has been recently designed to give different fluorescence responses upon binding to 
different secondary structure-forming oligonucleotides.[184] In fact, under physiological 
conditions it tends to aggregate and, as a result, its intrinsic fluorescence is essentially 
quenched. Upon interaction with DNA in solution, it disaggregates, producing a dramatic 
fluorescence enhancement when it binds to hybrid or antiparallel G4s; contrarily, a much 
weaker emission is observed when it binds to parallel G4s or duplex DNA (Figure 48).[184] 
This peculiar behaviour is explained considering the different binding modes of cex-NDI to 
different DNA structures: in the former cases, it interacts with the G4s grooves, while for the 
latter ones an end-stacking (for the parallel G4s) or intercalating (for the duplex) interaction 
mode occurs.[184] Thus, tel26-, ckit1- and ds27-functionalized supports were left in contact with 
cex-NDI, which in all cases bound each support-linked oligonucleotide by 98% (±2%) of the 
total loaded amount. After incubation with the cex-NDI, followed by exhaustive washings, the 
three supports were analyzed by confocal microscopy.  
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Figure 48. Fluorescent behaviour of cex-NDI in solution. When bound to hybrid or antiparallel G4s, cex-
NDI produces a dramatic fluorescence enhancement, while a weaker emission is observed when it binds 
to parallel G4s or duplex DNA. (Adapted from Zuffo et al.[184]) 
Using transmitted light detection, the supports appeared as irregular beads with a mean size of 
110 µm (Figure 49, middle), as expected.[164] On the other hand, by confocal fluorescence 
visualization (Figure 49, left), different fluorescence intensities were observed for the three 
functionalized glass beads, even if cex-NDI is able to bind all of them with comparable affinity. 
In particular, a high fluorescence emission was observed for tel26-functionalized CPG, a 
medium fluorescence for ckit1-functionalized CPG and a low fluorescence for the ds27-
functionalized support. In an effort to implement these analyses, we performed a semi-
quantitative determination of the fluorescence emission for all the investigated systems in a 
comparative manner. For each support, different images were acquired in several fields of view 
with a 63x magnification (Figures 50-53). Firstly, confocal fluorescence microscopy images 
were taken for proper controls. No intrinsic fluorescence was observed for the nude CPG or the 
G4- and hairpin duplex-functionalized CPGs in the absence of the cex-NDI, when excited at the 
maximum of absorption of the ligand (555 nm). Moreover, no fluorescence emission was found 
for the nude CPG or the functionalized CPGs in the presence of the cex-NDI by exciting outside 
the ligand absorption wavelengths range. In turn, negligible fluorescence was observed for the 
nude CPG upon incubation with cex-NDI (Figure 50), since only a small amount of this 
fluorescent probe (ca. 16% of the total loaded ligand) bound to the nude support. Then, for the 
three cex-NDI-linking supports, the average of the mean intensity values taken from different 
edge glass beads-containing regions of each image was calculated. The highest values of 
fluorescence intensity were found for the tel26-linking support, the lowest values for the ds27-
linking support, while an intermediate value was observed for ckit1-linking support, confirming 
the qualitative visual analysis (Figure 54). As mentioned above, cex-NDI interacts with 
secondary structure-forming oligonucleotides in solution resulting in a high fluorescence 
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quantum yield with hybrid and antiparallel G4s, in a medium fluorescence quantum yield with 
parallel G4s and in a low fluorescence quantum yield with duplex DNA.[184] Taking this into 
account and considering that, in the absence of Na+ ions, tel26 is not able to adopt antiparallel 
G4 conformations,[21] our semi-quantitative confocal microscopy analysis confirmed that tel26, 
ckit1 and ds27 sequences, linked to the CPG supports, were folded into a hybrid G4, a parallel 
G4 and a hairpin duplex, respectively, under the studied experimental conditions. 
 
Figure 49. Representative confocal images of G4- and hairpin duplex-functionalized CPG supports after 
incubation with the cex-NDI. Images were obtained using a 10x objective, exciting at 555 nm and 
recording emission in the 578-800 nm range. Left: fluorescence images; middle: transmitted light 
images; right: merged images. Scale bars correspond to 100 µm. 
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Figure 50. Representative confocal images using a 63x oil immersion objective, exciting at 555 nm and 
recording emission in the 578-800 nm range of the nude CPG after incubation with cex-NDI. Left: 
fluorescence image, middle: transmitted light image, right: merged image. Parameters settings through 
acquisition were kept identical to those used for tel26-, ckit1- and ds27-functionalized CPG. Scale bars 
correspond to 20 µm. 
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Figure 51. Representative confocal images using a 63x oil immersion objective, exciting at 555 nm and 
recording emission in the 578-800 nm range of the tel26-functionalized CPG after incubation with cex-
NDI. Left: fluorescence images, middle: transmitted light images, right: merged images. Parameters 
settings through acquisition were kept identical to those used for nude CPG, ckit1- and ds27-
functionalized CPG. Scale bars correspond to 20 µm. 
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Figure 52. Representative confocal images using a 63x oil immersion objective, exciting at 555 nm and 
recording emission in the 578-800 nm range of the ckit1-functionalized CPG after incubation with cex-
NDI. Left: fluorescence images, middle: transmitted light images, right: merged images. Parameters 
settings through acquisition were kept identical to those used for nude CPG, tel26- and ds27-
functionalized CPG. Scale bars correspond to 20 µm. 
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Figure 53. Representative confocal images using a 63x oil immersion objective, exciting at 555 nm and 
recording emission in the 578-800 nm range of the ds27-functionalized CPG after incubation with cex-
NDI. Left: fluorescence images, middle: transmitted light images, right: merged images. Parameters 
settings through acquisition were kept identical to those used for nude CPG, tel26- and ckit1-
functionalized CPG. Scale bars correspond to 20 µm. 
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Therefore, it can be concluded that these oligonucleotides, when anchored to CPG and left in 
contact with the selected buffer, adopt the same conformations they typically have in solution 
(Figure 44). This result further validates the efficacy and feasibility of our method for the 
identification of a large variety of effective G4 ligands. 
In addition, we have here provided proof-of concept that our novel approach is a powerful tool 
to identify not only structure-selective G4-ligands, but even conformation-selective G4-ligands, 
thus assuring higher selectivity and lower toxicity of the selected molecules in view of in vivo 
applications.  
 
 
Figure 54. Mean fluorescence intensity values (±S.D.) taken from different edge glass beads-containing 
regions of each image (63x magnification) acquired for G4-and hairpin duplex-functionalized CPG 
supports. p-values have been calculated using the Student's t-test (****p < 0.0001). 
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3.5 Experimental section 
 
3.5.1 General procedure adopted for the binding assays 
The investigated ligands were purchased from Sigma-Aldrich or Maybridge. Stock solutions 
for each ligand were prepared by dissolving a known amount of it in pure DMSO or H2O. A 
measured volume was taken from the stock solution to obtain a 60 µM ligand solution. All the 
binding assays were carried out in triplicate, using freshly prepared solutions for each tested 
ligand. The detailed general procedure adopted for the assays is described as follows: a weighed 
amount of the CPG supports (5-10 mg) was left in contact with 300 µL of the 60 µM ligand 
solution in a polypropylene column (4 mL volume, Alltech) equipped with a 
polytetrafluoroethylene frit (10 µm porosity), a stopcock and a cap. After incubation on a 
vibrating shaker for 4 min, each support was washed with defined volumes of the washing 
solution (50 mM KCl, 10% DMSO, 10% CH3CH2OH in H2O) or the releasing solution (2.5 M 
CaCl2, 15% DMSO in H2O or pure DMSO) and all the eluted fractions were separately analyzed 
by UV measurements. After treatment with the releasing solution, inducing G4s and hairpin 
duplex denaturation, the supports were suspended in the washing solution and then subjected 
to annealing, by taking them at 75 °C for 5 min and then slowly cooling to room temperature. 
 
3.5.2 Materials and general methods 
The sequences d[(TTAGGG)4TT] (tel26), d(AGGGAGGGCGCTGGGAGGAGGG) (ckit1) 
and d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27) selected for the solution studies 
were synthesized by automated solid phase oligonucleotide synthesis on an Applied Biosystem 
3400 DNA/RNA synthesizer. After ammonia deprotection and cleavage from the solid support 
carried out at 55 °C for 12 h, the crude oligonucleotides were purified by HPLC using a 
Nucleogel SAX (Macherey-Nagel, 1000-8/46) analytical column and then dialyzed against 
water using a Float-A-Lyzer G2 dialysis device (MWCO 0.5-1.0 kDa, three H2O changes over 
24 h). Each oligonucleotide was dissolved in pure H2O and its concentration was determined 
by measuring the absorbance at 260 nm and 85 °C, using the molar extinction coefficient 
calculated for the unstacked oligonucleotide.[181] All the studies in solution were carried out in 
a 50 mM KCl, 10% DMSO, 10% CH3CH2OH aq. solution. First, the annealing procedure was 
performed by dissolving the oligonucleotides at the proper concentration in the K+-containing 
solution. The resulting mixture was then heated in a water bath at 95 °C for 5 min, and 
successively slowly cooled to room temperature in 12 h.  
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UV spectra were recorded on a JASCO V-550 UV-vis spectrophotometer equipped with a 
Peltier Thermostat JASCO ETC-505T. The spectra were recorded in the range 240-320 nm, at 
20 °C and 85 °C, using a quartz cuvette with a path length of 1 cm, a scanning speed of 100 
nm/min and a bandwidth of 2.0 nm, in all cases subtracting the appropriate baseline.  
CD spectra were obtained in a quartz cuvette with a path length of 1 cm on a Jasco J-715 
spectropolarimeter associated with a Peltier-type temperature control system (model PTC-
348WI). The spectra were recorded at room temperature in the 240-320 nm range with 1 s 
response, 100 nm/min scanning speed and 2.0 nm bandwidth and corrected for the background. 
All the spectra were averaged over 3 scans.  
In both the UV and CD experiments, the oligonucleotides were analyzed at 2 µM concentration.  
 
3.5.3 Binding assays on nude CPG and nude OAS 
4.4 mg of support 2 (23 μmol/g loading, 100 nmol) and 3.3 mg of OAS support (30 μmol/g 
loading, 100 nmol) were treated with 3% TCA in CH2Cl2 to remove the DMT protecting group. 
After exhaustive washings with CH2Cl2, CH3OH, and again CH2Cl2, both supports were taken 
to dryness and then left in contact with 300 µL of a 60 µM solution (18 nmol) of the model 
ligand under investigation. After incubation on a vibrating shaker for 4 min, the surnatant was 
allowed flowing through the supports, which were then treated with several volumes of the 
washing solution. The eluted fractions were collected and analyzed by UV measurements. 
 
3.5.4 Use of G4-and hairpin duplex-functionalized CPG and OAS supports for the binding 
assays 
8.3, 7.7 and 9.1 mg of, respectively, dried tel26-, ckit1- and ds27-functionalized support 
obtained from 2 (tel26-2, ckit1-2 and ds27-2, 100 nmol of oligonucleotide each) and 5.0 mg of 
dried tel26-OAS (20 μmol/g loading, 100 nmol of oligonucleotide) were left in contact, in 
different columns, with 300 µL of the washing solution and subjected to the annealing 
procedure. After removing the surnatant, the supports were treated, analogously to the control 
nude CPG, with 300 µL of the ligand dissolved at 60 µM concentration (18 nmol) in the 
washing solution. After 4 min incubation, the supports were treated with several volumes of the 
washing solution and the eluted fractions were collected and analyzed by UV measurements. 
Finally, to allow the complete release in solution of the ligands retained by the oligonucleotides 
on the supports, these were then repeatedly washed with the releasing solution. 
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3.5.5 Confocal microscopy analyses 
To perform confocal microscopy analyses, nude CPG or G4- and hairpin duplex-functionalized 
supports were seeded on rectangle glass slides and mounted in water by using rectangle glass 
coverslips. Images were captured by using a confocal laser scanning microscope (Zeiss LSM 
710, Zeiss, Germany) and a 63x objective oil immersion system. When necessary, images were 
taken by using a 10x objective, in order to obtain information about the morphological 
homogeneity of the samples. For each CPG support, images were taken in at least three 
independent experiments. For each objective, images were taken under identical conditions. 
Fluorescence intensity analyses were performed by using the Zen Lite 2.3 software package. 
For this analysis, areas characterized by high fluorescence intensities were selected for each 
sample. The fluorescent probe, cex-NDI (Figure 47), was synthesized and purified according to 
a published procedure.[184] 
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CHAPTER 4 – SCREENING AND EVALUATION OF A LIBRARY OF 
MOLECULES FEATURED BY A FUROBENZOXAZINE 
NAPHTHOQUINONE CORE 
4.1 Introduction 
With a view to expanding the repertoire of drug-like G4 binders and speeding up the search for 
true hits, docking studies can be valid tools, especially to screen large libraries of putative 
ligands.[185] In this frame, a 6000 compounds library  ̶  from the commercially available Life 
Chemicals database  ̶  was recently virtually screened against the tetramolecular and parallel G4 
of sequence d[(TGGGGT)4] by exploiting Autodock4.2 software.
[186] Among the 6000 
compounds, 6 molecules (1-6, Figure 55) were found to be good G4 binders, as also 
experimentally confirmed by NMR studies.[186] These compounds were subsequently studied 
in their interaction with topologically different G-quadruplexes by biophysical techniques.[187] 
 
Figure 55. Chemical structures of compound 1-6 previously selected from a commercially available 
database by virtual screening.[186] 
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Remarkably, two of the six G4 binders (2 and 4, Figure 55) proved to be able to selectively 
stabilize parallel G4s, discriminating antiparallel or hybrid G4s and duplex DNA and inducing 
telomere damage in the µM range.[187] In particular, compound 4 proved to be the strongest 
ligand being able to largely stabilize both telomeric and extra-telomeric parallel G4s, as well as 
induce G4 formation in some G-rich oligonucleotides also in the absence of cations.[187] 
Encouraged by its promising activity, we identified and analyzed a focused library of structural 
analogs of 4, featured by different pendant groups on the N-atom of the oxazine ring (Table 4), 
with the aim of developing more potent and selective G4 ligands.[188]  
 
Table 4. Chemical structures of compound 4 and its analogs. 
 
 
                     D4 
Compound               R Compound                  R 
4 
 
S4-6 
 
S4-1 
 
S4-7 
 
S4-2 
 
S4-8 
 
S4-3 
 
S4-9 
 
S4-4 
 
S4-10 
 
S4-5 
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First, the selected molecules have been screened against topologically different G4s by our 
affinity chromatography-based method (G4-CPG assay). Then, the best analog, in terms of 
affinity towards G4s and selectivity over duplex DNA, has been characterized in its interaction 
with DNA secondary structure-forming oligonucleotide models by biophysical studies and 
analyzed for its biological activity.[188] 
4.2 Selection of compound 4 analogs 
Aiming at synthesizing G4-selective ligands with enhanced activity/toxicity ratio, a convenient 
synthetic strategy can be to start from a known lead compound featured by a suitable aromatic 
core and then functionalize it with a set of different decorations. In this way, the stabilizing 
stacking interactions with the target can be preserved, and an improved selectivity achieved, by 
exploiting additional specific interactions realized by the decorations with the G4 target 
grooves. In the present case, starting from lead compound 4, a set of its analogs, featured by the 
same pentacyclic core and bearing different decorations on the N-atom of the oxazine ring, were 
selected (Table 4). 
Given the relative synthetic accessibility of pentacyclic furobenzoxazine naphthoquinones, 
analogs of 4 were searched in commercial molecular databases. This approach has the 
advantage of quickly providing a library of structural analogs of the lead compound and being 
cost-effective. Therefore, the Dice similarity coefficient was computed between 4 and the 
compounds present in the ZINC database collection of commercially available compounds 
(https://zinc15.docking.org) setting the similarity threshold to 70%. This search resulted in 40 
compounds that were visually inspected revealing that, as desired, a number of 
furobenzoxazine-containing naphthoquinone derivatives were identified, as well as some 
analogs exhibiting different scaffolds. Ten of the furobenzoxazine naphthoquinone derivatives 
resulting from the filtered database were thus selected (S4-1–S4-10, Table 4). A 
furonaphthoxazine analog (D4, Table 4) was also included in this study to have a different 
scaffold as a reference. 
4.3 Experimental screenings by the G4-CPG assay 
Aiming at expanding the potential of the G4-CPG assay and extending it to a wide variety of 
topologically different G4 structures, the CPG support was functionalized with a set of 
biologically relevant G4-forming oligonucleotides. In addition to previously synthesized tel26, 
ckit1 and ds27, we selected for the elongation on the CPG support the following sequences: the 
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33-mer d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) (cmyc) from the nuclease 
hypersensitive element in the human c-myc promoter,[101] the 21-mer 
d(CGGGCGGGCGCGAGGGAGGGG) (ckit2) from c-kit oncogene promoter[114] and the 24-
mer d(AAGGGGAGGGGCTGGGAGGGCCCGGA) (hTERT1) from the G-rich region in the 
hTERT core promoter, which represents the main regulatory element of the hTERT gene.[119] 
The binding assays were performed on the functionalized CPG supports following the 
procedures described in Chapter 3. All the oligonucleotide-functionalized supports were first 
tested in their ability to bind known G4 ligands with different affinity for G4 structures. In 
particular, thiazole orange (TO) and resveratrol (Figure 42) were used as model molecules, 
being respectively a strong and a very weak G4 binder.[174,175] The obtained data, showing high 
affinity (bound ligand > 97%) for TO and very low affinity (bound ligand < 4%) for resveratrol 
on all the tested supports, proved the efficacy of the novel functionalized CPG supports. 
Successively, the stock solutions for compound 4 and its analogs were prepared by dissolving 
a weighed amount of the solid compound in pure DMSO; only compound S4-1 proved to be 
not completely soluble in DMSO at the concentration required for the binding assays and was 
therefore discarded. All the other compounds as well as compound 4 proved to be well soluble 
in the washing/releasing solutions used in our binding assays and at the concentration chosen 
for the binding experiments. After solubility checks for all the tested compounds, we verified 
the absence of unspecific binding on the solid support by incubating them with the nude CPG. 
Low-to-null unspecific interactions with the solid support have been observed for compound 4 
and its analogs (Table 5). These results further prove the inertness of the nude CPG, previously 
demonstrated for G4 model ligands, also with this novel and chemically different class of 
compounds, confirming the possibility of expanding the chemical space of potential ligands 
that can be tested on the support, as well as the general reliability of our method. Then, all the 
investigated ligands were tested on the G4s- and hairpin duplex-functionalized CPG supports 
(Table 5 and Figure 56). The obtained results showed that all the analyzed ligands had good 
affinity for tel26 immobilized on the solid support. However, no marked improvement was 
found with respect to 4, still the strongest binder in the series when tested on this G4-forming 
sequence, with the only exception of S4-4, showing comparable results as 4. In contrast, when 
tested on cmyc, compounds S4-2, S4-4, S4-7, S4-8 and S4-10 displayed higher affinity than 4. 
As far as ckit1 is concerned, almost all the tested compounds proved to be stronger binders than 
compound 4, with the sole exception of S4-3. In the case of ckit2, S4-2, S4-4, and S4-10 showed 
higher binding abilities than 4. Notably, also in this case compound S4-3 was the weakest binder 
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of the series. Finally, for hTERT1 all the tested analogs had comparable or higher affinity than 
4. 
Table 5. Summary of the binding assays data for compound 4 and its analogs on nude and 
functionalized CPG supports. 
Compound 
Bound ligand (%)a 
Nude 
CPG 
CPG-
tel26 
CPG-
cmyc 
CPG-
ckit1 
CPG-
ckit2 
CPG-
hTERT1 
CPG-
ds27 
4 0 86 86 70 82 74 18 
S4-2 0 80 94 85 91 82 46 
S4-3 0 73 84 55 67 73 16 
S4-4 0 86 93 90 92 91 2 
S4-5 0 80 84 78 80 82 0 
S4-6 10 80 87 76 83 78 12 
S4-7 11 80 89 77 84 92 33 
S4-8 0 78 90 88 83 87 20 
S4-9 5 75 73 72 68 76 16 
S4-10 0 79 94 90 88 89 28 
D4 7 76 74 75 70 78 22 
aBound ligand is calculated as a difference from the unbound ligand, recovered with 50 mM KCl, 
10% DMSO, 10% CH3CH2OH washing solution, and expressed as % of the amount initially loaded 
on the support. The errors associated with the % are within ± 2%. 
Overall, all the tested analogs proved to be effective G4 ligands ‒ also when compared with the 
known G4 binders, tested in previous experiments ‒ typically showing high binding affinities 
(bound ligand > 80%), in many cases better than compound 4. Among all the investigated 
compounds, D4 was the worst G4 ligand, evidencing that its polycyclic core, different from the 
other tested molecules, is not suitable for G4 targeting. On the other hand, the best G4 ligand 
seems to be compound S4-4 for its ability to tightly interact both with telomeric and extra-
telomeric G4s. In addition, the highest percentages of bound ligand were found for the cmyc 
sequence, probably the preferred target for the here screened chemotypes. In order to evaluate 
the G4s vs. duplex DNA selectivity, all the compounds were also tested in their interaction with 
the ds27 hairpin duplex-forming oligonucleotide. Overall, all the ligands proved to be able to 
effectively discriminate G4- vs. duplex-forming oligonucleotides. In particular, S4-4 and S4-5 
had a significantly lower affinity for ds27 than 4, with S4-5 showing zero affinity for duplex 
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DNA. Therefore, considering its good affinity for the G4 sequences and its high G4s vs. duplex 
DNA selectivity degree, S4-5 emerged as the most promising analog. Thus, we selected S4-5 
to gain a deeper insight, by means of biophysical techniques, into the binding to G4 and duplex 
models, in comparison with lead compound 4. 
 
Figure 56. Bound ligand expressed as percentage of the quantity initially loaded on each functionalized 
CPG support for all the investigated compounds. The errors associated to the percentages are within ± 
2%. 
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4.4 Solution studies on the interaction of the selected ligands with oligonucleotide models 
4.4.1 CD and CD-melting experiments 
Taking into account the results of the G4-CPG assay, we investigated the ability of compound 
S4-5, in parallel with compound 4, to interact with a human telomeric G4, an extra-telomeric 
G4 and a duplex structure by CD experiments. In particular, among the extra-telomeric G4s, 
we chose c-myc, for which S4-5, as well as the other analogs, showed the highest affinity. In 
addition, the same sequences elongated on the CPG supports (tel26, cmyc and ds27) were used 
as models. 2 µM solutions of the three secondary structure-forming oligonucleotides in 20 mM 
KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7) were titrated with increasing amounts of the 
two compounds, and spectra recorded after each addition. 
As expected in the above buffered conditions, tel26 folds into a hybrid II-type G4 featured by 
maximum at 290 nm and a shoulder at 270 nm,[83] cmyc forms a parallel G4 with a maximum 
centered at 263 nm,[22,101] while ds27 shows the characteristic positive band at 280 nm with a 
minimum at 251 nm relative to a B-DNA duplex structure[180] (Figure 57). In the case of tel26 
titration with S4-5, a dose-dependent increase of the intensity of the 290 nm band and a 
reduction of the 270 nm shoulder were observed (Figure 57A). In the titration experiments with 
cmyc, the addition of S4-5 produced only weak changes, with a slight reduction of the 263 nm 
band and an increase of the 288 nm band (Figure 57B). In contrast, in the titration of ds27 no 
detectable change in the CD profile of the duplex was observed, suggesting that this structure 
was essentially unaffected by the addition of even a large excess of ligand (Figure 57C). A 
similar behaviour was found for compound 4 towards G4s DNA, while a slight conformational 
variation was observed for ds27, with a reduction of the minimum at 251 nm. (Figure 58). In 
all cases, up to 5 equivalents of ligand were added to the oligonucleotide solutions, as the best 
compromise between the solubility of the analyzed ligands and the saturation of the 
oligonucleotide CD signals. No induced CD signal was observed for all the investigated systems 
(Figure 59). 
CD-melting experiments were also performed on all the oligonucleotide/ligand mixtures to 
evaluate if stabilizing or destabilizing effects on the G4s and hairpin duplex structures were 
obtained upon incubation with the two ligands (Figures 60 and 61). CD-melting curves of tel26, 
cmyc and ds27 in the absence or presence of each ligand (1:5 oligonucleotide/ligand ratio) were 
recorded by following the CD changes at the wavelength of intensity maximum (290, 263, and 
251 nm for tel26, cmyc and ds27, respectively). 
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Figure 57. CD spectra of 2 µM solutions of tel26 (A), cmyc (B) and ds27 (C) in 20 mM KCl, 5 mM 
KH2PO4, 10% DMSO buffer (pH 7) in the absence and presence of increasing amounts of S4-5 (up to 5 
equivalents). 
 
Figure 58. CD spectra of 2 µM solutions of tel26 (A), cmyc (B) and ds27 (C) in 20 mM KCl, 5 mM 
KH2PO4, 10% DMSO buffer (pH 7) in the absence and presence of increasing amounts of 4 (up to 5 
equivalents). 
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Figure 59. CD titrations of 2 µM solutions of tel26, cmyc and ds27 (top, middle and bottom, 
respectively) in 20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7) with S4-5 (1-5 equivalents) 
(left panels) and 4 (1-5 equivalents) (right panels). 
 
The results of the CD melting experiments clearly showed that compounds S4-5 and 4 did not 
significantly affect the stability of the tel26 and ds27 structures (Table 6). Conversely, both 
ligands appreciably stabilized the cmyc G4 structure (ΔTm > 8 °C).  
Overall, these results confirmed the ability of the here investigated pentacyclic scaffold to 
selectively interact with G4 structures discriminating duplex DNA, as proved by CD titrations, 
and to markedly stabilize parallel G4s, not affecting the stability of other G4 conformations and 
duplex DNA. 
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Figure 60. CD melting curves for tel26/S4-5 (A), cmyc/S4-5 (B) and ds27/S4-5 (C) mixtures (1:5) in 
20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7), recorded at 290, 263, and 251 nm, respectively. 
 
Figure 61. CD melting curves for tel26/4 (A), cmyc/4 (B) and ds27/4 (C) mixtures (1:5) in 20 mM KCl, 
5 mM KH2PO4, 10% DMSO buffer (pH 7), recorded at 290, 263, and 251 nm, respectively. 
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Table 6. Melting temperatures (Tm) of tel26, cmyc and ds27 in the absence or presence of the ligands 
(5 equivalents) as measured by CD melting experiments. 
Ligand 
Tm (°C) (±1) 
tel26 cmyc ds27 
No ligand 49 82 75 
4 49 > 90 76 
S4-5 50 > 90 76 
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4.4.2 NMR experiments 
In order to get information on the binding mode of compounds 4 and S4-5 to the G4 structures 
formed by the human telomeric and c-myc promoter DNA sequences, NMR titration 
experiments were performed in collaboration with the group of prof. Antonio Randazzo of the 
Department of Pharmacy of University of Naples Federico II.[188] The modified telomeric 
sequence d[TTGGG(TTAGGG)3A] (m-tel24)
[189] and the shortened c-myc sequence 
d(TGAGGGTGGGTAGGGTGGGTAA) (myc22)[190] were used for this study since they are 
characterized by a predominant G4 conformation in solution and therefore give higher quality 
NMR spectra than the wild-type, polymorphic sequences. Twelve well-resolved imino proton 
peaks were observed in the 1H NMR spectra of m-tel24 and myc22, perfectly matching the 
NMR data reported in the literature (Figures 62-65).[189,190] The investigated oligonucleotides 
were then titrated with 4 and S4-5, in parallel experiments, up to a 1:4 G4/ligand ratio. Addition 
of increasing amounts of ligands to the G4 solutions produced considerable proton resonance 
changes in both imino and aromatic proton regions of the spectra (Figures 62-65), thus 
suggesting that both 4 and S4-5 may not have a unique binding site. The relative line broadening 
observed for all the imino resonances and most of the aromatic ones also suggested that the 
ligands could explore different poses in fast exchange within the same G4 binding pocket. In 
detail, imino signals broadening was more prominent at low concentrations both of 4 and S4-5 
(up to 1 ligand equivalent), while at higher concentrations novel imino signals appeared, with 
the sole exception of m-tel24/S4-5 system. However, only in the case of myc22/4 system, 
twelve well-resolved imino signals were observed, therefore suggesting the formation of a 
single G4-ligand complex, as well as a peculiar binding stoichiometry of 1:3 myc22/4. On the 
other hand, some distinct aromatic protons of both m-tel24 and myc22 G4s were only weakly 
affected by the ligands. As far as 4 is concerned, for m-tel24 (Figure 62) this is the case of 
residues T6-T7-A8, which form the double-chain reversal loop of the G4; for myc22 (Figure 
63) this is the case of A6, which stacks on top of the 5’ G-tetrad, and of residues T10, T14-A15, 
and T19 (numbering according to Ambrus et al.),[190] which form the three double-chain 
reversal loops of the G4 structure. The NMR titrations with S4-5 show that in the interaction 
with m-tel24 G4 (Figure 64) the ligand does not appreciably affect the aromatic protons of A8, 
which is in the double-chain reversal loop, and of residues T18-T19-A20, which form a lateral 
loop close to the external G-tetrad; while in the interaction with myc22 (Figure 65), the least 
affected ones are the aromatic protons of A6, which stacks on top of the 5’ G-tetrad, and of 
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residues T14-A15 and T19, which form the second and third double-chain reversal loop of G4, 
respectively. 
Overall, these findings suggest that the loops are generally very little or not at all affected by 
both ligands. Thus, 4 and S4-5 may bind m-tel24 and myc22 either by interaction with the 
grooves not masked by the loops, or by stacking on the external G-tetrads.  
Aiming at investigating the G4 vs. duplex DNA selectivity of 4 and S4-5, NMR titrations were 
also carried out with a model duplex DNA formed by the Dickerson dodecamer 
d(CGCGAATTCGCG) (ds12). The 1H NMR spectrum of ds12 well matched the one reported 
in the literature (Figures 66 and 67).[191] Noteworthy, no significant variation of the chemical 
shift values of ds12 was observed upon treatment with S4-5 (Figure 66), up to a 1:4 DNA/ligand 
ratio, thus confirming that it does not bind the investigated duplex DNA. On the other hand, 4 
caused a small perturbation of the ds12 spectrum, in terms of both intensity decrease and line 
broadening of all the 1H NMR signals (Figure 67), suggesting that 4 could somehow interact 
with duplex DNA in a weak and unspecific way. These results are in full agreement with those 
obtained from G4-CPG assay. 
 
Figure 62. Imino and aromatic regions of the 1H NMR spectra of m-tel24 G4 titrated with 4. The ligand 
equivalents are shown on the left of the spectra. 
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Figure 63. Imino and aromatic regions of the 1H NMR spectra of myc22 G4 titrated with 4. The ligand 
equivalents are shown on the left of the spectra. 
 
  
92 
 
 
Figure 64. Imino and aromatic regions of the 1H NMR spectra of m-tel24 G4 titrated with S4-5. The 
ligand equivalents are shown on the left of the spectra. 
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Figure 65. Imino and aromatic regions of the 1H NMR spectra of myc22 G4 titrated with S4-5. The 
ligand equivalents are shown on the left of the spectra. 
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Figure 66. 1H NMR spectra of the ds12 duplex titrated with S4-5. The ligand equivalents are shown on 
the left of the spectra. 
 
Figure 67. 1H NMR spectra of the ds12 duplex titrated with 4. The ligand equivalents are shown on the 
left of the spectra. 
 
 
95 
 
4.4.3 Microscale thermophoresis (MST) experiments 
To obtain quantitative data about the affinity of S4-5 for the human telomeric and c-myc 
promoter G4s, microscale thermophoresis (MST) experiments were performed in collaboration 
with the group of prof. Antonio Randazzo at the Department of Pharmacy of University of 
Naples Federico II.[188] MST is a fast and easy technique used to characterize small molecule-
nucleic acid interactions in solution, which records the thermophoretic movement of a 
fluorescently-labeled molecule under microscopic temperature gradients.[192] This molecular 
motion strongly depends on changes in size, charge, and hydration shell. Since the binding of 
a small molecule to a given target affects at least one of these parameters, also its 
thermophoretic behaviour is affected. This effect can be used to determine equilibrium 
constants, such as the dissociation constant Kd. To this aim, serial dilutions of S4-5 were 
prepared, mixed with a constant concentration of Cy5-labeled oligonucleotides (tel26 or 
myc22), loaded into capillaries and analyzed by MST. MST measurements proved that 
compound S4-5 was able to bind both tel26 G4 (Kd = 26 (±4) µM) and myc22 G4 (Kd = 13 (±2) 
µM), indicating for this ligand twice higher affinity for the parallel than hybrid G4 structure 
(Figure 68). 
 
Figure 68. MST measurements for S4-5 with myc22 (A) and tel26 (B) G4s. (Top) Time traces recorded 
by incubating increasing concentrations of S4-5 with the labeled G4s and (bottom) the corresponding 
binding curves. 
A) B)
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4.5 Molecular docking 
To get a deeper insight into the binding mode of S4-5 with human telomeric and c-myc 
promoter G4s, molecular docking studies were carried out in collaboration with prof. Sandro 
Cosconati of the Department of Environmental, Biological, and Pharmaceutical Sciences and 
Technologies (DiSTABiF) of University of Campania "Luigi Vanvitelli".[188] S4-5 was docked 
into the solution G4 structure of c-myc (myc22, PDB ID: 1XAV) and into the hybrid-type G4 
structure formed in K+ solution by the 26-mer from the human telomere (tel26, PDB ID: 2JPZ). 
The software Autodock 4.2,[193] which is the same one previously exploited to identify 4 as a 
G4 ligand, was here employed. 
Analysis of the results obtained when S4-5 was docked into the myc22 G4 structure showed 
that the ligand is inserted into the G4 groove not covered by the loop, where it is stabilized by 
van der Waals interactions with G21, G22, and T23 residues and ionic interactions with the 
backbone phosphate oxygens of A24 residue through the protonated nitrogen of the oxazine 
ring (Figure 69). Furthermore, the pendant benzyl group is well positioned to form π-π 
interactions with the G9 guanine ring. Interestingly, both the (R)- and the (S)-isomer of S4-5 
were docked but no enantio-discriminating binding was detected. In contrast, the methyl 
substituent on the benzylic carbon seems to optimally orient the phenyl ring to give the 
aforementioned stacking interactions. Indeed, the obtained theoretical model was perfectly 
consistent with the binding mode indicated by NMR studies, proving the general reliability of 
docking results. 
 
Figure 69. Binding mode of S4-5 when docked into myc22 G4 solution structure. The ligand is 
represented as grey sticks while the DNA as dark cyan ribbons and sticks. H-bonds are represented as 
dashed yellow lines. DNA residues were numbered according to Ambrus et al.[190] 
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As far as tel26 is concerned, the docking software suggested three possible binding poses in 
which S4-5 is always inserted in the groove not occupied by the loop, between the first and 
fourth strand of the G4 structure (Figure 70). Indeed, the ligand adopts the same orientation 
with respect to the G4 but at different levels of the groove, one towards the 3’ end (here referred 
to as pose A), one in the middle (pose B), and one towards the 5’ end (pose C). 
 
 
Figure 70. Alternative binding poses predicted for S4-5 when docked into the tel26 solution structure. 
The ligand is represented as grey sticks, the DNA as magenta ribbons and sticks. H-bonds are 
represented by dashed yellow lines. 
In pose A the ligand forms an H-bond, through its furan oxygen, with the NH2 group of G24, 
and an ionic interaction, through its protonated oxazine nitrogen, with the T25 phosphate group. 
In pose B, an H-bond is formed between the ligand furan oxygen and the G23 NH2 group. In 
pose C, one of the two ligand quinone oxygens forms an H-bond with the NH2 group of the G4 
and a charged, reinforced H-bond through its protonated oxazine nitrogen and the sugar O4’ 
atom of G22. Moreover, the phenyl ring of the ligand benzyl moiety forms π-π interactions with 
the A3 and G22 aromatic rings. As observed for the myc22 structure, also for tel26 no enantio-
discriminating binding was detected. From the above-described docking results, we cannot give 
a preference for one of the obtained solutions; rather, it is possible to speculate that the ligand 
is able to slide into the G4 groove adopting almost isoenergetic binding conformations. This 
hypothesis is corroborated by the results of the NMR titration experiments, which were not 
helpful in indicating a specific binding region. 
 
 
A) B) C)
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4.6 Biological assays 
Specific biological experiments were carried out for the here studied ligands, in collaboration 
with the research group of dr. Annamaria Biroccio at Regina Elena Cancer Research Institute 
in Rome.[188] 
In order to investigate the telomere damage induced by the here tested ligands, 
immunofluorescence-based assays (IF) were used.[194] In particular, indirect IF is used to 
identify a cellular antigen by using a primary antibody that recognizes a specific protein. A 
secondary antibody conjugated with a fluorophore, visible under IF microscope, is used to 
recognize the immunoglobulins of the primary antibody and amplify its signal. When a DNA 
damage response is activated, the damage factor H2AX is phosphorylated (γH2AX) in 
correspondence of the DNA breaks.[195] This antigen can be visualized by indirect IF.[194] Using 
these experiments, qualitative and quantitative analysis of DNA damage can be performed. In 
fact, staining homogeneity grade is a qualitative measurement of the progress in cellular arrest 
growth, while the average number of spots per nucleus is a quantitative measurement of the 
extension of the damage along the DNA. Moreover, DNA damage can be quantified by 
evaluating the percentage of γH2AX-positive cells, i.e. the percentage of cells showing DNA 
damage on the total number of cells.[194] 
To determine if the damage is localized at the telomeres, it is necessary a co-immunostaining 
of DNA with both a DNA damage marker (γH2AX) and a telomeric marker (TRF1, one of the 
shelterin complex proteins); co-localization of these markers is called Telomere-Dysfunction 
Induced Foci (TIFs).[194,196] Telomere damage can be quantified by evaluating the percentage 
of TIF-positive cells, i.e. cells with more than four co-localizations per nucleus. Furthermore, 
co-localization analysis provides the main method to determine the ability of ligands to induce 
specific DNA damage at the telomeres vs. other DNA sites; in fact an easy count of the number 
of co-localizing vs. non co-localizing spots can give us the required information. Finally, the 
mean number of TIFs per cell is indicative of the intensity of telomere damage per single 
cell.[194] 
Thus, BJ-EHLT cells – a human foreskin-derived fibroblast cell line, expressing the human 
telomerase reverse transcriptase (hTERT) and SV40 early region[197] – were treated for 24 h 
with 0.5 µM of each compound and the DNA damage was evaluated. To appreciate possible 
improvements in terms of biological activity of the analogs over lead compound 4, the time and 
dose conditions previously optimized for 4 and able to induce a slight DNA damage were used. 
IF analysis showed relevant amounts of γH2AX, evidencing that all the tested ligands – with 
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the sole exception of D4, S4-9, and S4-10 – induced similar DNA damage extent as the lead 
compound (Figure 71A).  
 
 
Figure 71. Compound 4 analogs induce telomeric DNA damage. BJ-EHLT fibroblasts were untreated 
(CTR, white bar) or treated for 24 h with 4 (black bar) and the indicated analogs (light-grey bars) at 0.5 
μM concentration. Cells were processed for immunofluorescence (IF) using antibodies against γH2AX 
and TRF1 to visualize the DNA damage and telomeres, respectively. A) Percentages of γH2AX-positive 
cells. B) Representative merged images of IF of untreated and treated BJ-EHLT cells; γH2AX spots in 
green, TRF1 spots in red and nuclei in blue. Enlarged views of Telomere Induced Foci (TIFs) are 
reported on the right panels of each picture. The images were acquired with a Leica Deconvolution 
microscope (magnification 63x). C) Quantitative analysis of TIFs. The graph represents the percentages 
of TIF-positive cells (bars) and the mean number of TIFs for cell (red line) in the indicated samples. 
Cells with at least four γH2AX/TRF1 foci were scored as TIF positive. Histograms show the mean 
values ±S.D. of three independent experiments. 
 
A) B)
C)
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In parallel, we also evaluated whether the induced DNA damage was located at the telomeres 
(Figure 71B). Noteworthy, quantitative analysis confirmed and reinforced the previous 
observations, evidencing that all the compounds (with the only exception of D4, S4-9, and S4-
10) induced a percentage of TIF positive cells and average number of TIFs per cell similar to 
lead compound 4 (Figure 71C). These data are consistent with those found by the G4-CPG 
assays, relative to the affinities of compound 4 and its analogs towards the telomeric model 
sequence, which proved to be in all cases similar. 
Successively, to test the antitumor efficacy of compound 4 analogs, the cell colony-forming 
ability of the human cervical cancer cells, HeLa, untreated or treated with the different 
compounds, was evaluated. To set up the optimal dose of the drug, first a dose-response 
experiment was performed by using three different concentrations (0.5, 1 and 2 µM) of 4: the 
2 µM concentration proved to be the minimal effective dose and was thus selected for the 
successive tests (Figure 72A). Interestingly, cell survival experiments evidenced that 
derivatives S4-4, S4-6, S4-8, and S4-10, despite their high affinity for G4 structures in vitro 
(Table 5), were less effective than 4 in affecting tumour cell viability (Figures 72B and 72C). 
Compounds D4 and S4-3 also showed an antiproliferative activity lower than compound 4 
(Figures 72B and 72C), which could be related, in this case, to an overall G4-affinity lower than 
compound 4 (Table 5). Conversely, the potent cytotoxic activity observed for derivatives S4-2, 
S4-7 and S4-9 (Figures 72B and 72C) might be attributed to non-specific, G4-independent, 
effects since these ligands showed either a good affinity also for duplex DNA (S4-2 and S4-7) 
or, as in the case of S4-9, an affinity towards G4 structures generally lower than other analogs 
(Table 5). In summary, ligand S4-5, despite showing an antitumor activity similar to lead 
compound 4, emerged as the most interesting ligand of this series. Indeed, its high affinity for 
G4 structures associated with null affinity for duplex DNA (Table 5) suggests a promisingly 
improved target specificity compared to the starting compound. 
Finally, in order to evaluate the selectivity of S4-5 in cell, the effects of this compound were 
also tested on normal cells. Briefly, human immortalized BJ fibroblasts (BJ-hTERT) were 
treated with 4 or S4-5 at 1 and 2 µM concentrations and, after 6 days, the number of viable cells 
was evaluated. Remarkably, these experiments clearly evidenced that the cytotoxic effects of 
ligand S4-5 on normal cells were definitely lower than those produced by compound 4 (Figure 
73A). Moreover, IF analysis of γH2AX evidenced that S4-5, in contrast to 4, was unable to 
induce an appreciable DNA damage in normal cells (Figures 73B and 73C). Overall, these data 
unambiguously indicated that S4-5 has a much higher selectivity in killing cancer cells than 
lead compound 4, making it a promising candidate drug. 
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Figure 72. Anti-tumour efficacy of compound 4 analogs. A) Clonogenic activity of human cervical 
cancer cells, HeLa, untreated (CTR, white bar) or treated with 4 at the indicated doses. Surviving 
fractions were calculated as the ratio of absolute survival of the treated sample/absolute survival of the 
untreated sample. B) Clonogenic activity of HeLa cells, untreated (CTR, white bar), treated with 4 (black 
bar) or the indicated analogs (light-grey bars) at 2 μM dose. Surviving fractions were calculated as 
reported in A. C) Representative images of the clonogenic assay described in B. Histograms show the 
mean values ±S.D. of three independent experiments. 
 
Figure 73. A) Human immortalized fibroblasts (BJ-hTERT) were treated with compound 4 or S4-5 at 
the doses of 1 and 2 µM for 6 days. Viable cell number was determined by the Trypan Blue exclusion 
test. B) BJ-hTERT were treated with 4 or S4-5 at the 1 µM dose for 24 h and processed for IF using 
antibodies against γH2AX. The histogram represents the percentages of γH2AX-positive cells. C) 
Representative merged images of IF: γH2AX spots in green and nuclei in blue. Histograms show the 
mean values ±S.D. of three independent experiments. 
A) B) C)
A) B) C)
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4.7 Experimental section 
 
4.7.1 Chemistry 
All commercial reagents and solvents were purchased from Sigma-Aldrich or Link 
Technologies, unless otherwise stated. The selected compounds were purchased from Life 
Chemicals Europe (Germany) and used without further purification. Compound supplier codes: 
F1094-0196 (4), F1217-0039 (S4-1), F1094-0208 (S4-2), F1094-0205 (S4-3), F1094-0204 (S4-
4), F1094-0201 (S4-5), F1094-0200 (S4-6), F1094-0209 (S4-7), F1061-0006 (S4-8), F1094-
0199 (S4-9), F1094-0203 (S4-10), F1094-0190 (D4).  
 
4.7.2 G4-CPG assay 
Long Chain AlkylAmine-CPG 1000 Å was functionalized with 3'-O-acetyl-5'-O-(4,4'-
dimethoxytrityl)thymidine through a hexaethylene glycol spacer as previously described in 
section 2.4. Standard phosphoramidite chemistry on an automated Applied Biosystem 394 
DNA/RNA synthesizer was used to obtain the oligonucleotide-functionalized CPG supports. In 
particular, using a 1 µmol-scale, “DMT-ON” protocol, the following oligonucleotides were 
assembled on the CPG supports: d[(TTAGGG)4TT]
 (tel26), 
d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) (cmyc), 
d(AGGGAGGGCGCTGGGAGGAGGG) (ckit1), d(CGGGCGGGCGCGAGGGAGGGG) 
(ckit2), d(AAGGGGAGGGGCTGGGAGGGCCCGGA) (hTERT1), and 
d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27). The coupling efficiency of each base 
was monitored by spectrophotometric measurements of the DMT cation, released from the 
support by acidic treatment with 3% TCA in CH2Cl2 before the subsequent coupling step. 
Considering the number of couplings and the average yield per cycle of 99.8%, 99.7%, 99.9%, 
99.7%, 99.9% and 99.2%, respectively for tel26, cmyc, ckit1, ckit2, hTERT1 and ds27, the 
overall yield was determined to be 95%, 91%, 98%, 94%, 98%, and 80%. Stock solutions of 
each tested compound were prepared by dissolving a weighed amount of the solid compound 
in pure DMSO. G4-CPG binding assays were performed as described in section 3.5. The UV 
measurements were performed on a JASCO V-550 UV-vis spectrophotometer equipped with a 
Peltier Thermostat JASCO ETC-505T. The UV quantification of the ligands was determined 
by measuring the absorbance relative to the λmax characteristic of each ligand and referring it to 
the corresponding calibration curves. A quartz cuvette with a path length of 1 cm was used. 
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4.7.3 CD experiments 
CD spectra were recorded in a quartz cuvette with a path length of 1 cm on a Jasco J-715 
spectropolarimeter equipped with a Peltier-type temperature control system (model PTC-
348WI). The spectra were recorded at 20 °C in the range 240-800 nm with 2 s response, 200 
nm/min scanning speed, 2.0 nm bandwidth, and corrected by subtraction of the background 
scan with buffer. All the spectra were averaged over 3 scans. The oligonucleotides 
d[(TTAGGG)4TT] (tel26), d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) 
(cmyc) and d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27) were synthesized by 
standard automated solid phase oligonucleotide synthesis on an Applied Biosystem 394 
DNA/RNA synthesizer. After ammonia treatment (55 °C, 12 h) allowing both deprotection and 
detachment from the solid support, the crude oligonucleotides were purified by HPLC on a 
SAX analytical column and then dialyzed against water using a Float-A-Lyzer G2 dialysis 
device (MWCO 0.5-1.0 kDa, three H2O changes over 24 h). After lyophilization, the 
oligonucleotides were dissolved in a 20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7) 
to obtain 2 μM solutions, then annealed by heating to 95 °C for 5 min, followed by slow cooling 
to room temperature. The ligand stock solutions were 4 mM in DMSO. CD titrations were 
obtained by adding increasing amounts of the ligands (up to 5 molar equivalents, corresponding 
to a 10 μM solution in ligand) to tel26, cmyc and ds27. After each ligand addition, the system 
was allowed equilibrating before recording the spectra. For the CD-melting experiments, the 
ellipticity was recorded at 290, 263 and 251 nm for tel26, cmyc and ds27, respectively, with a 
temperature scan rate of 0.5 °C/min in the range 20-90 °C. 
 
4.7.4 NMR experiments 
NMR experiments were performed on a 700 MHz Varian Unity INOVA spectrometer. One 
dimensional 1H NMR spectra of the samples in H2O were recorded at 25 °C using pulsed-field 
gradient DPFGSE for H2O suppression. Data were processed on iMAC running iNMR software 
(www.inmr.net). DNA samples were prepared at 0.2-0.4 mM strand concentration in 0.6 mL of 
H2O/D2O (9:1) buffer solution. The following oligonucleotides were used for the NMR 
experiments: the truncation of human telomeric sequence d[TTGGG(TTAGGG)3A] (m-tel24), 
the d(TGAGGGTGGGTAGGGTGGGTAA) sequence from the NHE III element of the c-myc 
oncogene (myc22), containing two G to T substitutions (G14/T and G23/T, numbering 
according to Ambrus et al.), and the self-complementary duplex-forming dodecamer 
d(CGCGAATTCGCG) (ds12). In order to avoid different G4 foldings or conformational 
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heterogeneity in solution, DNA samples were prepared using the appropriate experimental 
conditions adopted for the determination of their 3D structures. Thus, the following buffers 
containing 10% D2O were used: 25 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA (pH 7.0) for 
myc22 and m-tel24; 20 mM NaH2PO4, 200 mM NaCl (pH 7.0) for ds12. The samples were 
heated at 90 °C for 5 min and then slowly cooled to room temperature overnight to achieve the 
correct folding of the oligonucleotides. Aliquots of 4 and S4-5 stock solutions in DMSO-d6 
were directly added to the DNA solution inside the NMR tube; the final DMSO concentration 
was 14%. A control titration was also performed by adding DMSO-d6 alone to the DNA 
solution. 
 
4.7.5 Microscale thermophoresis (MST) experiments 
MST measurements were performed using the Monolith NT.115 (Nanotemper Technologies, 
Munich, Germany). The Cy5-fluorescently labeled tel26 and myc22 oligonucleotides 
(Biomers) were prepared in 5 mM potassium phosphate buffer (pH 7.0) containing 20 mM KCl 
supplemented with 0.1% Tween. The concentration of the labeled oligonucleotide was kept 
constant at 80 nM, while a serial dilution of the ligand (1:2 from 4 mM ligand stock solution in 
100% DMSO) in the same buffer used for DNAs was prepared and mixed with the 
oligonucleotide solution with a volume ratio of 1:1. All the samples, containing 8% DMSO as 
the final concentration, were loaded into standard capillaries (NanoTemper Technologies). 
Measurements were performed at 20 °C, using auto-tune LED power and medium MST power. 
MST data analysis was performed by employing the MO. software. Affinity Analysis software 
(v2.3) provided with the instrument. Plots were rendered with GUSSI version 1.2.1 software 
(http://biophysics.swmed.edu/MBR/software.html). 
 
4.7.6 Molecular docking 
The latest version of the docking software AD4 (version 4.2), along with its graphical user 
interface AutoDockTools (ADT), were employed. The NMR structures used for the docking 
studies had the following PDB codes: 2JPZ, and 1XAV. The DNA G4s were prepared for the 
docking using the Maestro suite (Schrödinger Release 2017-2: Maestro, Schrödinger, LLC, 
New York, NY, 2017), which assigns bond orders, adds hydrogen atoms, deletes water 
molecules and generates the appropriate protonation states. The 2D Sketcher tool of Maestro 
was used to build S4-5. Of this ligand, the protonation, tautomeric, and isomeric states were 
calculated through LigPrep, part of the same suite. The ligand and the G4 DNA structures were 
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converted to the AD4 specific file format (PDBQT) using the python scripts prepare_ligand4.py 
and prepare_receptor4.py, part of ADT, applying the standard settings. The docking area was 
centered on the DNA center of mass. For each G4 structure, a set of grids of 60 Å × 60 Å × 60 
Å with 0.375 Å spacing was calculated around the docking area for the ligand atom types using 
AutoGrid4. For each G4, 100 separate docking calculations were performed. Each docking 
calculation consisted of 10 million energy evaluations using the Lamarckian genetic algorithm 
local search (GALS) method. The GALS method evaluates a population of possible docking 
solutions and propagates the most successful individuals from each generation into the 
subsequent generation of possible solutions. A low-frequency local search according to the 
method of Solis and Wets is applied to docking trials to ensure that the final solution represents 
a local minimum. All dockings were performed with a population size of 250, and 300 rounds 
of Solis and Wets local search were applied with a probability of 0.06. A mutation rate of 0.02 
and a crossover rate of 0.8 were used to generate new docking trials for subsequent generations, 
and the best individual from each generation was propagated over the successive generation. 
The docking results from each of the 100 calculations were clustered on the basis of root-mean 
square deviation (rmsd) (solutions differing by less than 2.0 Å) between the Cartesian 
coordinates of the atoms and were ranked on the basis of the free energy of binding (ΔGAD4). 
Molecular modeling figures were rendered using the UCSF Chimera software. 
 
4.7.7 Biological experiments 
Cells and culture condition. Human fibroblasts (BJ) and human cervical cancer cells (HeLa) 
were obtained as previously reported. BJ-hTERT cells were obtained infecting primary BJ cells 
with a retrovirus carrying hTERT (Addgene plasmid #1773); BJ-EHLT derived from the 
transformation of BJ fibroblasts with hTERT and SV40 early region (BJ-EHLT).[197] BJ-
hTERT, BJ-EHLT and HeLa were grown in Dulbecco Modified Eagle Medium (DMEM, 
Invitrogen Carlsbad, CA, USA) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-
glutamin and antibiotics at 37°C in a 5% CO2-95% air atmosphere. 
Immunofluorescence. Cells were fixed in 2% formaldehyde and permeabilized in 0.25% Triton 
X-100 in phosphate buffered saline (PBS) for 5 min at r.t. For immune-labeling, cells were 
incubated with primary antibody for 2 h at r.t., washed twice in PBS and finally incubated with 
the secondary antibodies for 1 h. The following primary antibodies were used: Mouse mAb 
anti-γH2AX (Millipore, Billerica, MA, USA) and Rabbit pAb anti-TRF1 N19 (Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA). The following secondary antibodies were used: Anti-
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Mouse IgG (H+L), F(ab’)2 Fragment (Alexa Fluor 488 Conjugate) (Cell Signaling) and Anti-
rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor 555 Conjugate) (Cell Signaling). Nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI, Sigma). Fluorescence signals were 
recorded by using a Leica DMIRE2 microscope equipped with a Leica DFC 350FX camera and 
elaborated by Leica FW4000 deconvolution software (Leica, Solms, Germany). For 
quantitative analysis of γH2AX positivity, 300 cells on triplicate slices were scored. For TIF 
analysis, a single plane was analyzed, and 30 γH2AX-positive cells were scored. Cells with at 
least four co-localizations (γH2AX/TRF1) were considered as TIF-positive. 
Clonogenic assay. Human cervical cancer cells, HeLa, were seeded in 60 mm-Petri dishes at 
the clonogenic density of 500 cells/plate in DMEM medium with 10% FBS. After 24 h, cells 
were treated with compound 4 or its analogues at 2 µM concentration. After 10 days, the cells 
were stained with 2% methylene blue in 50% ethanol and the number of colonies was counted. 
Surviving fractions were calculated as the ratio of absolute survival of the treated 
sample/absolute survival of the untreated sample. 
Cell viability. BJ-hTERT fibroblasts were seeded in 60-mm Petri dishes at a density of 5×104 
cells/plate. After 24 h from plating, cells were treated with compound 4 or S4-5 at the doses of 
1 and 2 µM. Cell viability (Trypan Blue dye exclusion) was determined after 6 days from 
treatment. 
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CHAPTER 5 – SCREENING AND EVALUATION OF A LIBRARY OF 
NAPHTHALENE DIIMIDES 
 
5.1 Introduction 
In the search for G-quadruplex selective ligands, naphthalene diimides (NDIs) emerged as 
promising compounds for their well-proved ability to interact with G-tetrads, chemical 
accessibility and possibility to easily functionalize their aromatic cores with multiple, diverse 
pendant groups, thus allowing a fine modulation of their affinity towards different secondary 
structure-forming oligonucleotides.[142,198,199] Indeed, it has been shown that the substitution 
pattern of the NDI core as well as the chemical nature of the substituents play a crucial role in 
G4 binding and selectivity toward G4 vs. duplex DNA.[141,142] For these peculiar features, NDIs 
have been extensively studied both as fluorescent probes and oligonucleotide-targeting 
ligands.[200,201] 
Recently, a series of monomeric NDIs with alkylamine substituents on the naphthalene core 
(1a-4a and 1-Br, Figure 74) were synthesized by prof. Mauro Freccero’s group at the 
Department of Chemistry of University of Pavia. These compounds proved to have excellent 
water solubility and cellular entry, thus emerging as promising compounds for both therapeutic 
and diagnostic applications.[139,202] In particular, the tetra-substituted compound 4a was able to 
generate singlet oxygen species, which produced photo-induced cytotoxicity.[202,203] Its efficient 
nuclear uptake was evidenced by fluorescence confocal imaging exploiting the intrinsic NDI 
fluorescence.[202] 
 
Figure 74. Chemical structures of previously synthesized tri-, tetra-substituted and dimeric naphthalene 
diimides.[139,204] 
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The chemical diversity of this class of compounds was further expanded producing the dimeric 
NDI 5a (Figure 74), obtained by coupling 1a with 3a connected through a ‒(CH2)7‒ flexible 
spacer.[204] Remarkably, this NDI has appealing properties for in vivo applications aiming at 
detecting and targeting G4 structures.[204] In fact, the non-fluorescent 5a compound, containing 
both a red and a blue NDI dyes, becomes red emitting upon G4 binding. Moreover, its average 
fluorescence lifetime is significantly different if 5a interacts with a G4 or with a duplex DNA, 
and this property can represent a key feature for the development of new rationally engineered 
G4-based sensors for detection applications.[204] In addition, although compound 5a did not 
discriminate between the different G4 structures investigated, it exhibited a good G4 vs. duplex 
DNA selectivity,[204] which made it an interesting lead compound for the design of novel 
putative G4-selective ligands.  
Here we focus on the potential of this class of G-quadruplex targeting NDIs as therapeutic 
agents. To this purpose, several novel NDI analogs have been synthesized by Freccero’s group. 
In detail, a novel library of derivatized NDIs, including the monomeric 1-4 (Figure 75), used as 
controls, as well as the dimeric systems 5-12, (Figure 76) were designed and characterized, 
aiming at enhancing the G4 vs. duplex selectivity of 5a and testing the ability of novel 
functionalized dimeric NDIs to discriminate diverse G4 conformations. 
The design of these novel putative G4-binders has been conceived following a general strategy 
recently proposed, counterintuitively based on the reduction of the overall ligand affinity for 
G4s.[205] The main idea is based on the evidence that the most potent ligands strongly interact 
with all DNA structures, regardless of their identity and conformation. Therefore, a possible 
way to potentiate their target selectivity is by reduction of their overall affinity. Most well-
studied G4-ligands carry amine moieties,[125,133,135,137,139] which being protonated at 
physiological pH are strongly attracted by the oligonucleotide backbone negative charges. 
Within the set of here investigated NDI derivatives, unspecific interactions resulting from 
electrostatic attractions between the oligonucleotide phosphates and the protonated ammonium 
groups are removed by making the NDIs intrinsically neutral. In this way, some degrees of 
affinity are lost, but the core selectivity can emerge. 
To this aim, eight new dimeric NDIs (Figure 76) were synthesized by linking one NDI unit 
displaying dimethyl amine groups, positively charged at physiological pH, with a second NDI 
unit functionalized with carboxylic groups, which at physiological pH are negatively charged. 
The here designed molecules should maintain charge neutrality at physiological pH, thus 
disfavouring the above unspecific electrostatic interactions. The nature of the spacer and the 
substituents on the aromatic core was also modulated. In detail, the here studied dimeric NDIs 
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contain ‒(CH2)7‒ or ‒(CH2CH2O)2CH2CH2‒ connecting spacers and bear (CH2)5COOH, 
(CH2)5COOMe or (CH2)3N(CH3)2 pendant groups on the imide nitrogen atoms, and 
NH(CH2)3N(CH3)2, Br or no substituent on the naphthalene cores (Figure 76). In parallel, 
monomeric NDIs (Figure 75) functionalized with similar substituents as in the dimeric 
structures, i.e. NH(CH2)2CH3, NH(CH2)3N(CH3)2, NH(CH2)7NH2 or 
NH(CH2CH2O)2CH2CH2NH2, and bearing the same pendant groups on the imide nitrogen 
atoms, i.e. (CH2)3N(CH3)2, were also synthesized and characterized. All these derivatives were 
then evaluated by the G4-CPG assay and successively analyzed by biological and biophysical 
experiments. 
 
Figure 75. Chemical structures of the monomeric naphthalene diimides here investigated. 
NDI-1 NDI-2
NDI-3 NDI-4
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Figure 76. Chemical structures of the dimeric naphthalene diimides here investigated. 
NDI-6NDI-5
NDI-7 NDI-8
NDI-10
NDI-11 NDI-12
NDI-9
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5.2 Experimental screenings by the G4-CPG assay 
With the aim of further expanding the potential of the G4-CPG assay and extending it to longer 
sequences able to fold into multiple consecutive G4 structures, better mimicking the multimers 
formed by telomeric G-quadruplexes,[78,82] the CPG support has been functionalized with the 
46-mer oligonucleotide of sequence d[AGGG(TTAGGG)7] (tel46),
[206,207] modelling the human 
telomeric DNA and able to form an intramolecular dimeric G4.[87] Then, we tested the library 
of the novel naphthalene diimides depicted in Figures 75 and 76 on four CPG supports: two 
systems functionalized with the telomeric sequences tel26 and tel46,[82] respectively, one with 
the extra-telomeric sequence cmyc,[101] and one with the control duplex ds27. Before 
performing the binding assays with the novel compounds, the tel46-functionalized support was 
first tested in its ability to bind known G4 ligands with different affinity for G4 structures, 
similarly to what previously carried out with CPG-tel26, CPG-cmyc and CPG-ds27. In detail, 
BRACO-19 (Figure 30, left), TMPyP4, TO, resveratrol and 9-Acr-COOH (Figure 42) were 
used as model molecules, known to have very high (BRACO-19, TMPyP4 and TO)[125,174,208] 
or low-to-null (resveratrol and 9-Acr-COOH)[175,177] affinity for G4 structures. The obtained 
data (Table 7), showing high affinity (bound ligand > 97%) for BRACO-19, TMPyP4 and TO, 
and very low affinity for resveratrol and 9-Acr-COOH (bound ligand ≤ 4%), proved the efficacy 
of the tel46-functionalized CPG support (tel46-2). 
The binding assays were performed as described in Chapter 3. Ligand stock solutions were 
prepared by dissolving a weighed amount of the solid compound in H2O or pure DMSO, 
respectively for the monomeric and dimeric naphthalene diimides. All the compounds proved 
to be well soluble in the washing/releasing solutions used in our binding assays and at the 
concentration chosen for the binding experiments. After solubility checks for all the tested 
compounds, we first verified the absence of unspecific binding on the solid support by 
incubating them with the nude CPG (Figure 41A) and then, all the investigated ligands were 
tested on the G4s- and hairpin duplex-functionalized CPG supports. The results of the binding 
assays are reported in Table 8 and Figures 77-80, showing no significant unspecific interactions 
with the solid support for the tested NDIs, as well as the quantitative recovery of the bound 
ligands by using washings with the releasing solutions. 
All the analyzed ligands exhibited good affinity for tel26 and cmyc monomeric G4s 
immobilized on the solid supports, with monomeric NDIs showing higher affinity than dimeric 
compounds (Table 8 and Figures 77-80). 
 
112 
 
Table 7. Summary of the binding assay data obtained for tel46-2 through UV measurements. 
 Support 2 
Ligand 
tel46-bound 
ligand (%)a,c 
Recovered ligand 
from tel46-2 (%)b,c 
BRACO-19 100 89 
TMPyP4 100 86 
TO 97 96 
Resveratrol 4 99 
9-Acr-COOH 0 - 
atel46-bound ligand (%) was calculated as a difference from 
the unbound ligand recovered with the washing solution 50 
mM KCl, 10% DMSO, 10% CH3CH2OH 
bRecovered ligand from tel46-2 (%) was obtained using as 
releasing solution either 2.5 M CaCl2,15% DMSO or 100% 
DMSO 
cThe amounts of bound/recovered ligands are expressed as 
percentage of the quantity initially loaded on the support; the 
errors associated to the reported percentages are within ± 2%. 
Moreover, the tested compounds proved to be stronger binders for tel46 than tel26 and cmyc 
G4s (Table 8), however being generally all effective G4 ligands, also in comparison with known 
G4 binders (Tables 2 and 7). Among all the investigated compounds, NDI-8 and NDI-9 showed 
the lowest affinity for G4s. On the other hand, the best G4 ligands appeared to be NDI-3 and 
NDI-4 for their ability to tightly interact with both telomeric and extra-telomeric G4s (Table 
8).  
In order to evaluate the G4s vs. duplex DNA selectivity, all the compounds were also tested in 
their interaction with the ds27 hairpin duplex-forming oligonucleotide. Overall, all the ligands 
proved to be able to effectively discriminate G4- vs. duplex-forming oligonucleotides, except 
NDI-11 and NDI-12 (Table 8 and Figures 79-80). In Table 9 selectivity indexes are reported, 
calculated as the ratio between the percentages of ligand bound to G4s- and hairpin duplex-
functionalized supports. In detail, NDI-3, NDI-4 and NDI-6 recognized both telomeric 
sequences (tel26 and tel46) and cmyc with a twice-higher affinity than ds27, while NDI-8 and 
NDI-9 bound tel26, tel46 and cmyc more than five times stronger compared to ds27 (Table 9). 
Overall, the best G4 vs. duplex selectivity was found for the weaker G4 binders NDI-8 and 
NDI-9, corroborating the initial hypothesis that losing some affinity allows the NDI core 
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selectivity emerging. On the other hand, these ligands showed similar affinity towards the two 
telomeric sequences, as well as no ability to discriminate between the two monomeric tel26 and 
cmyc G4s (Table 9).  
Therefore, considering their good affinity for the G4 sequences and high G4s vs. duplex DNA 
selectivity, NDI-3, NDI-4, NDI-6, NDI-8 and NDI-9 proved to be the most promising ligands. 
Thus, we decided to further investigate these five compounds and evaluate their cytotoxic 
activity on both cancer and normal cells. 
 
Table 8. Summary of the binding assays data for monomeric and dimeric naphthalene 
diimides on nude and functionalized CPG supports. 
Compound 
Bound ligand (%)a 
Nude CPG CPG-tel26 CPG-tel46 CPG-cmyc CPG-ds27 
NDI-1 4 85 98 95  50  
NDI-2 0 92 99 98  46  
NDI-3 0 100 100 97  48  
NDI-4 7 97 100 95  41  
NDI-5 5 90 100 87  71  
NDI-6 15 85 85 79  34  
NDI-7 11 73 82 78  38  
NDI-8 5 41 51 26  3  
NDI-9 0 67 72 64  12  
NDI-10 4 84 100 87  57  
NDI-11 14 77 55 75  61  
NDI-12 14 75 60 79  71  
aBound ligand is calculated as a difference from the unbound ligand, recovered with 50 mM 
KCl, 10% DMSO, 10% CH3CH2OH washing solution, and expressed as % of the amount 
initially loaded on the support. The errors associated with the % are within ± 2%. 
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Figure 77. Amount of the released ligands NDI1-NDI6, expressed as percentage of the quantity loaded 
on nude CPG (-■-), CPG-tel26 (-♦-), CPG-tel46 (-●-), CPG-cmyc (- -) and CPG-ds27 (-▲-) as a 
function of the volume of the washing solution 50 mM KCl, 10% DMSO, 10% CH3CH2OH (blue line) 
and the releasing solutions 2.5 M CaCl2, 15% DMSO (red line) or pure DMSO (green line). The errors 
associated with the % are within ± 2%. 
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Figure 78. Amount of the released ligands NDI7-NDI12, expressed as percentage of the quantity loaded 
on nude CPG (-■-), CPG-tel26 (-♦-), CPG-tel46 (-●-), CPG-cmyc (- -) and CPG-ds27 (-▲-) as a 
function of the volume of the washing solution 50 mM KCl, 10% DMSO, 10% CH3CH2OH (blue line) 
and the releasing solutions 2.5 M CaCl2, 15% DMSO (red line) or pure DMSO (green line). The errors 
associated with the % are within ± 2%. 
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Figure 79. Amount of the released ligands NDI1-NDI12, expressed as percentage of the quantity loaded 
on A) CPG-tel26 and B) CPG-tel46 as a function of the volume of the washing solution (50 mM KCl, 
10% DMSO, 10% CH3CH2OH). The errors associated with the % are within ± 2%. 
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Figure 80. Amount of the released ligands NDI1-NDI12, expressed as percentage of the quantity loaded 
on A) CPG-cmyc and B) CPG-ds27 as a function of the volume of the washing solution (50 mM KCl, 
10% DMSO, 10% CH3CH2OH). The errors associated with the % are within ± 2%. 
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Table 9. Selectivity indexes calculated as the ratio between the percentages of ligand bound to the 
indicated G4s- and hairpin duplex-functionalized supports. 
Compound 
Selectivity index 
CPG-tel26/ 
CPG-ds27 
 
CPG-tel46/ 
CPG-ds27 
CPG-cmyc/ 
CPG-ds27 
CPG-tel46/ 
CPG-tel26 
CPG-tel26/ 
CPG-cmyc 
NDI-1 1.7 2.0 1.9 1.2  0.9  
NDI-2 2.0 2.2 2.0 1.1  0.9  
NDI-3 2.1 2.1 2.0 1.0  1.0  
NDI-4 2.4 2.4 2.3 1.0  1.0  
NDI-5 1.3 1.4 1.2 1.1  1.0  
NDI-6 2.5 2.5 2.3 1.0  1.1  
NDI-7 1.9 2.2 2.0 1.1  0.9  
NDI-8 13.7 17.0 8.7 1.2  1.6  
NDI-9 5.6 6.0 5.3 1.1  1.0  
NDI-10 1.5 1.8 1.5 1.2  1.0  
NDI-11 1.3 0.9 1.2 0.7  1.0  
NDI-12 1.1 0.8 1.1 0.8  0.9  
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5.3 Biological assays 
In order to evaluate the antiproliferative activity of dimeric compounds NDI-6, NDI-8 and 
NDI-9 and monomeric compounds NDI-3, NDI-4, in vitro experiments were carried out in 
collaboration with dr. Annamaria Biroccio’s group at Regina Elena Cancer Research Institute 
in Rome. 
Human transformed fibroblasts (BJ-EHLT) were treated for 24 h with five different 
concentrations of NDIs (from 0.05 to 1 μM) and the DNA damage was evaluated. IF analysis 
showed relevant amounts of γH2AX, evidencing that the ligands NDI-8, NDI-3 and NDI-4 
were able to induce DNA damage to a greater extent than NDI-6 and NDI-9 (Figure 81A). The 
same assay was also performed on normal human fibroblasts (BJ-hTERT) for NDI-8, NDI-3 
and NDI-4 at the lowest concentration found, for each compound, to induce a DNA damage in 
more than 50% of the treated cells (Figures 81B and 81C). The effects of these compounds on 
normal cells proved to be twice less marked than on transformed BJ-EHLT cells (Figure 81C). 
In parallel, for the three most active compounds tested at the same concentration (0.5 μM), it 
was also evaluated whether the induced DNA damage was located at the telomeres (Figure 
81D). Notably, quantitative analysis showed that NDI-8 induced significant and higher 
percentage of TIF positive cells and average number of TIFs per cell than NDI-3 and NDI-4 
(Figure 81E). These data are consistent with the ones obtained by the G4-CPG assay confirming 
the ability of NDI-8 to selectively target telomeric sequences and discriminate duplex DNA 
better than all the other investigated ligands. 
Successively, to test the antitumor efficacy of compounds NDI-6, NDI-8, NDI-9, NDI-3 and 
NDI-4, the cell colony-forming ability of the human cervical cancer cells, HeLa, untreated or 
treated with the different compounds, was evaluated (Figure 82). Dose-response experiments 
were performed by using different concentrations of the tested compounds and IC50 values were 
calculated (Figure 82A). NDI-8, NDI-3 and NDI-4 proved to be highly cytotoxic, with IC50 
values in the low nanomolar range (6.6, 52 and 64 nM, respectively). Interestingly, cell survival 
experiments evidenced a good correlation between the antiproliferative activity and the relative 
G4s affinities obtained by G4-CPG assay (Table 8). Indeed, compounds NDI-6 and NDI-9, 
found weaker G4 binders than NDI-3 and NDI-4, proved to be the least active ones, while NDI-
3 and NDI-4, which were the strongest G4 ligands, were among the most active ones. 
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Figure 81. BJ-EHLT and BJ-hTERT fibroblasts were untreated or treated for 24 h with DMSO or the 
investigated NDIs at the indicated concentrations. Cells were processed for immunofluorescence (IF) 
using antibodies against γH2AX and TRF1 to visualize the DNA damage and telomeres, respectively. 
A) Percentages of γH2AX-positive BJ-EHLT cells. B) Percentages of γH2AX-positive BJ-hTERT cells. 
C) Comparison between the percentages of γH2AX-positive BJ-EHLT and BJ-hTERT cells.  
A)
B) C)
D) E)
NDI-6 NDI-8 NDI-9 NDI-3 NDI-4
NDI-4 (0.5 µM) 
NDI-3 (0.5 µM)
NDI-8 (0.2 µM)
NDI-8 NDI-3 NDI-4
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D) Representative merged images of IF of untreated and treated BJ-EHLT cells; γH2AX spots in green, 
TRF1 spots in red and nuclei in blue. Enlarged views of Telomere Induced Foci (TIFs) are reported on 
the bottom panels of each picture. The images were acquired with a Leica Deconvolution microscope 
(magnification 63x). E) Quantitative analysis of TIFs. The graph represents the percentages of TIF-
positive cells (bars) and the mean number of TIFs per cell (red line) in the indicated samples. Cells with 
at least four γH2AX/TRF1 foci were scored as TIF positive. Histograms show the mean values ±S.D. 
of three independent experiments. 
 
Figure 82. Antitumor efficacy of the tested NDIs. A) Clonogenic activity of human cervical cancer 
cells, HeLa, treated with the different NDIs at the indicated doses. Surviving fractions were calculated 
as the ratio of absolute survival of the treated sample/absolute survival of the untreated sample. B) 
Representative images of the clonogenic assay described in A). 
Finally, in order to evaluate the selectivity of NDIs in cell, the effects of these compounds were 
also tested on normal cells. Briefly, the human immortalized fibroblasts (BJ-hTERT) were 
treated with the tested NDIs at their lowest effective concentrations and the number of viable 
cells was evaluated (Figure 83). Remarkably, these experiments clearly evidenced that the 
cytotoxic effects of ligands on normal cells are lower than those produced on cancer cells. 
A)
B)
NDI-8 (IC50: 6.6 nM)
NDI-3 (IC50: 52 nM)
NDI-4 (IC50: 64 nM)
NDI-6 (IC50: 300 nM)
NDI-9 (IC50: 5800 nM)
NDI-6 NDI-8 NDI-9 NDI-3 NDI-4CTR
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Overall, these data unambiguously designated NDI-8 as the most promising candidate drug 
since it proved to be the most active compound against cancer cells, also having high selectivity 
in killing cancer cells than normal cells. 
 
Figure 83. BJ-EHLT and BJ-hTERT cells were treated with compounds NDI-6, NDI-8, NDI-9, NDI-
3 and NDI-4 at the indicated doses. Viable cell number was determined by the Trypan Blue exclusion 
test. Histograms show the mean values ±S.D. of three independent experiments. 
 
5.4 Solution studies on the interaction of NDI-8 with oligonucleotide models by CD and 
fluorescence experiments 
 
Considering the interesting results of the G4-CPG and biological assays, we decided to get a 
deeper insight into the interaction of compound NDI-8 with the human telomeric G4s tel26 and 
tel46, the extra-telomeric G4 cmyc and the duplex structure ds27 by analysing these systems in 
solution via CD experiments. 2 µM solutions of all the investigated oligonucleotides in a 20 
mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7) were titrated with increasing amounts of 
NDI-8, and spectra recorded after each addition. 
As expected in the above buffered conditions, CD spectra showed that tel26 and tel46 
respectively folded into hybrid G4 structures, featured by a maximum at 290 nm and a shoulder 
at 270 nm, cmyc formed a parallel G4 with a maximum centered at 263 nm, while ds27 showed 
a positive band at 280 nm with a minimum at 251 nm, characteristic of a B-DNA duplex 
structure (Figure 84). In the case of tel26 and tel46 titrations with NDI-8, a dose-dependent 
increase of the intensity of the 290 nm band and a reduction of the 270 nm shoulder were 
observed, as well as the presence of an isosbestic point at 277 nm (Figures 84A and 84B). In 
the titration experiments with cmyc, a slight reduction of the 263 nm band, an increase of the 
NDI-6 (1 µM)
NDI-8 (0.05 µM)
NDI-9 (3 µM)
NDI-3 (0.1 µM)
NDI-4 (0.1 µM)
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288 nm band and an isosbestic point at 273 nm were observed (Figure 84C). As far as the 
titration of ds27 is concerned, the addition of NDI-8 produced a slight reduction of the 250 nm 
band and an increase of the 280 nm band (Figure 84D). In all cases, a maximum of 6 equivalents 
was added to the oligonucleotide solutions, as the best compromise between solubility of the 
analyzed ligand and saturation of the oligonucleotide CD signals. No induced CD signal was 
observed for all the investigated systems. 
 
Figure 84. CD spectra of 2 µM solutions of: A) tel26, B) tel46, C) cmyc and D) ds27 in 20 mM KCl, 5 
mM KH2PO4, 10% DMSO buffer (pH 7) in the absence and presence of increasing amount of NDI-8 
(up to 6 equivalents). Isosbestic points in A), B) and C) are showed as black dots; black arrows indicate 
intensity variations of the specific bands going from 1:1 to 1:6 oligonucleotide/NDI-8 ratio. 
CD-melting experiments were also performed on all the oligonucleotide/ligand mixtures to 
evaluate if stabilizing or destabilizing effects on the G4s and hairpin duplex structures were 
obtained upon incubation with NDI-8 (Table 10). CD melting curves of tel26, tel46, cmyc and 
ds27 in the absence or presence of the ligand (1:6 oligonucleotide/NDI-8 ratio) were recorded 
by following the CD changes at the wavelength of intensity maximum (290 nm for tel26 and 
tel46, 263 and 251 nm for cmyc and ds27, respectively). The results of the CD melting 
experiments showed that compound NDI-8 preferably stabilized tel26, tel46 and cmyc G4s 
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structure (ΔTm > 9 °C), but however produced an appreciable stabilization also of ds27 with 
ΔTm of 6 °C (Table 10).  
Overall, both CD titrations and CD-melting experiments demonstrated the ability of the here 
investigated NDI-8 to affect the structure and stabilization of telomeric G4s and cmyc G4 to a 
greater extent than duplex DNA.  
Table 10. Melting temperatures (Tm) of tel26, tel46, cmyc and ds27 in the absence or presence of NDI-
8 (6 equivalents) measured by CD melting experiments. 
Ligand 
Tm (°C) (±1) 
tel26 tel46 cmyc ds27 
No ligand 49 49 82 75 
NDI-8 58 59 92 81 
 
The capacity of NDI-8 to induce the formation of G4 structures was also investigated, taking 
the telomeric sequences as models. Solutions of tel26 and tel46 in 10 mM Tris-HCl, 10% 
DMSO buffer (pH 7) were titrated with increasing amounts of the NDI, and CD spectra were 
recorded after each addition (Figure 85). Remarkably, NDI-8 was able to induce the formation 
of hybrid-type and antiparallel G4s, respectively starting from unfolded tel26 and tel46, 
featured by Tm of 37 and 36 °C in 10 mM Tris-HCl, 10% DMSO buffer (pH 7). On the other 
hand, cmyc and ds27 proved to fold into stable secondary structures, i.e. a parallel G4 and a 
hairpin duplex respectively, even in the absence of cations; it was not therefore possible to gain 
information about the ability of this NDI to induce G4 formation on cmyc and ds27. 
To investigate the binding stoichiometry of the complexes formed between NDI-8 and the here 
studied tel26, tel46, cmyc and ds27 secondary structure-forming sequences, fluorescence 
experiments were carried out. Fluorescence spectra were recorded for different DNA/ligand 
mixtures, prepared varying the NDI mole fraction from 0 to 1 and keeping constant the total 
molar concentration ([ligand] + [DNA]) at 2 µM (Figures 86A, 86C, 86E and 86G). The 
analysis of the Job plot for tel26/NDI mixtures showed changes at NDI mole fractions of 0.48 
and 0.63, corresponding to stoichiometry ratios of approximately 1:1 and 2:3 tel26/NDI-8 
(Figure 86B). These stoichiometries of binding suggest the formation of a complex in which 
first one NDI binds one G4, and then a dimeric G4 structure is formed, with two NDI molecules 
likely bound by end stacking and an additional NDI inserted at the G4-G4 interface. On the 
other hand, the analysis of the Job plot for the tel46/NDI mixtures showed slope changes at 
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NDI mole fractions of 0.54 and 0.84, corresponding to stoichiometry ratios of approximately 
1:1 and 1:5 tel46/NDI-8 (Figure 86D). Taking into account the above suggested model for 
tel26/NDI-8, probably two NDI molecules bind the tel46 dimer at its extremities, a third NDI 
at the G4-G4 interface and the other two NDIs interact with each of the two G4s forming tel46 
dimer at the loops or grooves. For cmyc/NDI mixtures, slope changes were found at NDI mole 
fraction of 0.68, corresponding to stoichiometry ratio of 1:2 cmyc/NDI-8 (Figure 86F). Finally, 
the Job plot analysis for ds27/NDI mixtures allowed separating the total stoichiometry in two 
binding events at NDI mole fractions of 0.52 and 0.85, corresponding to stoichiometry ratios 
of approximately 1:1 and 1:6 ds27/NDI-8 (Figure 86H). In the first binding event one NDI 
molecule binds to ds27 hairpin duplex, in the second binding event other five NDI molecules 
bind ds27, suggesting non-specific interactions of NDI-8 to the duplex structure.  
Further studies on the interaction in solution of NDI-8 with the here investigated G-quadruplex 
structures have been carried out to better elucidate their binding mode and are discussed in the 
following chapter. 
 
Figure 85. CD spectra of: A) tel26 and B) tel46, each 20 µM solutions in 10 mM Tris-HCl, 10% DMSO 
buffer (pH 7), in the absence and presence of increasing amounts of NDI-8 (up to 4 equivalents), and 
related melting curves for: C) tel26/NDI-8 and D) tel46/NDI-8 mixtures (1:4) recorded at 290 and 293 
nm, respectively. 
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Figure 86. Fluorescence spectra of NDI-8 in the absence and presence of: A) tel26, C) tel46, E) cmyc 
and G) ds27 and related Job plot analyses for the binding of NDI-8 to: B) tel26, D) tel46, F) cmyc and 
H) ds27. The total molar concentration ([ligand] + [DNA]) was kept constant at 2 µM. The experiments 
were performed in 20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7). The excitation wavelength 
was 502 nm. The arrows indicate the increasing NDI concentration. 
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5.5 Experimental section 
 
5.5.1 Chemistry 
NDIs 1-12 were provided by prof. Mauro Freccero’s group of the Department of Chemistry of 
University of Pavia with 95% purity as checked by 1H and 13C NMR. 
5.5.2 G4-CPG assay 
Long Chain AlkylAmine-CPG 1000 Å was functionalized with 3'-O-acetyl-5'-O-(4,4'-
dimethoxytrityl)thymidine through a hexaethylene glycol spacer as previously described in 
section 2.4. Solid phase synthesis protocols by standard phosphoramidite chemistry on an 
automated Applied Biosystem 394 DNA/RNA synthesizer were used to obtain the 
oligonucleotide-functionalized CPG supports. In particular, using a 1 µmol-scale, “DMT-ON” 
protocol, the following oligonucleotides were assembled on the CPG supports: 
d[(TTAGGG)4TT]
 (tel26), d[AGGG(TTAGGG)7] (tel46), 
d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) (cmyc), and 
d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27). The coupling efficiency of each base 
was monitored by spectrophotometric measurements of the DMT cation, released from the 
support by acidic treatment with 3% TCA in CH2Cl2 before the subsequent coupling step. 
Considering the number of couplings and the average yield per cycle of 99.8%, 99.0%, 99.7%, 
and 99.2%, respectively for tel26, tel46, cmyc and ds27, the overall yield was determined to be 
95%, 63%, 91% and 80%. Stock solutions of each tested compound were prepared by 
dissolving a weighed amount of the solid compound in H2O or pure DMSO. G4-CPG binding 
assays were performed as described in section 3.5, using weighed amounts of functionalized 
CPG supports to have 100 nmol of oligonucleotide for tel26, cmyc and ds27 and 50 nmol for 
tel46. The UV measurements were performed on a JASCO V-550 UV-vis spectrophotometer 
equipped with a Peltier Thermostat JASCO ETC-505T. The UV quantification of the ligands 
was determined by measuring the absorbance relative to the λmax characteristic of each ligand 
and referring it to the corresponding calibration curves. A quartz cuvette with a path length of 
1 cm was used. BRACO-19, TMPyP4, TO, resveratrol and 9-Acr-COOH were purchased from 
Sigma-Aldrich. 
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5.5.3 Biological experiments 
Cells and culture condition. Human fibroblasts (BJ) and human cervical cancer cells (HeLa) 
were obtained as previously reported. BJ-hTERT cells were obtained infecting primary BJ cells 
with a retrovirus carrying hTERT (Addgene plasmid #1773); BJ-EHLT derived from the 
transformation of BJ fibroblasts with hTERT and SV40[197] early region (BJ-EHLT). BJ-
hTERT, BJ-EHLT and HeLa were grown in Dulbecco Modified Eagle Medium (DMEM, 
Invitrogen Carlsbad, CA, USA) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-
glutamin and antibiotics at 37°C in a 5% CO2-95% air atmosphere. 
Immunofluorescence. Cells were fixed in 2% formaldehyde and permeabilized in 0.25% Triton 
X-100 in phosphate buffered saline (PBS) for 5 min at r.t. For immune-labeling, cells were 
incubated with primary antibody for 2 h at r.t., washed twice in PBS and finally incubated with 
the secondary antibodies for 1 h. The following primary antibodies were used: Mouse mAb 
anti-γH2AX (Millipore, Billerica, MA, USA) and Rabbit pAb anti-TRF1 N19 (Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA). The following secondary antibodies were used: Anti-
Mouse IgG (H+L), F(ab’)2 Fragment (Alexa Fluor 488 Conjugate) (Cell Signaling) and Anti-
rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor 555 Conjugate) (Cell Signaling). Nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI, Sigma). Fluorescence signals were 
recorded by using a Leica DMIRE2 microscope equipped with a Leica DFC 350FX camera and 
elaborated by Leica FW4000 deconvolution software (Leica, Solms, Germany). For 
quantitative analysis of γH2AX positivity, 300 cells on triplicate slices were scored. For TIF 
analysis, a single plane was analyzed, and 30 γH2AX-positive cells were scored. Cells with at 
least four co-localizations (γH2AX/TRF1) were considered as TIF-positive. 
Clonogenic assay. Human cervical cancer cells, HeLa, were seeded in 60 mm-Petri dishes at 
the clonogenic density of 500 cells/plate in DMEM medium with 10% FBS. After 24 h, cells 
were treated with compounds NDI-6, NDI-8, NDI-9, NDI-3 and NDI-4. After 10 days, the 
cells were stained with 2% methylene blue in 50% ethanol and the number of colonies was 
counted. Surviving fractions were calculated as the ratio of absolute survival of the treated 
sample/absolute survival of the untreated sample. 
Cell viability. BJ-hTERT fibroblasts were seeded in 60-mm Petri dishes at a density of 5×104 
cells/plate. After 24 h from plating, cells were treated with compounds NDI-6, NDI-8, NDI-9, 
NDI-3 and NDI-4. Cell viability (Trypan Blue dye exclusion) was determined after 6 days from 
treatment. 
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5.5.4 CD experiments 
CD spectra were recorded in a quartz cuvette with a path length of 1 cm on a Jasco J-715 
spectropolarimeter equipped with a Peltier-type temperature control system (model PTC-
348WI). The spectra were recorded at 20 °C in the range 240-800 nm with 2 s response, 200 
nm/min scanning speed, 2.0 nm bandwidth, and corrected by subtraction of the background 
scan with buffer. All the spectra were averaged over 3 scans. The oligonucleotides 
d[(TTAGGG)4TT] (tel26), d[AGGG(TTAGGG)7] (tel46), 
d(TGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA) (cmyc) and 
d(CGCGAATTCGCGTTTCGCGAATTCGCG) (ds27) were synthesized by standard 
automated solid phase oligonucleotide synthesis on an Applied Biosystem 394 DNA/RNA 
synthesizer. After ammonia treatment (55 °C, 12 h), allowing both deprotection and detachment 
from the solid support, the crude oligonucleotides were purified by HPLC on a SAX analytical 
column and then dialyzed against water using a Float-A-Lyzer G2 dialysis device (MWCO 0.5-
1.0 kDa, three H2O changes over 24 h). After lyophilization, the oligonucleotides were 
dissolved in a 20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer (pH 7) to obtain 2 μM solutions, 
then annealed by heating to 95 °C for 5 min, followed by slow cooling to room temperature. 
The ligand stock solution was 4 mM in DMSO. CD titrations were obtained by adding 
increasing amounts of the ligands (up to 6 molar equivalents, corresponding to a 12 μM solution 
in ligand) to tel26, tel46, cmyc and ds27. After each ligand addition, the system was allowed 
equilibrating before recording the spectra. For the CD-melting experiments, the ellipticity was 
recorded at 290 nm for tel26 and tel46, 263 and 251 nm for cmyc and ds27, respectively, with 
a temperature scan rate of 0.5 °C/min in the range 20-90 °C. For the CD-monitored experiments 
to evaluate the G-quadruplex structuring induction of NDI-8, 20 µM solutions of tel26 and 
tel46 were prepared in 10 mM Tris-HCl, 10% DMSO buffer (pH 7) and titrated with increasing 
amounts of NDI (up to 4 molar equivalents, corresponding to a 80 μM solution in ligand). Then 
the melting curves of these solutions were recorded at 290 and 293 nm, respectively for 
tel26/NDI-8 and tel46/NDI-8 1:4 ratio mixtures, with a temperature scan rate of 0.5 °C/min in 
the range 20-90 °C. 
 
5.5.5 Fluorescence experiments 
Fluorescence spectra were recorded at 20 °C on HORIBA Jobin Yvon Inc. FluoroMax®-4 
spectrofluorometer equipped with F-3004 Sample Heater/Cooler Peltier Thermocouple Drive, 
by using a quartz cuvette with a 1 cm path length. NDI-8 was excited at 502 nm and emission 
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spectra were recorded between 515 and 800 nm. Both excitation and emission slits were set at 
5 nm. The experiments were performed in 20 mM KCl, 5 mM KH2PO4, 10% DMSO buffer 
(pH 7). For the construction of the Job plot, the mole fraction of NDI-8 was varied from 0 to 1 
and the total molar concentration ([ligand] + [DNA]) was kept constant at 2 µM. 
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CHAPTER 6 - STRUCTURAL STUDIES ON THE INTERACTION OF 
THE DIMERIC NAPHTHALENE DIIMIDE NDI-8 WITH G-
QUADRUPLEX MODELS 
6.1 Selection of the G-quadruplex-forming oligonucleotide models for NMR studies 
To get in-depth information on the binding mode of the dimeric naphthalene diimide NDI-8 
(Figure 87A) to different DNA G-quadruplex conformations, NMR experiments were 
performed with two model G-rich oligonucleotides able to fold into stable and well-
characterized G-quadruplex structures, respectively a parallel and hybrid-1 type topology 
(Figures 87B and 87C, respectively).[189,209] This study was carried out during my research 
activities at the Slovenian NMR Centre, National Institute of Chemistry, Ljubljana, Slovenia 
under the supervision of prof. Janez Plavec.  
The primary sequences of the herein used oligonucleotides, M2 
d(TAGGGACGGGCGGGCAGGGT) and m-tel24 d[TTGGG(TTAGGG)3A], are in line with 
vastly accepted consensus motif for G-quadruplex formation.[189,209] M2 G-quadruplex exhibits 
all strands with parallel orientation, a common feature of most G-quadruplex-forming 
sequences found in oncogene promoter regions.[209] On the other hand, m-tel24 corresponds to 
the sequence taken from human telomeric DNA and designed to favour hybrid-1 G-quadruplex 
topology,[189] thus reducing the high polymorphism of telomeric DNA and allowing a detailed 
NMR characterization.[210,211]  
Both models gave high quality NMR spectra, with the predominant G4 conformation observed 
in solution at above 90% in the here used conditions, i.e. 100 mM KCl, 20 mM KH2PO4, pH 
7.0. 
6.2 NMR structures of the here studied DNA G-quadruplex models 
Twelve narrow and well-resolved imino proton signals were observed in the 1H NMR spectra 
of M2 and m-tel24, consistently, in both cases, with the formation of G-quadruplexes with three 
stacked G-quartets.[189,209] Under the studied conditions, M2 adopts a parallel G-quadruplex 
consisting of three stacked G-quartets G3:G8:G12:G17, G4:G9:G13:G18 and 
G5:G10:G14:G19, sandwiched between the 5’- and 3’-end overhanging residues (T1A2 and T20, 
respectively), and connected by three propeller-type loops involving G5-G8, G10-G12 and 
G14-G17 residues (Figure 87B).[209] Our NMR study on m-tel24 was carried out at slightly 
higher K+ concentration than in published articles (100 mM KCl vs. 70 mM KCl).[189]  
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Figure 87. A) Chemical structure of the herein studied dimeric NDI-8 and schematic representation of 
G-quadruplexes adopted by: B) M2 and C) m-tel24. 
 
Hence, we used NOESY 2D NMR experiments (Figure 88) combined with 1H NMR analysis 
of m-tel24 modified sequences containing specific thymine-to-uracil substitutions (the latter 
one necessary to assign the methyl groups of the different thymidines, see Figure 89) to verify 
that the here used conditions did not alter m-tel24 G-quadruplex structural features. The 1H 
NMR chemical shifts of m-tel24 G-quadruplex are reported in Table 11. Further experiments 
(e.g., HMBC) are needed to unambiguously assign A14, A20 and A24 H2 protons, which were 
far from other protons. Overall, our results consistently showed that under the herein used 
conditions, m-tel24 G-quadruplex adopts hybrid-1 type topology containing G3:G21:G17:G9, 
G4:G10:G16:G22, G5:G11:G15:G23 quartets, with G3, G9, G15, G16 and G21 in syn 
conformation along the N-glycosidic bond (Figure 87C).[189] 
A)
B) C)
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Figure 88. Anomeric-aromatic region of the NOESY spectrum of m-tel24 (at 25 °C, 0.2 mM DNA, 100 
mM KCl, 20 mM KH2PO4, pH 7 buffer) with a mixing time of 200 ms. 
 
 
Figure 89. Methyl regions of the 1H NMR spectra of the wild-type (wt) m-tel24 and its modified 
sequences containing T-to-U substitutions (at 25 °C, 0.2 mM DNA, 100 mM KCl, 20 mM KH2PO4, pH 
7 buffer). Wild-type m-tel24 methyl peaks not present in the spectra of the modified sequences are 
marked with crosses. 
12U
13U
19U
wt
T18 T6,T7 T12
T19
T1,T2
T13
x
x
x
δ/ppm
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Table 11. 1H NMR chemical shifts of m-tel24, structured into a G-quadruplex. The chemical shifts are 
given in ppm and correspond to spectra recorded at 0.2 mM DNA, 100 mM KCl and 20 mM KH2PO4, 
pH 7 buffer. 
Proton H6/H8 H1/Me 
H2/H5 
H1’ H2’/H2” H3’ 
Residue      
T1 7.394 1.476 5.778 1.791/2.300 4.620 
T2 7.503 1.474 6.072 2.095/2.326 3.742 
G3 7.425 12.027 6.073 3.391/2.958 4.409 
G4 7.941 11.752 5.782 2.565/2.629 5.022 
G5 7.801 11.044 6.389 2.609/2.571 5.029 
T6 7.725 2.014 6.389 2.529/2.475 4.869 
T7 7.577 1.999 6.157 2.038/2.381 4.838 
A8 8.468 8.271 6.536 2.864/3.039 5.152 
G9 7.332 11.871 5.940 3.430/2.987 5.023 
G10 8.019 12.175 5.650 2.636 5.067 
G11 7.919 11.267 6.279 2.549/2.677 5.054 
T12 7.577 1.883 6.254 2.398/2.489 4.702 
T13 6.599 1.330 5.351 1.323/2.135 4.501 
A14 7.771 - 6.300 2.258/2.500 4.998 
G15 7.337 11.329 6.095 3.495/2.979 4.240 
G16 7.302 11.206 5.756 2.521/2.460 4.990 
G17 7.648 11.785 5.956 2.652/2.607 5.169 
T18 7.909 2.035 6.343 2.355/2.529 4.936 
T19 7.187 1.500 5.711 0.901/1.707 4.670 
A20 8.090 - 6.108 2.915/2.746 4.987 
G21 7.343 11.440 6.033 3.467/2.952 4.974 
G22 8.042 11.641 5.776 2.668 5.059 
G23 7.400 10.653 5.893 2.152/2.543 4.925 
A24 7.845 - 6.104 2.668/2.412 4.684 
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6.3 Study on the interaction of NDI-8 with M2 and m-tel24 G-quadruplexes  
Before performing the NMR experiments, we checked NDI-8 solubility in the concentration 
range typically used for NMR studies by means of UV spectroscopy. Remarkably, a linear 
correlation between absorbance and NDI-8 concentration was found in the 0.1-0.8 mM range 
(Figure 90), indicating the absence of intermolecular aggregation and/or precipitation 
phenomena under the studied conditions. 
 
 
Figure 90. Absorbance vs. NDI-8 concentration dependence. The samples were prepared by adding 1.8, 
3.6, 7.2 and 14.4 µL of NDI-8 dissolved at 10 mM concentration in DMSO-d6 to the 100 mM KCl, 20 
mM KH2PO4, pH 7.0 buffer so to reach the final volume of 180 µL. DMSO concentration was, 
respectively, 1%, 2%, 4%, 8% for the four samples. The absorbance was monitored at 495 nm. 
 
Titrations of M2 and m-tel24 with NDI-8 up to 1:4 DNA/ligand ratio were then monitored by 
1H NMR spectra. 
As far as M2 is concerned, 1H NMR imino signals corresponding to the free M2 G-quadruplex 
were so dramatically broadened to be practically almost undetectable from the baseline already 
upon addition of 0.5 molar equivalents of NDI-8 (Figure 91). On the contrary, broad humps 
appeared in the region between δ 10.5 and 11.4 ppm, which became more intense and shifted 
slightly upfield (ca. 0.2 ppm) upon further addition of NDI. Aging the sample at 1:4 ratio of 
M2/NDI resulted in evident signals at δ 10.7, 11.0, 11.1 and 11.3 ppm, indicating slow 
formation of multiple complexes (Figure 91). Importantly, upon interaction with NDI-8, M2 
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retained a G-quadruplex folding, as inferred from the presence of imino 1H NMR signals in the 
spectral region characteristic of Hoogsteen-type hydrogen bonds. Furthermore, the line 
broadening observed for all the imino (Figure 91) and methyl resonances as well as most of the 
aromatic ones (Figure 92) suggests that the ligand could explore different binding poses and/or 
different G4/NDI-8 complexes could form, with fast-to-moderate rate equilibria on the 1H 
NMR time scale.[212] In this regard, the low intensity of the 1H NMR signals in the imino as 
well as in the other spectral regions of this system discouraged more detailed NMR studies. 
 
 
Figure 91. Imino regions of the 1H NMR spectra of M2 G-quadruplex (at 25 °C, at 0.2 mM DNA, 100 
mM KCl, 20 mM KH2PO4, pH 7 buffer) titrated with NDI-8 (from 0.5 to 4 equivalents). Resonances 
are assigned according to Trajkovski et al.[209]  
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Figure 92. Aromatic and methyl regions of the 1H NMR spectra of M2 G-quadruplex (recorded at 25 
°C, at 0.2 mM DNA, 100 mM KCl, 20 mM KH2PO4, pH 7 buffer) titrated with NDI-8 (from 0.5 to 4 
equivalents). Resonances are assigned according to Trajkovski et al.[209] 
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Titration of m-tel24 G4 with NDI-8 resulted in a stepwise broadening of the signals 
corresponding to the major G4 species, approaching the plateau at 1:2 DNA/NDI ratio, where 
imino signals were no longer observed (Figure 93).  
 
Figure 93. Imino regions of the 1H NMR spectra of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM KCl, 
20 mM KH2PO4, pH 7 buffer) titrated with NDI-8 (from 0.5 to 4 equivalents). Top: 1H NMR spectrum 
of 0.1 mM NDI-8 solution (at 25 °C, 100 mM KCl, 20 mM KH2PO4, pH 7 buffer). 1H NMR signals 
appearing in titrated solutions corresponding to m-tel24/NDI-8 complex(es) are labeled with stars. 
The complete disappearance of the minor species 1H NMR imino signals was also observed 
already at 1:0.5 DNA/NDI ratio. In parallel, new 1H NMR signals (labelled with stars in Figures 
93-95) appeared in the 1H NMR spectra of the titrated solutions at δ 9.72, 9.59, 8.30, 8.06, 3.00, 
2.97, 2.87, 2.79, 2.27 and 1.63 ppm. Considering that the chemical shifts of these signals did 
not correspond to the free NDI (Figures 93-95, top) nor to free m-tel24 G4 (Figures 93-95, 
bottom), we assigned them to m-tel24/NDI-8 complex(es). On the other hand, no significant 
change in the chemical shifts (> 0.05 ppm) of imino, aromatic and methyl signals of m-tel24 
G4 was observed up to 1:4 DNA/NDI ratio. Furthermore, no spectral change was observed at 
1:4 DNA/NDI ratio after aging the sample for 7 days at room temperature. Binding of NDI-8 
to m-tel24 was also evident from dramatic line broadening – even at 0.5 molar equivalents – 
observed for the imino signals of G3, G4, G9, G17, G21 and G22 (Figure 93). Notably, the 
m-tel24:NDI-8
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guanine residues for which the line broadening was most marked are structurally related among 
them as they form the upper G3:G21:G17:G9 quartet and half of the consecutive middle quartet 
(G4 and G22). This points to a specific binding mode of NDI-8 to m-tel24 G4. Line broadening 
was also evident for the aromatic protons of G17, T19, A20 and G22 and methyl group of T1, 
T2, T18 and T19 (Figure 94-95). Overall, these findings clearly proved the preferential binding 
of this NDI to the 5’-end spatially close residues and to the G3:G21:G17:G9 quartet, as 
schematically reported in Figure 96. Moreover, the differences in the imino 1H NMR signals 
within the middle G4:G22:G16:G10 quartet, showing a more prominent broadening for G4 and 
G22 compared to G10 and G16, indicated that two structural features, i.e. the width of the 
groove and accessibility of the loop residues, seemed to be crucial for the interaction with the 
NDI. Indeed, among narrow and wide grooves formed by GGG tracts connected by lateral loops 
and two medium grooves, one loop-free and one containing a propeller loop, NDI-8 preferred 
binding to the m-tel24 groove of medium width which is not covered by a loop (Figure 96). 
Increasing the concentration of NDI-8 resulted in increased line broadening at 35 °C, while no 
significant effects were observed at 5 and 15 °C (Figure 97). Interestingly, for a given NDI 
concentration, the broadening of the imino signals of the structurally related guanines was 
temperature-dependent: indeed, it was moderate at 25 °C, while it diminished at lower (i.e., 5 
°C) and increased at higher (35 °C) temperatures (Figure 97). Noteworthy, in the 1H NMR 
spectra of the NDI alone, the signals became sharper upon heating in the 5 to 35 °C range 
(Figure 98). This observation, complemented by UV analysis - performed in the same buffer 
with the same DMSO concentration used in the NMR samples, showing absence of 
intermolecular interaction among NDIs at r.t. - could be explained considering that NDI-8 
indeed produced intramolecular interactions at low temperatures. In this regard, the 
temperature-induced broadening of imino 1H NMR signals of m-tel24 G4 in the presence of 
NDI-8 could be the consequence of reduced extent of NDI intramolecular interactions, which 
in turn favoured its binding to m-tel24 G4. 
To get a deeper insight into the binding mode of NDI-8 towards the hybrid-1 G4 model, 
H2O/D2O exchange experiments were carried out. Two samples of 0.2 mM m-tel24 in 100 mM 
KCl, 20 mM KH2PO4, 9:1 H2O/D2O buffer with or without 0.1 mM NDI were prepared in 
parallel, lyophilized and then dissolved in 99.9% D2O. 
1H NMR spectra were then recorded at 
different times after the dissolution (Figure 99). For both samples, the slowest exchangeable 
protons were found to be G4, G10, G16, G21 and G22 imino protons.  
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Figure 94. Aromatic regions of the 1H NMR spectra of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM 
KCl, 20 mM KH2PO4, pH 7 buffer) titrated with NDI-8 (from 0.5 to 4 equivalents). Top: 1H NMR 
spectrum of 0.1 mM NDI-8 solution (at 25 °C, 100 mM KCl, 20 mM KH2PO4, pH 7 buffer). 1H NMR 
signals appearing in titrated solutions corresponding to m-tel24/NDI-8 complex(es) are labeled with 
stars. 
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Figure 95. Methyl regions of the 1H NMR spectra of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM 
KCl, 20 mM KH2PO4, pH 7 buffer) titrated with NDI-8 (from 0.5 to 4 equivalents). Top: 1H NMR 
spectrum of 0.1 mM NDI-8 solution (at 25 °C, 100 mM KCl, 20 mM KH2PO4, pH 7 buffer). 1H NMR 
signals appearing in titrated solutions corresponding to m-tel24/NDI-8 complex(es) are labeled with 
stars. 
 
m-tel24:NDI-8
1:0
1:0.5
1:1
1:1.5
1:2
1:3
1:4
NDI-8-0.1 mM
*
*
*
*
*
**
*
*
*
*
*
T13
T1,T2
T19T12
T6
T18 T7
*
*
*
*
*
*
*
*
*
*
*
**
**
**
*
*
*
*
δ/ppm
 142 
 
 
 
Figure 96. Schematic representation of the complex between m-tel24 and the dimeric NDI-8 as 
hypothesized on the basis of the collected NMR data. Residues which showed important line broadening 
already at 1:0.5 G4/NDI ratio are highlighted in red. 
 
 
Figure 97. Imino regions of the 1H NMR spectra of m-tel24 G4 (at 0.2 mM, 100 mM KCl, 20 mM 
KH2PO4, pH 7 buffer) A) in the absence of ligand, or in presence of B) 0.10 mM NDI-8 and C) 0.15 
mM NDI-8, recorded at different temperatures (from 5 to 35 °C). 
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Figure 98. 1H NMR spectra of 0.1 mM NDI-8 in 100 mM KCl, 20 mM KH2PO4, pH 7 buffer at different 
temperatures. 
 
Figure 99. Imino regions of the 1H NMR spectra of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM KCl, 
20 mM KH2PO4, pH 7 buffer) in: A) absence of ligand and B) presence of 0.10 mM NDI-8 recorded at 
different times (from 10 to 280 min) after dissolution in 99.9% D2O. 
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Different exchange rates were found for the slowest exchangeable imino protons (i.e., G4, G10, 
G16, G21 and G22) in the absence or presence of the ligand (Figure 100), further corroborating 
the localization of NDI-8 in the proximity of the upper and middle quartets of m-tel24 G-
quadruplex.  
 
Figure 100. Normalized imino peaks integrals of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM KCl, 
20 mM KH2PO4, pH 7 buffer) in the absence (left panels) or presence (right panels) of NDI-8 (0.10 mM) 
calculated for G4, G10, G16, G21 and G22 and reported as a function of different times (10, 60 and 280 
min) after dissolution of the samples in 99.9% D2O. 
 
In order to evaluate if the translational diffusion of m-tel24 G4 is perturbed by the ligand, 
diffusion ordered spectroscopy (DOSY) experiments were performed in the absence and 
presence of 0.5 and 1 molar equivalents of NDI-8.[213–215] The diffusion coefficient of the G4 
proved to be ~1.7 x 10-10 m2·s-1 in the absence of NDI while a coefficient of ~1.4 x 10-10 m2·s-1 
was found in the presence of 0.5 and 1 molar equivalents of NDI (Figures 101 and 102). These 
findings indicated that in the presence of NDI the formed G4 species dispersed more slowly. 
Notably, the diffusion coefficients for the predominant species at 0.5 and 1.0 molar equivalents 
of NDI was basically the same. In this regard, it is interesting to highlight that the diffusion 
coefficient calculated for the system without the NDI differed by 0.3 x 10-10 m2·s-1 from the one 
found for the system in the presence of 0.5 or 1.0 molar equivalents NDI, which perfectly 
matched the difference previously reported for monomeric and dimeric G-quadruplexes.[216] 
Indeed, from the diffusion coefficient found for the G4 in the absence of NDI (~1.7 x 10-10 m2·s-
1), calculations utilizing a spherical model[217] provided a hydrodynamic diameter of 22.4 Å (not 
including the hydration layer of 2 x 2.8 Å[218]), which is in reasonable agreement with the size 
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(∼21 and ∼25 Å, for the length and diameter, respectively) of monomeric m-tel24 G4 (PDB 
entry 2GKU).[189] A hydrodynamic diameter of 28.4 Å (not including the hydration layer of 2 
x 2.8 Å[218]) was in turn derived for m-tel24 G4 in the presence of the ligand (diffusion 
coefficient ~1.4 x 10-10 m2·s-1), suggesting the formation of a dimeric structure. This result was 
fully consistent with the fluorescence data discussed in Chapter 5, showing a 2:3 stoichiometry 
for the DNA/NDI complex obtained by the Job plot experiments on titrating tel26. In addition, 
the value here obtained for m-tel24 in the presence of the NDI was in good agreement with size 
of ∼28 Å found for previously reported dimeric G4 structures (PDB entry 2KYO and 
2LED).[114,216,219] Attempts to utilize a cylindrical model in lieu of a spherical one did not result 
in a better representation of the hydrodynamic behaviour of the here studied G-quadruplex 
structures under the used conditions.[217] 
Finally, peaks from minor species (labeled with stars in Figure 102), also found in the 1H NMR 
spectrum of the G4 in the absence of NDI, were observed only in DOSY spectra of 1:0.5 and 
1:1 G4/NDI samples because the severe signal broadening induced by the presence of the ligand 
and lower threshold required for spectra processing than in the case of 1:0 G4/NDI sample 
allowed them emerging. 
 
Figure 101. Diffusion coefficients for methyl 1H NMR signals of m-tel24 G4 as assessed from DOSY 
NMR spectra (at 25 °C, 0.2 mM DNA, 100 mM KCl, 20 mM KH2PO4, pH 7 buffer) in the absence 
(black squares) or presence of 0.5 (red dots) and 1 (blue triangles) NDI-8 equivalents. 
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Figure 102. 2D DOSY analysis of methyl signals of m-tel24 G4 (at 25 °C, 0.2 mM DNA, 100 mM KCl, 
20 mM KH2PO4, pH 7 buffer) A) in the absence or presence of B) 0.5 and C) 1 molar equivalents of 
NDI-8. Peaks from minor species are labeled with stars. 
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NOESY experiments were also carried out on a 0.2 mM m-tel24 sample in the presence of 0.1 
mM NDI-8. Interproton distances were calculated from NOESY spectra for m-tel24 G4 in the 
absence or presence of 0.5 molar equivalents of NDI (Table 12), using the following equation: 
rij = rref (aref/aij)
1/6 
where aij is the NOE cross-peak volume and rij is the interproton distance of the two protons i 
and j; cross-peak volumes and related distances between thymines H2'/H2'' (1.80 Å) were used 
as the reference. Differences greater than 0.5 Å were found for G17H1'-T18Me and T18H2'-
T19H6, located in the upper quartet and in the close lateral loop, and for G23H8-A24H8 in the 
3’-flanking region (Table 12). However, no significant difference was found in other G4 
regions, suggesting that the major folding was preserved even upon interaction with the NDI, 
as also corroborated by the fact that NOESY spectra for m-tel24 G4 in the absence or presence 
of NDI could be almost fully overlapped (Figure 103). Novel putative NOE peaks appeared in 
correspondence of the chemical shifts assigned to m-tel24/NDI-8 complex(es) in the 1H NMR 
spectra (see for example the aromatic-aromatic region in Figure 104), but unfortunately the 
weakness of these signals, not easily distinguishable from the noise, did not allow us obtaining 
a high-resolution model for m-tel24/NDI-8 complex(es).  
 
Table 12. Differences between interproton distances calculated for m-tel24 G4 (at 25 °C, 0.2 mM DNA, 
100 mM KCl, 20 mM KH2PO4, pH 7 buffer) in the absence or presence of 0.5 molar equivalents of 
NDI-8 from NOESY spectra with a mixing time of 200 ms.  
Assignment 
Distance (Å) 
m-tel24 
Distance (Å) 
m-tel24:NDI-8, 1:0.5 
Difference 
T1H2'-H1' 2.14 2.33 0.19 
T1H2'-H2'' 1.79 1.68 -0.10 
T1H2'-H4' 2.74 2.54 -0.20 
T1H2'-H6 2.20 2.37 0.16 
T1H2'-T2H6 2.63 2.89 0.26 
T1H2''-H1' 1.96 1.94 -0.02 
T1H2''-H6 2.58 2.61 0.03 
T1H3'-H6 2.82 2.72 -0.10 
T1Me-H6 1.90 2.04 0.13 
T2H1'-H6 2.53 2.47 -0.05 
T2H2'-H6 2.48 2.04 -0.44 
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T2H2''-H6 2.02 2.11 0.09 
T2Me-H6 2.05 2.09 0.04 
G3H2'-H1' 2.13 2.44 0.31 
G3H2'-G4H8 2.04 2.14 0.10 
G3H2''-H8 2.68 2.81 0.13 
G3H2''-G4H8 1.94 2.13 0.19 
G4H1'-H8 2.56 2.68 0.12 
G4H1'-G5H8 2.35 2.55 0.20 
G5H1'-H8 2.59 2.98 0.40 
G5H3'-H8 2.41 2.35 -0.06 
T6H1'-H6 2.19 2.20 0.00 
T6Me-H1' 2.50 2.26 -0.24 
T6Me-H6 1.94 1.93 -0.01 
T7H1'-H6 2.56 2.31 -0.25 
T7H2'-H6 1.97 1.76 -0.21 
T7H2'-A8H8 2.85 2.78 -0.08 
T7H2''-H1' 2.19 1.94 -0.25 
T7H2''-A8H8 2.51 2.83 0.32 
T7H3'-H6 2.46 2.40 -0.06 
A8H1'-H8 2.33 2.49 0.17 
A8H2'-H1' 1.89 1.78 -0.11 
A8H2'-H8 2.29 2.25 -0.03 
A8H2''-H1' 2.21 2.20 -0.01 
A8H2''-H8 1.93 1.99 0.05 
A8H3'-H1' 2.91 2.54 -0.38 
A8H3'-H8 2.47 2.60 0.13 
A8H4'-H1' 2.30 2.33 0.03 
G9H1'-H8 1.77 1.88 0.11 
G9H2'-G10H8 2.17 2.20 0.03 
G9H2''-H1' 2.04 1.92 -0.12 
G9H2''-H3' 2.21 2.77 0.56 
G9H2''-G10H8 1.90 1.95 0.05 
G10H1'-H8 2.64 2.61 -0.03 
G10H1'-G11H8 2.43 2.30 -0.13 
G10H2'/H2''-H1' 1.74 1.83 0.09 
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G10H2'/H2''-H8 1.78 1.77 0.00 
G10H3'-H1' 2.93 2.43 -0.50 
G10H4'-H1' 2.22 2.15 -0.07 
G11H1-G10H1 2.67 2.94 0.27 
G11H1'-H8 2.69 2.60 -0.08 
G11H2'-H1' 2.02 1.72 -0.30 
T12H1'-H6 2.32 2.16 -0.16 
T12H2''-H1' 2.07 1.90 -0.16 
T12H3'-H6 2.64 2.38 -0.27 
T12Me-H6 2.06 2.08 0.02 
T13H1'-H6 2.72 2.91 0.19 
T13H1'-A14H8 2.55 2.65 0.11 
T13H2'-H2'' 1.83 1.80 -0.03 
T13H2''-H1' 1.94 2.01 0.06 
T13H2''-H3' 2.04 2.13 0.08 
T13H2''-H6 2.45 2.45 0.00 
T13H2''-A14H8 2.07 2.09 0.02 
T13H3'-H6 2.59 2.87 0.28 
T13H3'-A14H8 2.96 2.83 -0.13 
T13H4'-H1' 2.44 2.38 -0.07 
T13H4'-H3' 2.20 2.16 -0.03 
T13H5'-H3' 2.49 2.46 -0.02 
T13H5'-H6 2.54 2.56 0.02 
T13H5''-H3' 2.25 2.17 -0.08 
T13H5''-H6 2.68 2.69 0.01 
T13Me-G5H1 2.70 3.12 0.42 
T13Me-G11H8 2.96 2.58 -0.38 
T13Me-H3' 1.94 2.01 0.07 
T13Me-H6 1.78 1.85 0.07 
T13Me-A14H8 2.25 2.33 0.09 
A14H1'-H8 2.73 2.60 -0.13 
A14H2'-H8 2.28 2.17 -0.11 
G15H1'-H8 1.83 1.91 0.08 
G15H2'-H1' 2.21 2.07 -0.13 
G16H1'-H8 1.75 1.85 0.09 
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G16H2'-H1' 2.32 2.47 0.15 
G16H3'-G17H8 2.52 2.74 0.22 
G17H1-G10H1 2.57 2.97 0.39 
G17H1'-H8 2.68 2.81 0.13 
G17H2'-H3' 1.98 2.23 0.26 
G17H2''-H3' 2.10 2.16 0.06 
G17H3'-H8 2.43 3.01 0.57 
T18H1'-H6 2.44 2.52 0.08 
T18H2'-H1' 2.16 2.20 0.04 
T18H2'-H6 2.11 2.03 -0.08 
T18H2'-T19H6 3.39 4.22 0.84 
T18H2''-T19H6 2.80 3.18 0.37 
T18H3'-H6 2.76 2.69 -0.07 
T18H3'-T19H6 3.49 3.29 -0.20 
T18Me-G17H1' 2.46 2.98 0.53 
T18Me-H6 1.95 2.00 0.05 
T19H1'-H6 2.39 2.61 0.22 
T19H2'-H1' 2.15 2.60 0.45 
T19H2'-H2'' 1.78 2.01 0.23 
T19H2'-H6 1.97 2.26 0.29 
T19H2'-A20H8 2.49 2.66 0.16 
T19H2''-H1' 1.96 2.18 0.23 
T19H2''-H6 2.32 2.44 0.12 
T19H2''-A20H8 2.49 2.77 0.28 
T19H3'-H6 2.31 2.70 0.39 
T19H4'-H6 2.96 3.03 0.07 
T19Me-H6 1.85 1.99 0.14 
A20H1'-G17H8 3.32 3.50 0.19 
A20H1'-H8 2.39 2.34 -0.05 
A20H2'-H8 1.82 1.90 0.07 
A20H2''-H8 2.05 2.06 0.01 
A20H3'-H8 2.55 2.66 0.11 
G21H1'-H8 1.76 1.70 -0.05 
G21H1'-G22H8 2.92 2.58 -0.34 
G21H2'-H1' 2.25 2.13 -0.12 
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G21H2'-H3' 2.65 2.94 0.29 
G21H2'-G22H8 2.06 2.17 0.11 
G21H2''-H1' 1.90 1.89 -0.01 
G21H2''-G22H8 1.87 1.97 0.10 
G21H3'-G22H8 3.08 2.65 -0.43 
G22H1-G3H1 3.01 2.80 -0.21 
G22H1'-H8 2.75 2.49 -0.26 
G22H2'/H2''-H8 1.76 1.98 0.22 
G22H3'-H8 3.05 2.77 -0.28 
G22H3'-G23H8 2.98 3.04 0.06 
G23H2'-H1' 2.14 2.37 0.23 
G23H2'-H8 2.14 2.06 -0.08 
G23H2'-A24H8 2.52 2.46 -0.06 
G23H2''-H1' 1.91 1.92 0.01 
G23H2''-H8 2.68 2.27 -0.41 
G23H2''-A24H8 2.21 2.37 0.16 
G23H3'-H8 2.83 2.71 -0.12 
G23H3'-A24H8 2.96 2.69 -0.27 
G23H8-A24H8 3.37 2.71 -0.65 
A24H1'-H8 2.37 2.54 0.17 
A24H2'-H8 2.40 2.06 -0.34 
A24H2''-H1' 2.02 1.90 -0.12 
A24H2''-H8 2.20 2.45 0.24 
A24H3'-H8 3.01 2.68 -0.33 
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Figure 103. Overlapped NOESY spectra of m-tel24 (at 25 °C, 0.2 mM DNA, 100 mM KCl, 20 mM 
KH2PO4, pH 7 buffer) in the absence (red peaks) or presence of 0.5 molar equivalents NDI-8 (cyan 
peaks) with a mixing time of 200 ms. For a better visualization, peaks assignments are not reported. 
 
Figure 104. Aromatic-aromatic region of the NOESY spectrum of m-tel24 (at 25 °C, 0.2 mM DNA, 
100 mM KCl, 20 mM KH2PO4, pH 7 buffer) in the presence of 0.5 molar equivalents NDI-8 with a 
mixing time of 200 ms. Top: 1H NMR spectrum of m-tel24/NDI-8 1:0.5 solution (at 25 °C, 100 mM 
KCl, 20 mM KH2PO4, pH 7 buffer). 1H NMR signals corresponding to m-tel24/NDI-8 complex(es) are 
labeled with stars. 
* *
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6.4 PAGE experiments 
To obtain further information on the binding mode of NDI-8 to the human telomeric DNA G-
quadruplexes, gel electrophoresis experiments were also carried out. The same G4-forming 
oligonucleotide used for NMR studies (m-tel24) was here chosen as model for telomeric DNA. 
Native PAGE experiments were performed analysing the oligonucleotide sample at 20 µM 
concentration mixed with different ligand amounts (from 1:0.5 to 1:4 m-tel24/NDI-8 ratio, 
using the same ratios adopted in 1H NMR titrations) in 100 mM KCl, 20 mM KH2PO4, pH 7 
buffer (Figure 105). Furthermore, a step ladder, with 5 bp differences between adjacent DNA 
fragments, was used as size marker. Gels were visualized either exploiting NDI-8 emission 
(Figure 105A) or by GelGreen™ staining (Figure 105B). A single band was observed for m-
tel24 in the absence of the ligand (Figure 105B): considering the migration rate of the ladder, it 
corresponds to a monomeric G4 folding of m-tel24. Addition of NDI-8 resulted in the 
appearance of a lower mobility band already at 1:0.5 m-tel24/NDI-8 ratio (Figure 105B). By 
overlapping the two gels in Figure 105, this band was attributed to m-tel24 G4/NDI-8 complex. 
As a control, NDI-8 in the absence of m-tel24 was also loaded on 20% PAGE at two different 
concentrations (Figures 105A and 105B). NDI-8 is neutral at pH 7 since it bears two amino and 
two carboxylic groups. When free in solution, NDI-8 should not migrate on gel. However, we 
observed the migration of NDI bands in the same direction as DNA, probably due to the 
formation of negative NDI species in the here used conditions. The presence of free ligand in 
solution, gradually increasing with the concentration, suggested that low m-tel24/NDI-8 ratios 
were not favoured, consistently with binding stoichiometries obtained by Job plot analysis for 
monomeric G4s. Higher DNA concentration (200 µM), previously used for the NMR 
experiments, resulted in worse bands resolution. Thus, native PAGE confirmed that NDI-8 was 
able to interact with hybrid monomeric m-tel24 G4 and promote the formation of stable, slowly 
moving species, consistently with NMR and fluorescence data. 
Furthermore, to evaluate the ability of NDI-8 to induce the formation of G-quadruplex 
structures in the absence of cations, 20 µM solutions of m-tel24 in 10 mM Tris-HCl buffer (pH 
7) were prepared and loaded on 20% PAGE with increasing amounts of the ligand (Figure 106). 
Noteworthy, NDI-8 proved to be able to promote the formation of a more compact species, 
likely the monomeric m-tel24 G4, in perfect agreement with the CD induction experiments. 
Bands of lower mobility were also observed and associated to free NDI (Figure 106).  
Overall, these results further validated NDI-8 as a strong binder for G4-forming telomeric 
sequences. 
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Figure 105. Native PAGE. Oligonucleotide samples were loaded at 20 µM concentration in 100 mM 
KCl, 20 mM KH2PO4, pH 7 buffer and resolved on 20% native PAGE. Lane L: 5 bp DNA ladder. Lane 
1: m-tel24 (1:0). Lane 2-7: mixtures m-tel24/NDI-8 (from 1:0.5 to 1:4). Lane 8: NDI-8, 40 µM in 100 
mM KCl, 20 mM KH2PO4, pH 7 buffer. Lane 9: NDI-8, 80 µM in 100 mM KCl, 20 mM KH2PO4, pH 
7 buffer. Gels were visualized exploiting NDI-8 emission (A) or by GelGreen™ staining (B). 
 
Figure 106. Native PAGE experiments. Oligonucleotide samples were loaded at 20 µM concentration 
in 10 mM Tris-HCl buffer (pH 7) and resolved on 20% native PAGE. Lane L: 5 bp DNA ladder. Lane 
1: m-tel24 (1:0). Lane 2-7: mixtures m-tel24/NDI-8 (from 1:0.5 to 1:4). Lane 8: NDI-8, 40 µM in 10 
mM Tris-HCl buffer (pH 7). Lane 9: NDI-8, 80 µM in 10 mM Tris-HCl buffer (pH 7).  
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6.5 Materials and methods 
6.5.1 Sample preparation 
The sequences d(TAGGGACGGGCGGGCAGGGT) (M2) and d[TTGGG(TTAGGG)3A] (m-
tel24), as well as its modified sequences (6U, 7U, 12U, 13U, 18U and 19U), were synthesized 
on H-8 synthesizer (K&A LaborGerëate) with the use of standard phosphoramidite chemistry 
and deprotected with aqueous ammonia. Purification and desalting of DNA oligonucleotides 
were performed by means of: i) RP-HPLC using a Kromasil EternityXT-5-PhenylHexyl 21.2 × 
250 mm column, then ii) FPLC using a HiPrep™ 26/10 Desalting 10 cm × 26 mm column, and 
finally iii) Amicon-15 centrifuge filter with 3.0 kDa MWCO. The oligonucleotide concentration 
was determined by measuring the absorbance at 260 nm and 90 °C, using the molar extinction 
coefficients calculated for the unstacked oligonucleotide.[181] Samples for NMR measurements 
were prepared in 100 mM aqueous KCl and 20 mM potassium phosphate buffer (pH 7). For 
M2, the temperature treatment of the samples included 5 min incubation at 95 °C immediately 
followed by cooling in an ice-water bath for 5 min. For m-tel24, the major monomeric folding 
was formed without annealing. The NDI-8 stock solution was prepared by dissolving the solid 
compound in DMSO-d6 at 10 mM concentration. 
The samples for the calibration curve were prepared by adding 1.8, 3.6, 7.2 and 14.4 µL of 
NDI-8 dissolved at 10 mM concentration in DMSO-d6 to 100 mM KCl, 20 mM KH2PO4, pH 
7.0 buffer to the final volume of 180 µL. DMSO concentration was, respectively, 1%, 2%, 4%, 
8% for the four samples. Absorbance measurements were performed at 495 nm on a JASCO 
V-550 UV-vis spectrophotometer equipped with a Peltier Thermostat JASCO ETC-505T. 
 
6.5.2 NMR spectroscopy 
NMR data were collected on Varian NMR Systems 600 and 800 MHz in temperature range 
between 5 and 35 °C. However, most of the spectra were collected at 25 °C. NMR samples 
were prepared in 90%/10% H2O/D2O or 99.9% D2O at 0.2 mM oligonucleotide concentration. 
In titration experiments, aliquots of the NDI-8 stock solution in DMSO-d6 were directly added 
to the DNA solutions inside the NMR tube; the final DMSO concentration was 8%. Control 
titrations were also performed by adding DMSO-d6 alone to the DNA solutions; in all cases, no 
conformational change was observed for both sequences. For experiments in D2O, H2O was 
replaced with D2O by lyophilization and dissolution in 99.9% D2O. NMR spectra were acquired 
with the use of the DPFGSE solvent suppression method. NOESY spectra were acquired at 
mixing times between 80 and 400 ms. Twenty different gradient strengths (2.4-60.4 G/cm) were 
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used in diffusion NMR experiments. From diffusion coefficients obtained from DOSY 
experiments, hydrodynamic radius for m-tel24 in the absence or presence of the NDI was 
calculated by using Stokes-Einstein equation:[217]  
 
D = kbT/6πηR  → R = kbT/6πηD 
 
where R is the hydrodynamic radius, kb is the Boltzmann constant (1.38·10
-23 m2·kg·K·s-2), T 
is the temperature (298.15 K), η is the fluid viscosity for 9:1 H2O/D2O solution calculated as 
previously described (0.917 mPa·s)[220] and D is the experimentally determined diffusion 
coefficient. 
DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) was used as a reference to calibrate the 
chemical shifts, assuming that DSS resonates at 0 ppm. NMR spectra were processed and 
analyzed with the use of VNMRJ (Varian Inc.) software and Sparky (UCSF) software.  
 
6.5.3 Native PAGE 
The mixtures m-tel24/NDI-8 (up to 1:4 ratio), free m-tel24 G4 and NDI-8 samples together 
with a O'RangeRuler™ 5 bp DNA Ladder (ThermoFisher Scientific) were loaded and resolved 
on native 20% polyacrylamide (19:1 acrylamide:bisacrylamide) PAGE. TBE 1X supplemented 
with 100 mM KCl was used as running buffer. The oligonucleotide samples loaded on gels 
were from 2 to 200 µM in oligonucleotide concentration per strand, in 100 mM aqueous KCl 
and 20 mM potassium phosphate buffer (pH 7). For induction experiments, oligonucleotide 
samples were prepared at 20 µM concentration in 10 mM Tris-HCl buffer (pH 7) and TBE 1X 
was used as running buffer. No migration marker was used. Samples were electrophoresed for 
3 h at 100 V at room temperature. The bands were visualized by exploiting NDI-8 emission or 
using GelGreen™ staining.   
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CHAPTER 7 – CONCLUSIONS AND PERSPECTIVES 
 
The identification of selective DNA binders, able to discriminate in vivo non-canonical nucleic 
acids conformations, as G-quadruplexes, having crucial roles in tumour and/or viral diseases, 
is of paramount importance for the development of effective and minimally toxic anticancer 
and/or antiviral drugs. Taking into account that the existing therapies are always associated with 
heavy side effects, due to the intrinsically poor selectivity of known anticancer/antiviral 
drugs,[221–224] the discovery of an efficient targeted therapy, causing limited-to-null toxicity, 
results in a revolutionary challenge from a scientific and medical point of view.  
In the last decade, increasing efforts in the G4 research field have been devoted to the search of 
selective G4-binders, able not only to fully discriminate G4 vs. duplex DNA, but also to 
specifically recognize different G4 topologies, thus resulting into effective ligands, and 
expectedly into useful anticancer/antiviral drugs with limited side effects. To reach this 
ambitious goal, an integrated approach is required, involving the massive production of large 
libraries of new putative G4 ligands, coupled with High Throughput Screening methodologies 
for the fast and reliable analysis of the selected compounds. 
In this context, we recently described a highly reproducible affinity chromatography-based 
method – named G4-OAS assay – for the identification of putative G4-ligands.[159,160] Though 
rapid, simple and effective, a major limitation emerged when using the G4-OAS assay, resulting 
from the intrinsic chemical nature of the OAS support, i.e. unspecific binding of some lipophilic 
aromatic ligands on the polystyrene nude resin.[160] In this PhD thesis this crucial problem, 
dramatically limiting the scope of the assay, was addressed, moving from polystyrene to 
chemically inert CPG supports. However, all the commercially available CPG supports, 
typically functionalized with linkers rapidly hydrolyzed under basic conditions, were not 
suitable to our objectives. In fact, main requirement for our design was the attachment of the 
first nucleoside through a linker chemically stable to the final deprotection step, so to obtain 
fully deprotected oligonucleotides bound to the support on which the affinity chromatography 
binding assays could be performed. To solve this problem, we designed a novel 
functionalization for CPG supports, involving a linker – made of a flexible spacer of 
hexaethylene glycol attached to the first nucleoside monomer (i.e., 5’-O-DMT-3’-O-
acetylthymidine) through the nucleobase – being suitable for oligonucleotide elongation by 
standard phosphoramidite chemistry and chemically stable to the final deprotection procedure.  
Once synthesized the G4-forming oligonucleotides of interest on the CPG, a set of model 
ligands were flown through the glass supports. The molecules with high affinity for the G4s 
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were retained by the solid supports, while those with low affinity were eluted with a washing 
solution and quantified by UV measurements. The specific interaction of a given ligand with a 
G4 structure was confirmed by inducing its unfolding on the support by a denaturing solution, 
resulting in full release in solution of the captured ligand. After each binding assay, 
functionalized CPG supports were annealed again to allow the correct G4 refolding and reuse 
the same batch of support for other binding assays. Noteworthy, our results proved that the 
novel support had low-to-null unspecific interactions with the tested model ligands, in contrast 
with previously used OAS. Indeed, all the investigated ligands were generally recovered in 
higher amounts from nude CPG, requiring smaller volumes of the washing solution for their 
quantitative recovery compared to nude OAS. In addition, highly specific binding was 
maintained for those ligands which are well characterized G4-binders, displaying in our tests 
binding data with a trend respecting the order of the binding affinities determined in solution. 
Furthermore, for its lower unspecific binding and higher thermal stability, the same batch of 
functionalized CPG could be used for typically more than 50 experiments, i.e. about three times 
the number of binding assays generally carried out on the OAS resin, moreover offering much 
cleaner and more reliable results. Finally, compared to the other methodologies currently 
exploited to select G4 ligands[19,225–227] – such as FRET-based melting,[228] G4-FID,[229,230] 
SPR,[19] NMR,[210] ESI-MS[231] and small molecule microarray-based screenings[232] – the 
advantages of the G4-CPG assay consist in the possibility of attaching to the support the wild-
type oligonucleotide sequence without necessarily modifying it to detect ligand-G4 binding, 
and of studying the ligand-G4 interaction in pseudo-physiological conditions.  
Indeed, the conformational behaviour of the oligonucleotides linked to the CPG support was 
also studied by exploiting a water-soluble fluorescent naphthalene diimide dye, known to give 
different fluorescent responses upon binding to topologically different G4 structures.[184] We 
proved that the oligonucleotides, when anchored to CPG and left in contact with the selected 
buffer, adopt the same conformations they typically have in solution. This result provided a 
proof-of concept that our novel approach is a powerful tool to identify not only structure-
selective G4-ligands, but even conformation-selective G4-ligands. 
After full optimization of the G4-CPG assay, two different libraries of putative G4 ligands, 
based on furobenzoxazine naphthoquinone or naphthalene diimide scaffolds, were evaluated. 
As far as the library of furobenzoxazine naphthoquinone derivatives is concerned, these were 
selected as analogs of a lead-like G-quadruplex targeting compound (4),[187] differing for the 
pendant groups on the N-atom of the oxazine ring. These molecules were tested vs. 
topologically different G4s by the G4-CPG assay. The obtained results showed that all the 
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compounds were able to bind several G4 structures, even though with peculiar preferences, and 
two of them fully discriminated G4 vs. duplex DNA. Biological assays proved that almost all 
the compounds produced effective DNA damage, also at the telomeric level, showing marked 
antiproliferative effects on tumour cells in the low µM range. Combined analysis of the G4-
CPG binding assays and biological data led us to focus on compound S4-5, being less cytotoxic 
than the parent compound 4 on normal cells. An in-depth biophysical characterization of the 
binding of S4-5 to different G4s was carried out by CD, NMR and Microscale Thermophoresis, 
demonstrating that the here identified ligand had higher affinity for the model G4s and higher 
ability to discriminate G4 vs. duplex DNA than 4. Molecular docking studies, in agreement 
with the NMR data, suggested that S4-5 interacted with the accessible grooves of the target G4 
structures, giving clues for its increased binding selectivity. Considering that targeting the most 
variable regions of the G4 structures, i.e. the grooves and the loops, could be a successful, even 
though still poorly explored, approach for the specific recognition of different G4 
conformations, and that very few G4-groove binders have been thus far characterized, these 
results are of great relevance to develop novel effective candidate anticancer drugs. 
As far as the naphthalene diimide library is concerned, novel functionalized dimeric NDIs were 
designed, synthesized and evaluated by G4-CPG assay. Overall, all the tested compounds 
proved to be effective G4 ligands and stronger binders for intramolecular dimeric than 
monomeric G4s. In particular, NDI-3, NDI-4, NDI-6, NDI-8 and NDI-9 emerged as the most 
promising compounds, due to their high G4s vs. duplex DNA selectivity. In addition, G4-CPG 
assay results allowed us demonstrating that mitigating the affinity of the NDI binding core for 
G4s allowed the core selectivity emerging. Biological assays unambiguously designated, 
among the five selected NDIs, NDI-8 as the most promising candidate due to its strong activity 
against cancer cells (IC50 = 6.6 nM) and high selectivity in killing cancer cells than normal cells. 
Therefore, NDI-8 was further investigated by CD, fluorescence, NMR and gel electrophoresis 
analyses. By combination of CD titrations and CD-melting experiments, NDI-8 was proved to 
preferentially affect G4 structures than duplex DNA. Moreover, the ability of NDI-8 to induce 
G4 structure formation in the absence of cations was proved by CD and native PAGE 
experiments. Furthermore, fluorescence experiments revealed binding stoichiometries of 1:1 
and 3:2 for complexes of NDI-8 with telomeric G4 monomer, while binding stoichiometries of 
1:1 and 5:1 were found for NDI-8 complexes with a telomeric G4 dimer. In-depth NMR 
analyses showed the preferential binding of the NDI-8 to the 5’-end spatially close residues, 
the upper quartet and half of the middle quartet of a G4 structure taken from the human 
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telomeric DNA. Finally, the remarkable ability of NDI-8 to promote the formation of dimeric 
G4 species was demonstrated by DOSY experiments.  
Overall, the novel developed G4-CPG method based on our newly designed CPG support 
allowed us identifying two promising candidate drugs for in vivo studies, S4-5 and NDI-8, 
showing respectively binding preferences for parallel G4s and monomeric or higher order 
telomeric G-quadruplex structures, in addition to their high G4s vs. duplex DNA selectivity.  
Our current efforts are devoted to the extension of the G4-CPG assay to biologically relevant 
human i-motif-forming[233–235] and viral G4-forming DNA sequences,[12,236,237] in order to 
analyze novel libraries of putative conformation-selective ligands, as well as to automate our 
method with the aim of speeding up the search for effective anticancer/antiviral drugs in 
targeted therapies. 
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Abbreviation 
Ac, Acetyl 
ACN, Acetonitrile 
AD4.2, Autodock 4.2 
ADP, Adenosine Diphosphate 
ADT, AutoDockTools 
AFM, Atomic Force Microscope 
ALT, Alternative Length Telomere 
AMA, Ammonium hydroxide/Methylamine 
BRCA, Breast Related Cancer Antigens 
CD, Circular Dichroism 
cex-NDI, core extended Naphthalene Diimide 
CPG, Controlled Pore Glass 
CTR, Control 
DAPI, 4’,6-diamidino-2-phenylindole 
DCC, N,N’-dicyclohexylcarbodiimide 
DCM, Dichloromethane 
DDR, DNA Damage Response 
DEAD, Diethyl Azodicarboxylate 
DMAP, 4-dimethylaminopyridine 
DMEM, Dulbecco's Modified Eagle's Medium 
DMF, N,N-dimethylformamide 
DMSO, Dimethyl Sulfoxide 
DMT, 4,4'-dimethoxytrityl 
DOSY, Diffusion Ordered Spectroscopy 
DPFGSE, Double Pulsed Field Gradient Spin Echo 
DSS, 4,4-dimethyl-4-silapentane-1-sulfonic acid 
ESI-MS, Electrospray Ionization Mass Spectrometry 
ETT, 5-ethylthio-1H-tetrazole 
FBS, Fetal Bovine Serum 
FID, Fluorescence Intercalator Displacement 
FPLC, Fast Protein Liquid Chromatography 
FRET, Fluorescence Resonance Energy Transfer 
 162 
 
G4, G-quadruplex  
GALS, Genetic Algorithm Local Search 
GIST, Gastrointestinal Stromal Tumours 
GMP, Guanosine Monophosphate 
γH2AX, phosphorylated form of histone H2AX 
HOBt, 1-hydroxybenzotriazole 
HPLC, High Performance Liquid Chromatography 
hTERT, human Telomerase Reverse Transcriptase 
hTR, human Telomerase RNA Component 
HMBC, Heteronuclear Multiple Bond Correlation 
HTS, High Throughput Screening 
IC50, Median Inhibition Concentration  
IF, Immunofluorescence 
IgG, Immunoglobulin G 
Kd, dissociation Constant 
LCAA-CPG, Long Chain AlkylAmine-CPG 
M1, Mortality stage 1 
M2, Mortality stage 2 
MI, N-methylimidazole 
MST, Microscale Thermophoresis 
MWCO, Molecular Weight Cut-Off 
NDI, Naphthalene Diimide 
NHE, Nuclease Hypersensitivity Element 
NMR, Nuclear Magnetic Resonance 
NOESY, Nuclear Overhauser Spectroscopy 
OAS, Oligo Affinity Support 
PAGE, Polyacrylamide Gel Electrophoresis 
PARP, Poly ADP Ribose Polymerase  
PBS, Phosphate Buffered Saline 
PDAC, Pancreatic Ductal Adenocarcinoma 
PDB, Protein Data Bank 
PDS, Pyridostatin 
PIPER, N,N'-bis-(2-(1-piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide 
POT1, Protection of Telomeres protein 1 
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PP, Polypropilene 
PS, Polystyrene/polyethylene glycol 
PTFE, Polytetrafluoroethylene 
Py, Pyridine 
RP-HPLC, Reversed-phase High-performance Liquid Chromatography  
SAX, Strong Anion Exchange 
S.D., Standard Deviation 
Sp1, Specificity protein 1 
SPR, Surface Plasmon Resonance 
TBE, Tris-borate-EDTA 
TEMPO, 2,2,6,6-tetramethyl-1-piperidinyloxy 
TBA-Cl, Tetrabutylammonium Chloride 
TCA, Trichloroacetic Acid 
THF, Tetrahydrofuran 
TIF, Telomere Induced Foci 
TMPyP4, 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin 
TO, Thiazole Orange 
TRF1, Telomere Repeat Factor 1 
TRF2, Telomere Repeat Factor 2 
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Abstract 
Contrary to what was believed for many years, cis-PtI2(NH3)2, the diiodido analogue of cisplatin, 
displays high in vitro antiproliferative activity toward a set of tumour cell lines, overcoming 
resistance to cisplatin in a platinum-resistant cancer cell line. In the context of a general reappraisal 
of iodinated Pt(II) derivatives, aiming at a more systematic evaluation of their chemical and 
biological profiles, here we report on the reactivity of cis-PtI2(NH3)2 with selected DNA model 
systems, in single, double strand or G-quadruplex form, using cisplatin as a control. A combined 
approach has been exploited in this study, including circular dichroism (CD), UV-visible 
spectroscopy and electrospray mass spectrometry (ESI-MS) analyses. The data reveal that cis-
PtI2(NH3)2 shows an overall reactivity towards the investigated oligonucleotides significantly higher 
than cisplatin. 
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Abstract 
Nucleic acid aptamers are single-stranded DNA or RNA molecules identified to recognize with high 
affinity specific targets including proteins, small molecules, ions, whole cells and even entire 
organisms, such as viruses or bacteria. They can be identified from combinatorial libraries of DNA 
or RNA oligonucleotides by SELEX technology, an in vitro iterative selection procedure consisting 
of binding (capture), partitioning and amplification steps. Remarkably, many of the aptamers 
selected against biologically relevant protein targets are G-rich sequences that can fold into stable 
G-quadruplex (G4) structures. Aiming at disseminating novel inspiring ideas within the scientific 
community in the field of G4-structures, the emphasis of this review is placed on: 1) recent 
advancements in SELEX technology for the efficient and rapid identification of new candidate 
aptamers (introduction of microfluidic systems and next generation sequencing); 2) recurrence of 
G4 structures in aptamers selected by SELEX against biologically relevant protein targets; 3) 
discovery of several G4-forming motifs in important regulatory regions of the human or viral 
genome bound by endogenous proteins, which per se can result into potential aptamers; 4) an 
updated overview of G4-based aptamers with therapeutic potential and 5) a discussion on the most 
attractive G4-based aptamers for diagnostic applications.  
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Abstract 
BACKGROUND: 
G-quadruplex (G4) structures are key elements in the regulation of cancer cell proliferation and their 
targeting is deemed to be a promising strategy in anticancer therapy. 
METHODS: 
A tandem application of ligand-based virtual screening (VS) calculations together with the 
experimental G-quadruplex on Oligo Affinity Support (G4-OAS) assay was employed to discover 
novel G4-targeting compounds. The interaction of the selected compounds with the investigated G4 
in solution was analysed through a series of biophysical techniques and their biological activity 
investigated by immunofluorescence and MTT assays. 
RESULTS: 
A focused library of 60 small molecules, designed as putative G4 groove binders, was identified 
through the VS. The G4-OAS experimental screening led to the selection of 7 ligands effectively 
interacting with the G4-forming human telomeric DNA. Evaluation of the biological activity of the 
selected compounds showed that 3 ligands of this sub-library induced a marked telomere-localized 
DNA damage response in human tumour cells. 
CONCLUSIONS: 
The combined application of virtual and experimental screening tools proved to be a successful 
strategy to identify new bioactive chemotypes able to target the telomeric G4 DNA. These 
compounds may represent useful leads for the development of more potent and selective G4 ligands. 
GENERAL SIGNIFICANCE: 
Expanding the repertoire of the available G4-targeting chemotypes with improved physico-chemical 
features, in particular aiming at the discovery of novel, selective G4 telomeric ligands, can help in 
developing effective anti-cancer drugs with fewer side effects. 
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Abstract 
BACKGROUND: 
trans-Resveratrol (tRES) is a polyphenolic stilbene found in plant products which has attracted great 
attention because of its antioxidant, anti-inflammatory and anticancer properties. 
METHODS: 
The possible correlation between tRES-induced suppression of melanoma cell growth and its 
influence on telomerase expression has been investigated by biological assays. Moreover, in order 
to gain new knowledge about possible mechanisms of action of tRES as antineoplastic agent, its 
interaction with biologically relevant secondary structure-forming DNA sequences, its aggregation 
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properties and copper-binding activity have been studied by CD, UV and fluorescence 
spectroscopies. 
RESULTS: 
Biological assays have confirmed that growth inhibitory properties of tRES well correlate with the 
reduction of telomerase activity and hTERT gene transcript levels in human melanoma cells. 
Biophysical studies in solution have proved that tRES binds all the studied DNA model systems 
with low affinity, however showing high ability to discriminate G-quadruplex vs. duplex DNA. In 
addition, tRES has shown no propensity to form aggregates in the explored concentration range and 
has been found able to bind Cu2+ ions with a 2:1 stoichiometry. 
CONCLUSIONS: 
From these biological and biophysical analyses it has emerged that tRES produces cytotoxic effects 
on human melanoma cells and, at a molecular level, is able to bind Cu2+ and cancer-involved G-
quadruplexes, suggesting that multiple mechanisms of action could be involved in its antineoplastic 
activity. 
GENERAL SIGNIFICANCE: 
Expanding the knowledge on the putative mechanisms of action of tRES as antitumour agent can 
help to develop novel, effective tRES-based anticancer drugs. 
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Fluorescence sensing using DNA aptamers in cancer research and clinical diagnostics 
Cancers, 2017, 9: 174-217, DOI:10.3390/cancers9120174 
 
Abstract 
Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a 
large number of chemical modifications within their backbone or at the termini without losing 
significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups 
or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable 
molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports 
an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer 
biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary 
structure switches induced by target recognition are suitably translated in a detectable fluorescent 
signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, 
producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the 
extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical 
assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for 
applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-
invasive in vivo imaging tools for cancer pre- and post-treatment assessment. 
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Controlled Pore Glass-based oligonucleotide affinity support: towards High Throughput Screening 
methods for the identification of conformation-selective G-quadruplex ligands 
Analytica Chimica Acta, 2018, 1030: 133-141, DOI: 10.1016/j.aca.2018.04.071 
 
Abstract 
Target selectivity is one of the main challenges in the search for small molecules able to act as 
effective and non-toxic anticancer and/or antiviral drugs. To achieve this goal, handy, rapid and 
reliable High Throughput Screening methodologies are needed. We here describe a novel 
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functionalization for the solid phase synthesis of oligonucleotides on Controlled Pore Glass, 
including a flexible hexaethylene glycol spacer linking the first nucleoside through the nucleobase 
via a covalent bond stable to the final deprotection step. This allowed us preparing fully deprotected 
oligonucleotides still covalently attached to their supports. In detail, on this support we performed 
both the on-line synthesis of different secondary structure-forming oligonucleotides and the affinity 
chromatography-based screenings of conformation-selective G-quadruplex ligands. By using a 
fluorescent core-extended naphthalene diimide with different emitting response upon binding to 
sequences folding into G-quadruplexes of different topologies, we have been able to discriminate 
not only G-quadruplex vs. duplex DNA structures, but also different G-quadruplex conformations 
on the glass beads by confocal microscopy. 
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Tailoring a lead-like compound targeting multiple G-quadruplex structures 
European Journal of Medicinal Chemistry, 2019, 163: 295-306, DOI: 
10.1016/j.ejmech.2018.11.058. 
 
Abstract 
A focused library of analogs of a lead-like G-quadruplex (G4) targeting compound (4), sharing a 
furobenzoxazine naphthoquinone core and differing for the pendant groups on the N-atom of the 
oxazine ring, has been here analyzed with the aim of developing more potent and selective ligands. 
These molecules have been tested vs. topologically different G4s by the G4-CPG assay, an affinity 
chromatography-based method for screening putative G4 ligands. The obtained results showed that 
all these compounds were able to bind several G4 structures, both telomeric and extra-telomeric, 
thus behaving as multi-target ligands, and two of them fully discriminated G4 vs. duplex DNA. 
Biological assays proved that almost all the compounds produced effective DNA damage, showing 
marked antiproliferative effects on tumor cells in the low μM range. Combined analysis of the G4-
CPG binding assays and biological data led us to focus on compound S4-5, proved to be less 
cytotoxic than the parent compound 4 on normal cells. An in-depth biophysical characterization of 
the binding of S4-5 to different G4s showed that the here identified ligand has higher affinity for 
the G4s and higher ability to discriminate G4 vs. duplex DNA than 4. Molecular docking studies, 
in agreement with the NMR data, suggest that S4-5 interacts with the accessible grooves of the target 
G4 structures, giving clues for its increased G4 vs. duplex selectivity. 
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Metodo per la preparazione di un supporto a basso legame aspecifico per cromatografia di affinità 
e/o sintesi diretta di oligonucleotidi 
The Content Is Object of the Italian Patent Application Number 102017000030473 Filed on March 
20, 2017. 
 
Abstract 
È presentato un metodo per preparare supporti solidi funzionalizzati da utilizzarsi in cromatografia 
di affinità e/o per la sintesi diretta di oligonucleotidi legati al supporto, completamente deprotetti 
formanti strutture secondarie. 
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2. C. Platella, D. Musumeci, J. Amato, A. Randazzo, B. Pagano, D. Montesarchio 
Method for the preparation of a low unspecific binding-support for affinity chromatography and/or 
on-line synthesis of oligonucleotides 
The Content Is Object of the European Patent Application Number EP18161706.9 Filed on March 
14, 2018. 
 
Abstract 
A method for preparing functionalized solid supports to be used in the on-line synthesis of support-
bound, fully deprotected secondary structure-forming oligonucleotides and/or for low unspecific 
binding affinity chromatography is disclosed. 
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